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SUMMARY 
Gas microbubbles are the contrast agent of choice for ultrasound (US) imaging. 
These agents are excellent for highlighting vasculature on imaging. However, their 
relatively large (1-10 µm) size prevents them from efficient trafficking within 
extravascular spaces. Microbubbles cannot extravasate from leaky cancer neovessels into 
the tumor stroma, nor can they transport within lymphatics without appreciable mechanical 
stimulation. Perfluorocarbon nanodroplets (PFCnDs) are a phase-change class of US 
contrast agents that were designed to address the challenge of contrast-enhanced US 
imaging within extravascular locations. PFCnDs are structurally similar to microbubbles, 
but they contain a fluoroalkane core that is kept in the liquid state at physiological 
temperature. In the liquid-cored state, PFCnDs are stable at submicrometer sizes but they 
produce minimal imaging contrast. Upon a user-triggered input of energy, however, the 
fluoroalkane core can vaporize, transforming the PFCnDs into microbubbles in situ. 
Here, we utilize optically triggered perfluorohexane nanodroplets (PFHnDs) with 
an encapsulated near-infrared dye that allow a pulsed laser to trigger the phase change. 
Because the phase change is triggered optically, these particles also provide photoacoustic 
(PA) contrast in addition to US contrast. Moreover, because the perfluorohexane core has 
a bulk boiling temperature above physiological temperature, these particles will repeatably 
vaporize and recondense in response to a series of laser pulses. This enables longitudinal 
imaging of a single PFHnD population, in contrast to traditional PFCnDs that are only 
capable of a single vaporization event. 
 xxix 
In Aim 1, we optimized the synthesis of and imaging sequence for PFHnDs in order 
to improve their trafficking and detection, respectively, within extravascular spaces. We 
discovered that increasing the percentage of PEGylated lipids within lipid shelled PFHnDs 
reduces their average size and size variance over several hours post-synthesis. This 
discovery provides a facile method for achieving small, monodisperse PFCnDs and 
synergizes with downstream diagnostic and therapeutic syntheses that necessitate long 
incubation steps prior to particle use. We also implemented a novel imaging sequence 
based on pulse inversion that enhances the US contrast from PFHnDs relative to 
background, and we demonstrated this sequence both in phantoms and in vivo. 
In Aim 2, we explored the use of optically triggered PFHnDs within the lymphatic 
system. We developed a post-processing algorithm to exploit the dual US/PA contrast of 
these particles along with the unique temporal dynamics of their repeated phase change. 
We acquired longitudinal volumetric images of PFHnDs trafficking through tumor-
draining and naïve murine lymphatics, and we assessed various confounding factors for 
observing US/PA contrast enhancement. In parallel, we also developed a new class of 
adjuvant-carrying PFHnDs for use as an image-guided therapeutic vehicle in tumor-
draining lymphatics. After characterizing these particles, we demonstrated their efficacy as 
a therapeutic in an in vitro model of antigen presenting cells. 
In Aim 3, we attempted to tackle the “White Whale” of PFCnD research: 
demonstration of PFCnD extravasation from neovasculature into the primary tumor 
stroma. First, we developed a facile method of bioconjugation of PFHnDs to monoclonal 
antibodies for tumor surface markers, and we demonstrated the specificity of these targeted 
PFHnDs for tumor cells in vitro. Then, we proceeded to test these targeted PFHnDs in vivo, 
 xxx 
utilizing syngeneic and transgenic models of primary breast cancer as model organisms. 
We implemented losartan microdosing in an attempt to reduce tumor solid stress and 
improve particle delivery. Ultimately, our proof-of-concept in vivo results were 
inconclusive, but they draw a compelling blueprint for future investigative efforts. In this 
vein, we also developed a new class of on-particle Fluorescence Resonance Energy 
Transfer (FRET) PFCnDs that can be used as a sensor for the intact status of particles on 
whole organ or histological fluorescence imaging. We characterized successful FRET 
sensitized emission from these particles and plan to further optimize them for future in vivo 
studies. 
Finally, I reflect on the studies presented in this dissertation and offer my vision for 
ongoing and future work in each arena. These dissertation studies represent a novel 
contribution to the field of contrast-enhanced ultrasound research, as they develop and 
explore new avenues of extravascular applications for PFCnDs. Our findings have the 
potential to inspire new lines of investigation with PFCnDs and to push the envelope with 





CHAPTER 1. INTRODUCTION 
Contrast agents allow clinicians to highlight areas of disease and even to deliver 
therapeutics in conjunction with standard diagnostic imaging platforms. Ultrasound greatly 
benefits from the use of contrast agents, as endogenous ultrasound contrast between unique 
soft tissues is low compared to competing non-ionizing imaging paradigms. Gas 
microbubbles are the most ubiquitously utilized ultrasound contrast agent and have high 
echogenicity relative to background tissue. However, microbubbles have a limited lifetime 
due to gas diffusion from the core, and microbubbles’ large size (1-10 µm) restricts them 
to the vasculature. Microbubbles will neither extravasate from blood vessels nor traffic 
through lymphatics in times permissive of clinical imaging. As such, their utility is highly 
limited in diseases where much of the pathology and markers of disease exist outside of 
the vascular space. Cancer is one constellation of diseases that exemplify these design 
constraints. 
Amongst women in the United States, breast cancer is the most commonly 
diagnosed cancer and results in the second highest mortality rate.1 Although the treatment 
paradigm for breast cancer has evolved in recent years, detection of metastases to regional 
lymph nodes remains a critical aspect of the clinical protocol and has strong implications 
for recurrence and survival in patients with early-stage breast cancer. Sentinel lymph node 
biopsy has emerged as a relatively low-morbidity option for the clinical evaluation of 
regional lymphatic metastases, but this procedure relies on radioisotopes and also carries a 
relatively high false-negative rate in detecting metastases. Alternative methods for sentinel 
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lymph node detection and diagnosis have been explored, but they are not without 
weaknesses and have yet to gain clinical traction. 
In terms of primary or recurrent tumors, foci of rapidly dividing cancer cells will 
rapidly outgrow their supply of nutrients. To maintain a growth advantage, these tumor 
cells will secrete pro-angiogenic factors that induce blood vessels to supply the growing 
neoplasm. Due to their rapid synthesis, the neovessels induced in this process contain large 
gaps, or fenestrations, between endothelial cells. These “leaky” vessels can be exploited to 
deliver diagnostic or therapeutic agents to tumors via intravascular routes though the 
enhanced permeability and retention (EPR) effect. 
A contrast agent with the ability to reach and to traffic through extravascular spaces 
has the potential to add tremendous value to image-guided diagnostic and therapeutic 
applications in breast cancer. To this end, we developed optically-triggered phase-change 
perfluorocarbon nanodroplets (PFCnDs) for use with ultrasound imaging. Perfluorocarbon 
nanodroplets can be functionalized to afford molecular specificity and loaded with 
therapeutic cargo for controlled delivery and release. This contrast-enhanced imaging 
approach can be used to detect sentinel lymph nodes and assess them for metastases via 
subcutaneous delivery. It can also probe primary or recurrent tumors following 
intravascular administration. As such, this platform can have a profound impact on the 
diagnosis and treatment of breast cancer and its nodal metastases. Therefore, the overall 
goal of this dissertation was to develop and validate this platform in murine models of 
metastatic breast cancer. 
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To develop and demonstrate this theranostic platform, the specific aims of this 
dissertation work were as follows: 
1.1 Aim 1: Optimize the Synthesis and Detection of Laser-Activated 
Perfluorocarbon Nanodroplets for the Extravascular Space 
We undertook efforts to reduce the size and size distribution of PFCnDs for improved 
extravascular trafficking. By increasing the percentage of PEGylated lipids within the 
phospholipid shell, we were able to achieve a stable size reduction without having to resort 
to more technically challenging, non-scalable synthesis methods. In parallel, we 
investigated methods to improve the ultrasonic detection of laser activated PFCnDs. We 
developed a novel pulse-inversion-based imaging sequence and leveraged the unique time-
decaying ultrasound dynamics of perfluorohexane nanodroplets to improve the ability to 
detect these agents within hyperechoic background environments. 
1.2 Aim 2: Apply Perfluorocarbon Nanodroplets to Imaging and Therapeutic 
Delivery in Tumor-Draining Lymphatics 
We utilized the perfluorohexane nanodroplet platform developed in Aim 1 to image 
PFCnDs longitudinally in lymphatics over 24 hours. We compared naïve mice to those 
with orthotopic 4T1 tumors and assessed the path of drainage via histology of bilateral 
lymph nodes. Furthermore, we developed a new class of adjuvant-carrying nanodroplets 
for ultrasound image-guided immunotherapy in tumor-draining lymph nodes. We 
conducted proof-of-principle in vitro studies in antigen presenting cells and demonstrated 
that these particles can effectively elicit an immune response. 
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1.3 Aim 3: Assess Perfluorocarbon Nanodroplet Extravasation within Primary 
Breast Tumors 
We pursued avenues to increase the extravasation of systemically delivered PFCnDs 
in primary breast tumors. First, we developed antibody functionalized PFCnDs and 
demonstrated their molecular specificity for extracellular tumor markers in vitro. Then, we 
utilized targeted PFCnDs in two murine models of primary breast cancer. We performed 
concomitant tumor neovascular modulation and assessed the results of particle delivery 
with ultrasound and photoacoustic imaging as well as histology. 
1.4 Significance and Innovation 
The accomplished work is significant in that it addresses fundamental challenges that 
have stymied the preclinical utilization of PFCnDs and presents their use in realistic small 
animal models of neoplastic disease. It demonstrates longitudinal imaging of PFCnDs in 
vivo with a single bolus delivery, which has yet to be reported in the literature. Additionally, 
this work lays the foundation for yet-unexplored avenues of applications-based research 
with PFCnDs in the cancer domain and beyond. This work is innovative in establishing 
several new classes of nanodroplets as well as in its use of genetically engineered mouse 
models and tumor microenvironment modulation strategies.  
 5 
CHAPTER 2. BACKGROUND 
2.1 Ultrasound Imaging 
Ultrasound (US) imaging is a non-ionizing imaging modality with widespread 
clinical use, particularly in point-of-care settings. In brief, ultrasound imaging transmits 
sound waves into a tissue of interest and receives backscattered waves to create an image 
of the tissue with contrast proportional to changes in underlying tissue density. This 
technique does well when imaging soft tissue structures; however, it is not typically used 
to image structures with drastically different densities than soft tissue, such as the lungs 
and bone. 
The sound waves transmitted in US imaging are above the human audible range 
(i.e., greater than 20 kHz). Waves with a center frequency 1 MHz and lower can be 
appreciably absorbed by the body, leading to thermal deposition, and sound waves in this 
range are typically reserved for therapeutic ablative procedures.2 Sound waves above 1 
MHz in frequency are mostly scattered by physiological tissues, and thus these are used 
for imaging purposes. 
In US imaging, the transducer serves as both source and receiver for sound waves. 
Modern “phased array” transducers in US imaging systems contain an array of 
piezoelectric elements, each of which can convert electric potential energy into mechanical 
energy and vice versa.3 When a voltage is applied to a piezoelectric element, it vibrates and 
generates an ultrasonic wave. Conversely, when an acoustic wave vibrates a piezoelectric 
element, it produces an electrical potential that can be recorded as a voltage. 
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A pulser can apply a voltage to the piezoelectric elements of the transducer, which 
generate an US wave that can propagate through biological tissue. When this longitudinal 
pressure wave encounters an interface between two different mediums, some percentage 
of the wave is transmitted into the new medium and the rest is reflected back towards the 
transducer. The reflection fraction, 𝑎, which is the ratio of reflected wave intensity or the 






where 𝑍2 and 𝑍1 are the acoustic impedances at the two mediums making up a boundary.
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Acoustic impedance, 𝑍, is a material property that defines how much resistance an 
ultrasound wave encounters as it passes through tissue. It is defined as: 
𝑍 = 𝜌𝑐 (2) 
where 𝜌 is the density of the medium and 𝑐 is the speed of sound in the medium. In most 
soft tissues, the speed of sound is similar and is assumed to be a constant 1540 m/s. 
Therefore, the amount of reflected ultrasound at an interface is proportional to the 
difference in density between the two media at the boundary.5 
 Although differences in density lead to reflected waves, and thus imaging contrast, 
in US, too drastic of a difference can lead to the majority of the waves being reflected and 
none being transmitted. If no waves are transmitted, then an US image cannot be 
reconstructed past the highly reflective boundary. This manifests as a hypoechoic (i.e., 
dark) “acoustic shadow,” which tails underneath a hyperechoic (i.e., bright) surface. Both 
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low-density and high-density regions can create this effect;6 thus, US imaging is not 
typically used to image the lungs or through bone. Similarly, this explains why a layer of 
coupling gel, with similar acoustic impedance to tissue, is necessary to ensure US waves 
are transmitted into and out of the body. An internal matching layer sits between the 
piezoelectric elements and external cladding of the transducer to ensure efficient 
transmission and receipt of US waves by the system. 
 To collect a standard “brightness mode,” or “B-mode,” US image, the pulser applies 
a voltage to the piezoelectric elements of the transducer. Variable time delays are applied 
across the elements to generate a parabolic, converging wavefront that is focused at a 
particular depth, centered along one of the elements of the transducer. After firing the US 
wave, the transducer receives and records all back-reflected waves for a period of time. 
The receive time is defined by the round trip of a sound wave for the maximum depth 
within the desired imaging plane. This process is repeated for each element across the face 
of the transducer for a single “line-by-line” image acquisition. A variable time gain 
compensation (TGC) is applied to received signals as a function of time in order to account 
for depth-dependent attenuation of sounds waves propagating within tissue. 
 The “delay-and-sum” method is typically employed to create an image from the 
collected “line-by-line” data.7,8 To reconstruct the signal along the line of an US 
acquisition, a variable time delay is applied to the received signals at each element to 
account for the variable distance travelled from reflected signals from points in this line 
back to the transducer. After this delay is applied, the signals are summed together. This 
process amplifies coherent signals from the line of interest and suppresses incoherent 
signals from scatterers outside of this line. Next, one of several methods is employed in 
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order to extract the magnitude of the envelope of the complex summed US waveform. This 
receive beamforming process is repeated for each line of the line-by-line acquisition until 
the entire imaging plane is reconstructed. Finally, for visualization purposes, the 
reconstructed signal is typically normalized and displayed on a logarithmic (i.e., dB) scale.  
2.1.1 Plane Wave Ultrasound Imaging 
Plane wave US imaging is a variation of the workflow for B-mode imaging described 
above. In contrast to the line-by-line acquisition regime, plane wave US imaging uses a 
single planar wave transmit in contrast to the multiple converging wave transmits across 
the elements of the transducer. By reducing the number of transmit events, plane wave 
imaging can achieve up to two orders of magnitude increased temporal resolution in 
comparison to line-by-line over the same lateral field of view.9 Plane wave imaging is 
consistently utilized for ultrafast (i.e., greater than 500 frames per second) US imaging 
applications. 
Although plane wave US imaging can increase temporal resolution dramatically 
compared to traditional line-by-line acquisitions, this increase comes at a cost. Because of 
the lack of transmit focusing, the entire volume beneath the transducer is insonified with 
every transmit. As a result, appreciable coherent, off-axis received signals persist when 
reconstructing images with the delay-and-sum method. This leads to “side lobe” artifacts 
and overall reduced contrast-to-noise ratio (CNR) within reconstructed images when 
compared to equivalent line-by-line acquisitions over the same volume. To address this 
drawback, researchers developed the method of angular compounding.10 In angular 
compounding, time delays are applied in order to transmit and receive a series of tilted 
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plane waves that are swept through angles relative to the transducer, where 0° defines a 
traditional plane wave parallel to the transducer face. Static structures remain spatially 
coherent upon reconstruction regardless of plane wave transmit angle, whereas off-axis 
signals are spatially variant. Therefore, when successive angularly swept plane wave 
acquisitions are compounded, or added prior to reconstruction, side lobe artifacts are 
suppressed in the resultant images. This enhancement comes at the cost of some of the 
temporal resolution benefit of plane wave US imaging, as multiple transmit-and-receive 
events become necessary to form the compounded images. 
The enhanced temporal resolution afforded by plane wave US imaging is necessary 
to capture the transient ultrasound contrast created by perfluorohexane nanodroplets. As 
will be discussed in Section 2.4, these contrast agents only serve as ultrasound reflectors 
for milliseconds after an energy pulse. Therefore, this fast phenomenon requires an 
ultrafast regime to capture on US imaging. Plane wave US imaging allows for successful 
imaging of perfluorohexane nanodroplets without a reduction in the field of view, as would 
be necessary in a line-by-line acquisition approach. 
2.2 Photoacoustic Imaging 
Photoacoustic (PA) imaging is an adjunct to US imaging. It utilizes some of the same 
hardware and signal processing techniques as US imaging, but it produces fundamentally 
different images. PA imaging can be thought of as “lightning and thunder.” Upon exposure 
to a pulse of laser irradiation (the “lightning”), chromophores within the tissue absorb light. 
This absorption leads to localized heating and thermal expansion, which produces a 
pressure wave (the “thunder”). The laser-induced pressure waves can be recorded with an 
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ultrasound transducer and processed to form an image. Here, the contrast is proportional to 
the optical absorption of tissue, as opposed to changes in its density. Because of the 
similarity in hardware, a single imaging system can be used to acquire both US and PA 
(US/PA) images, which can be co-registered for a plane of interest. 
Photoacoustic imaging is based on the photoacoustic effect, which is the formation 
of sound waves from a material irradiated by time-varying light. This phenomenon was 
first discovered by Alexander Graham Bell when he reported that a material produced 
sound waves after exposure to sunlight that was interrupted by a rotating slotted wheel.11 
Although the photoacoustic effect was discovered in the late nineteenth century, it wasn’t 
until after the development of nanosecond pulsed lasers nearly a century later that 
photoacoustic imaging was born.12-16 
When biological tissue is irradiated with a short (i.e., nanosecond) pulse of laser light, 
photons can be absorbed by local chromophores within the beam path. This process 
produces heat due to non-radiative relaxation of the chromophores. In turn, the heating 
leads to rapid thermal expansion of the surrounding tissue. This causes localized extension 
and compression of the tissue, which generates an acoustic wave.17 The initial pressure, 𝑝0, 
of the generated acoustic wave immediately after the laser pulse can be defined as follows: 
𝑝0 = 𝜇𝑎𝐹Γ (3) 
Here, 𝜇𝑎 is the absorption coefficient of the optical absorber, 𝐹 is the local optical 
fluence from the illuminated light, and Γ is the Grüneisen parameter.18 The Grüneisen 
parameter is a quantity that accounts for the volumetric thermal expansion of, speed of 
 11 
longitudinal sound waves in, and heat capacity at constant pressure of the surrounding 
medium. Under the assumption of negligible shear stress induced by the photoacoustic 
effect induced by pulsed laser light, the Grüneisen parameter is a measure of the 
thermoelastic efficiency of the medium.19 
After compensating for changes in local fluence or assuming a constant fluence, 
changes in the intensity of received PA signals are proportional to changes in optical 
absorption of local chromophores. A PA image is acquired and processed in an equivalent 
to a receive-only event on US. The receive time for a PA event is half that of an equivalent 
US event because the sound waves only need to complete a unidirectional trip towards the 
transducer. 
The choice of wavelengths for pulsed laser irradiation in PA imaging is critical. 
There are many endogenous chromophores, such as hemoglobin and fat, that have unique 
optical absorption spectra. However, it is sometimes necessary to distinguish populations 
of photoabsorbers with similar absorption characteristics, such as oxy- and 
deoxyhemoglobin. In these cases, it is necessary to acquire multiple PA images with 
different excitation wavelengths and perform spectral unmixing based on the differences 
in predicted PA signals predicated on underlying spectral characteristics of the 
photoabsorbers of interest.20,21 
2.3 Contrast-Enhanced Ultrasound/Photoacoustic Imaging 
Ultrasound is widely utilized for soft tissue imaging. However, the most significant 
deficiency of this imaging modality is that image contrast amongst soft tissues is poor due 
to the abundant subwavelength sound scattering present in tissue.22-24 This low contrast can 
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make it difficult to discern many organs or identify small lesions indicative of disease. As 
with other imaging modalities when endogenous contrast is poor, US imaging can utilize 
exogenous agents to improve imaging contrast. 
The contrast agents utilized for clinical US imaging are gas microbubbles.25 
Microbubbles have a gas core, which is typically comprised of oxygen or perfluorocarbon, 
surrounded by a biocompatible protein or phospholipid shell. In practice, microbubbles are 
injected intravenously and imaged within the vasculature. Commercial microbubbles are 
typically naïve, but microbubbles functionalized with VEGFR2 antibody have received an 
IND from the FDA and are being tested for molecularly-specific imaging of solid 
tumors.26,27 Microbubbles have multiple mechanisms for producing US contrast. First, 
microbubbles are excellent ultrasound reflectors due to their gas core and the resultant 
acoustic impedance mismatch experienced by incident ultrasound waves. Second, and 
perhaps more significant, microbubbles experience nonlinear oscillations when placed into 
an acoustic field.28 
Researchers have exploited the nonlinear oscillations of microbubbles to create 
imaging systems and sequences for contrast-enhanced ultrasound (CEUS). By transmitting 
and receiving with independent transducers, it is possible to induce microbubble 
oscillations with low frequency US and to receive their harmonic oscillatory waves with a 
high frequency transducer.29-31 In this “harmonic imaging” regime, the reflections at the 
transmit frequency are suppressed, although some biological tissue may produce harmonic 
reflections. In addition to this dual-transducer approach, a single-transducer method called 
“pulse inversion” also exploits the nonlinear oscillations of microbubbles for enhanced 
contrast.32 Pulse inversion necessitates two successive transmit and receive events with 
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inverted waveforms, which are compounded to form a single CEUS image. The underlying 
logic is similar to adding two sine waves that are 180° out of phase; these two waves will 
completely cancel when added. However, the harmonic oscillations of microbubbles are 
higher frequency than the incident US wave, and they are independent of the transmit 
phase. Therefore, when pulse inversion frames are compounded, the harmonic 
microbubble oscillations persist and are amplified. Again, tissue harmonics may confound 
the imaging results, but the magnitude of tissue harmonics is generally low. Pulse inversion 
acquisition sequences are available on many commercial US systems. 
Like US imaging, PA imaging can also benefit from the introduction of contrast 
agents. Unique contrast in PA imaging can be achieved through the use of exogenous 
optical absorbers. Spectral unmixing may also be used to differentiate endogenous from 
exogenous sources of PA contrast. However, in with exogenous absorbers it is also possible 
to design contrast agents to have unique absorption characteristics compared to biological 
tissue. Biological tissues have two “optical windows” between 650 and 1350 nm in which 
endogenous chromophores have minimal absorption.33,34 By tuning the absorption of PA 
contrast agents into one of these two windows, it is possible to achieve high imaging 
contrast without resorting to spectroscopic PA imaging. 
Because of the same underlying physical phenomenon of optical absorption, PA 
imaging shares many of its contrast agents with optical imaging. For example, plasmonic 
nanoparticles are featured prominently throughout preclinical PA imaging research.35-37 
Biocompatible dyes and dye constructs can also be used as exogenous PA contrast 
agents.38-40 In particular, indocyanine green (ICG) has FDA approval and can already be 
used for contrast-enhanced photoacoustic imaging in the clinic. In order to develop more 
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clinically relevant PA contrast agents, researchers will need to balance the need for long-
term biocompatibility and successful clearance with the need for strong and uniquely 
discernable optical absorption. 
2.4 Perfluorocarbon Nanodroplets 
Perfluorocarbon nanodroplets (PFCnDs) leverage beneficial aspects of both US and 
PA contrast agents. This class of particles was initially developed to address the 
shortcomings of microbubbles: chiefly, their relatively large average size (1+ µm) and 
short (minutes) circulation time. Kept as a liquid at physiological temperature by high 
Laplace pressure,41 PFCnDs are small enough to extravasate or to rapidly traffic through 
lymphatics prior to user-controlled activation to produce US contrast. As such, PFCnDs 
may successfully reach and be functionalized to extravascular targets. Because of their size 
relative to US wavelength and smaller difference in acoustic impedance from tissue, 
PFCnDs produce minimal contrast in their nascent, liquid-cored state. However, when 
exposed to a burst of energy, typically acoustic, the perfluorocarbon core undergoes a phase 
change. This phase-change event effectively transforms the PFCnDs into microbubbles in 
situ,42,43 which allows for traditional CEUS imaging. By encapsulating optical absorbers 
within PFCnDs, the phase-change event can be triggered with a pulse of laser light. This 
process, known as optical droplet vaporization (ODV), allows for both PA and US contrast 
to be generated by PFCnD vaporization. 
Classically, the mechanism of phase-change induction in PFCnDs was thought to 
be a result of overcoming the Laplace pressure of the nanodroplet construct with the input 
energy pulse.41,44 Laplace pressure scales inversely with the particle radius and would 
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explain the stability of PFCnDs in a liquid-cored state where the ambient temperature and 
pressure should normally dictate bulk perfluorocarbon vaporization. More recently, an 
alternate theory based on homgenous nucleation has been proposed and supported by 
experimental data.45 The homogenous nucleation theory states that suppressed vaporization 
in the PFCnD core is the result of a kinetic barrier: namely, the energy necessary for the 
chemical potential gradient to overcome the Laplace pressure-volume work.45 This occurs 
at the peak of the Gibbs free energy when plotted against radius of a vapor embryo within 
the perfluorocarbon core. When a vapor embryo of critical size forms, the entire 
perfluorocarbon core will rapidly vaporize.46-48 Unlike the Laplace pressure theory, the 
homogenous nucleation theory accurately predicts the pressure necessary to condense 
microbubbles into nanodroplets49 and the spontaneous vaporization of PFCnDs near the 
perfluorocarbon spinodal,50,51 which occurs at 80-90% of its critical temperature.52 In the 
context of these two prevailing theories, it remains to be seen if there are fundamental 
mechanistic differences in the phase changes induced by acoustic droplet vaporization 
(ADV) versus ODV. 
The phase-change behavior of PFCnDs has previously been used to provide 
contrast in multimodal imaging53,54 and to indicate cargo release in vivo.55 However, the 
vast majority of previous studies with PFCnDs have relied upon a one-time, ADV event to 
produce contrast. With an acoustic trigger, it is impossible to selectively interrogate 
distinctly targeted PFCnD populations within a single imaging acquisition. In response to 
this limitation, our group has developed a new imaging technique using optically triggered 
PFCnDs. By utilizing PFCnDs with a relatively high-boiling-point core (e.g., 
perfluorohexane [56°C] vs. perfluoropentane [28°C]) and an encapsulated near-infrared 
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photoabsorber, we are able to selectively trigger PFCnD contrast via irradiation with pulsed 
near-infrared laser light well below the ANSI safety limit.56-58 This regime allows for 
multiplexed imaging by permitting user-controlled triggering of distinct populations of 
contrast agents via tuning of the incident laser irradiation to match specific photoabsorbers 
within different groups of PFCnDs. Therefore, optically triggered PFCnDs have the 
potential to be used to interrogate multiple molecular targets to produce a true in vivo 
“optical biopsy.” 
Nanodroplets may also contain therapeutic cargo and thus be used for controlled 
drug delivery and release.42,55,59 The current clinical protocol for treating many metastatic 
solid tumors involves the surgical resection of nodes, which may lead to chronic 
morbidities.60 Conversely, diffuse metastases are typically treated with systemically 
delivered biologics and chemotherapeutics. In this case, the systemic route of 
administration leads to undesirable off-target effects, such as gastrointestinal symptoms, 
hair loss, paresthesias, and fatigue.61 Targeted PFCnDs could provide a focal means of 
image-guided, user-controlled delivery of encapsulated therapeutics to localized areas of 
disease, triggered by near-infrared laser irradiation. 
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CHAPTER 3. OPTIMIZATION OF THE SYNTHESIS AND 
DETECTION OF LASER-ACTIVATED PERFLUOROCARBON 
NANODROPLETS 
3.1 The Effect of Variable Shell PEGylation on Nanodroplet Size and Size Stability 
This subsection was adapted from: Yarmoska, S. K., Yoon, H. & Emelianov, S. Y. 
Lipid Shell Composition Plays a Critical Role in the Stable Size Reduction of 
Perfluorocarbon Nanodroplets. Ultrasound in medicine & biology 45, 1489-1499 (2019). 
3.1.1 Abstract 
Perfluorocarbon nanodroplets (PFCnDs) are phase-change contrast agents that have 
the potential to enable extravascular contrast-enhanced ultrasound and photoacoustic 
(US/PA) imaging. Producing consistently small, monodisperse PFCnDs remains a 
challenge without resorting to technically challenging methods. We investigated the impact 
of variable shell composition on PFCnD size and US/PA image properties. Our results 
suggest that increasing the molar percentage of PEGylated lipid reduces the size and size 
variance of PFCnDs. Furthermore, our imaging studies demonstrate that nanodroplets with 
more PEGylated lipids produce increased US/PA signal compared to those with the 
standard formulation. Finally, we highlight the ability of this approach to facilitate US/PA 
imaging in a murine model of breast cancer. These data indicate that, through a facile 
synthesis process, it is possible to produce monodisperse, small-sized PFCnDs. Novel in 
their simplicity, these methods may promote the use of PFCnDs among a broader user base 
to study a variety of extravascular phenomena. 
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3.1.2 Introduction 
Ultrasound is a portable, cost-effective, non-ionizing imaging modality that is 
increasingly gaining clinical traction in point-of-care clinical settings. Ultrasound image 
contrast is determined by variations in underlying tissue density and the speed of sound, 
which define the acoustic impedance to incident sound waves.5 Unfortunately, soft tissues 
have similar echogenicity,22-24 and so it is difficult to distinguish some organs or to identify 
small lesions indicative of disease using standard “B-mode” ultrasound alone. To address 
this limitation, gas microbubbles were developed for use as exogenous ultrasound contrast 
agents.62 The density and compressibility of these microbubbles allows them to oscillate 
within an applied acoustic field, leading to enhanced backscatter of incident waves to 
increase contrast in ultrasound imaging.25,63 
Although a measureable portion of particles from standard microbubble 
formulations are submicrometer in size,64,65 the fraction of these agents that produce 
perceptible echogenicity on ultrasound have diameters on the micrometer scale.28,64,66 
Therefore, these agents are practically restricted to use within the systemic vasculature. 
Their minutes-long stability within systemic vasculature notwithstanding,66-68 
microbubbles within the useable fraction are still too large to extravasate through “leaky” 
cancer neovasculature or to traffic within extravascular locations in times permissive of 
clinical imaging. In order for contrast agents to interact with tumor cells, metastases, and 
other sources of pathology, they must first reach and travel through extravascular spaces. 
Extravascular trafficking necessitates small contrast agent size. Gaps between endothelial 
cells in leaky tumor neovasculature have been reported to be between 380 to 780 nm,69-71 
and the xenograft models used to produce these estimates were likely biased towards the 
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larger side of what is observed clinically in human solid tumors.72 Similarly, though 
particles larger than 100 nm will preferentially drain to lymphatics versus blood vessels, 
particles larger than this will also exhibit size-dependent reduction in lymphatic trafficking 
speed and uptake efficiency.73-75 
 
Figure 1: Schema for Perfluorohexane Nanodroplets. A) Absorption spectrum of the 
near-infrared photoabsorber encapsulated within PFCnDs; B) A schematic of optical 
droplet vaporization (ODV). First, a laser pulse is absorbed by encapsulated 
photoabsorbers within PFCnDs (i) to induce a phase change (ii). This mechanism can 
produce contrast through both US and photoacoustic (PA) imaging (ii, insets). “High-
boiling point” perfluorocarbons, such as perfluorohexane (BP: 56°C), may recondense into 
the droplet state after the laser pulse ends (iii), allowing for repeatable contrast generation 
from the same PFCnD population (i-iii); C) Cartoon depicting extravascular imaging of a 
primary tumor with PFCnDs. Only PFCnDs smaller than the gaps between endothelial gaps 
in cancer neovasculature (blue) will be able to extravasate into the tumor stroma. Larger 
PFCnDs (red-orange) will be restricted to the vasculature.76 
To achieve the nanoscale particle size necessary for successful extravascular 
imaging, perfluorocarbon nanodroplets (PFCnDs) were created as a new class of 
ultrasound contrast agent (Figure 1A, inset).41,53 Nanodroplets are structurally similar to 
microbubbles; however, they contain a core composed of liquid perfluorocarbon instead of 
gas. This change allows PFCnDs to remain stable at the nanoscale. Because of their size 
relative to ultrasound wavelength and smaller difference in acoustic impedance from tissue, 
 20 
PFCnDs produce minimal contrast in their nascent, liquid-core state. However, when 
exposed to a burst of energy, typically acoustic, the perfluorocarbon core undergoes a phase 
change. This phase-change event effectively transforms the PFCnDs into microbubbles in 
situ,42,43 which allows for traditional contrast-enhanced ultrasound imaging. 
The phase-change event can also be optically-triggered (Figure 1B, i) by 
incorporating a photoabsorber, such as a near-infrared dye, within the nanodroplet 
construct (Figure 1A). In this case, the initial pressure waves created from PFCnD 
vaporization events can be received ultrasonically to reconstruct a high-contrast 
photoacoustic image (Figure 1B, ii).53,77 When using a “low-boiling point” 
perfluorocarbon (e.g., perfluoropentane; Boiling Point [BP]: 28°C), the PFCnD phase 
change is permanent.77,78 Conversely, PFCnDs constructed with “high-boiling point” 
perfluorocarbons (e.g., perfluorohexane; BP: 56°C) will recondense into their original 
liquid state after exposure to an energy pulse (Figure 1B, iii).58 The ability to repeatably 
induce a phase change in “high-boiling point” nanodroplets allows for more robust and 
longitudinal imaging studies with a single PFCnD population.79 
Extravascular ultrasound imaging applications with PFCnDs are predicated on the 
ability to produce a small and monodisperse nanodroplet population. In solid tumors, for 
instance, only nanodroplets that are smaller than a tumor-specific pore cutoff size will be 
able to extravasate through gaps between neovascular endothelial cells into the tumor 
stroma (Figure 1C).80 Using a monodisperse population of PFCnDs would allow for a 
higher percentage of the injected dose to reach the extravascular space, assuming the 
median size is below the pore cutoff. Additionally, the acoustic response from 
monodisperse PFCnDs would be relatively uniform, allowing for more accurate, image-
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based estimates of in vivo nanodroplet concentration. Unfortunately, many facile synthesis 
methods (e.g., sonication, extrusion) produce nanodroplets closer to 500 nm than to 100 
nm in size,42,53-55 and these larger, polydisperse droplets may be ill-suited for extravascular 
use. Several methods have been employed to achieve a stable reduction in PFCnD size and 
particle dispersity: condensation synthesis, 41,81 size-separation,82 and microfluidics.83,84 
Still, each of these methods is technically challenging and has its own weaknesses. 
Condensation synthesis, which requires the formation of stable microbubbles, 
cannot be applied practically to “high-boiling point” perfluorocarbon formulations. Size-
separation techniques have high variability in size reduction, low particle yields, and often 
require differential centrifugation, which adds time to the manufacturing process and is 
challenging to execute at scale. Microfluidic devices also have small sample yields and can 
be prohibitively expensive without local expertise in their fabrication. The ability to 
achieve PFCnD size reduction and monodispersity without these methods would facilitate 
their use amongst a broader cadre of researchers and would have the potential to place more 
emphasis on applications-based research with nanodroplets. 
In the context of these lingering challenges, we investigated the impact of 
alterations in the nanodroplet shell composition on the size of PFCnDs. We restricted this 
analysis to lipid-shelled formulations because of their strong translational benefits: chiefly, 
their demonstrable biocompatibility and well-studied linker strategies for downstream 
functionalization. Previous research notes that the yield of and ultrasound signal produced 
by nanodroplets is increased by using a higher molar percentage of unsaturated 
phospholipids.85 These same studies also describe that nanodroplets formed with 10% and 
20% molar DSPE-mPEG2000 demonstrate a solid-liquid disordered phase existence, 
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which is structurally similar to the formulations displaying the most ideal yields and 
imaging properties.85 Standard formulations for nanodroplets with acoustically-triggered 
vaporization have historically utilized no more than 10% molar PEGylated 
phospholipid.41,57,81,86 However, literature from mixed-micelles, which have similar 
structure to the lipid shells of nanodroplets, suggests that increasing the molar 
concentration of PEGylated lipids up to 90% would confer stable size reduction,87,88 
potentially due to increased steric stabilization. 
The objectives of this work were to assess the effect of varying the percentage of 
PEGylated phospholipids on the size and size distribution of lipid-shelled PFCnDs and to 
assess the impact of these changes on the ultrasound and photoacoustic contrast produced 
by the PFCnDs. Changes in the shell composition may have both direct and indirect, via 
size modulation, effects on the PFCnDs’ acoustic response. 
3.1.3 Materials and Methods 
Nanodroplet Synthesis 
Perfluorocarbon nanodroplets (PFCnDs) were synthesized using a sonication-based 
method, modified from one described by our group previously.57,58 In this protocol, 2 µmol 
of phospholipids, consisting of a mixture of DSPC and DSPE-mPEG2000 (Avanti Polar 
Lipids, Inc.), were isolated from a chloroform suspension using a rotary evaporator 
(Rotavapor R-215, Büchi AG) with water bath, adhering to the “20/40/60 Rule.” For 
PFCnDs used in imaging experiments, the evaporated chloroform suspension also 
contained 2 mg of near-infrared absorbing dye (Epolight™ 3072; Epolin, Inc.), which was 
 23 
obtained from a 2 mg/mL chloroform suspension. After a minimum of 30 minutes in the 
Rotavapor, the resulting lipid cake was allowed to dry under vacuum overnight. 
After drying, the lipids were resuspended in 1 mL of phosphate buffered saline. 
This solution was vortexed for 2 minutes and sonicated with 20 kHz ultrasound in a water 
bath sonicator (1510 Ultrasonic Cleaner; Branson Ultrasonics Corp.) at room temperature 
(25°C) in 5-minute increments until homogeneous. To this mixed micelle solution, we 
added 50 µL of perfluorohexane (FluoroMed, L.P.). The mixture was placed into an ice 
bath and positioned within a microtipped probe sonicator (QSonica). The ice-cold mixture 
was allowed to equilibrate for 5 minutes and then exposed to two rounds of probe 
sonication, one low intensity (1% power, 1 s on, 5 s off, 20 total pulses) and one high 
intensity (50% power, 1 s on, 10 s off, 5 total pulses), with 5 minutes in between sequences. 
Prior to size measurements or use in imaging, these PFCnDs were diluted 1:20 in phosphate 
buffered saline and exposed to 5 minutes of 20 kHz water bath sonication at room 
temperature to produce the final samples. 
Size Characterization 
Size characterization studies were performed on 1 mL samples of 1:1 phosphate 
buffered saline dilutions of the 1:20 dilution of PFCnDs described above. Size 
measurements were taken by a standard dynamic light scattering (DLS) instrument 
(Zetasizer Nano ZS; Malvern Instruments Ltd.) at various time points spanning from 
immediately post-synthesis to 6 hours post-synthesis. The quartz cuvette containing the 1 
mL sample was inverted immediately prior to each measurement, and the cuvette remained 
within the 25°C temperature-buffered instrument holder between measurements. After a 
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60-second sample equilibration period, the DLS instrument obtained three measurements 
at each time point, each measurement an average of 10 individual measurements. The 
measurement sequence for each time point was executed over approximately eight minutes, 
including the equilibration step. Measurement data were exported as comma-separated 
values and displayed in R (R Core Team) using the ggplot2 data visualization package. 
Absorption Characterization 
The absorption of the near-infrared dye encapsulated within the PFCnDs was 
characterized by UV-Vis spectroscopy. A UV-Vis spectrophotometer (Evolution 220; 
Thermo Scientific) was used to measure the absorbance of 1:1000 PBS dilutions of both 
unloaded PFCnDs and PFCnDs containing the near-infrared dye. The spectrum of the 
unloaded PFCnDs was subtracted from that of the dye-loaded PFCnDs, and the resulting 
differential absorption spectrum was normalized for display purposes. 
Ultrasound/Photoacoustic Imaging of Phantom 
Ultrasound and photoacoustic (US/PA) imaging was performed using an integrated 
setup described elsewhere 89. This system combines a custom ultrasound system (Vantage 
256, Verasonics, Inc.) with a tunable nanosecond pulsed Nd:YAG laser (Phocus Mobile, 
Opotek, Inc.). 
The Nd:YAG laser was used to produce pulses at the fundamental 1064 nm 
wavelength at a 10 Hz pulse repetition frequency (PRF). Within this imaging study, each 
laser pulse deposited 28 mJ of energy, resulting in a local fluence of approximately 13 
mJ/cm2. The laser pulses were delivered via optical fibers coupled to the imaging 
 25 
transducer. These fibers were oriented such that the incident light intersected the imaging 
plane at 20±3 mm in the axial dimension. 
The coupled Vantage 256 ultrasound system utilized an L11-4v (Verasonics, Inc.) 
linear array transducer, which has a −6 dB bandwidth ranging from 11 to 4 MHz. These 
imaging studies utilized a transmit center frequency of 5 MHz and a transmit voltage of 
40V. Each ultrasound frame is the result of three angularly compounded plane waves. 
These plane waves span 6 degrees (-3°, 0°, 3°) and were acquired at 3 kHz for a resulting 
ultrasound imaging frame rate of 1 kHz. 
Each imaging acquisition consisted of six packets of data. The last five packets 
were preceded by a single laser pulse. Each packet contains one photoacoustic image 
(receive only) followed by 50 ultrafast ultrasound frames, as described above. The resulting 
imaging sequence occurs over the course of 600 ms, as dictated by the 10 Hz laser PRF, 
with the resulting US/PA data acquired over the first 50 ms in each 100 ms packet. 
Imaging data were processed offline in MATLAB (Mathworks). All images were 
linearly interpolated in two-dimensions by a factor of three for display purposes. 
Quantitative values from images were obtained from the raw (i.e., non-interpolated) data. 
Imaging Phantom Setup 
The base of the imaging phantoms were created from polyacrylamide in a process 
detailed by our lab previously.58,89 In brief, 40% (w/v) acrylamide (OmniPur® Acrylamide 
Bis-acrylamide 29:1; MilliporeSigma) and 10% (w/v) ammonium persulfate (ACS Grade; 
VWR International) solutions were diluted to 10% and 0.002%, respectively, in degassed, 
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deionized water. To this solution, we added silica gel particles (40-63 µm particle size; 
MilliporeSigma) to achieve a final 1% (w/v) concentration of silica. A catalytic amount of 
TEMED (Proteomics Grade; AMRESCO Inc.) was added to initiate the crosslinking of 
aqueous acrylamide to solid polyacrylamide gel. 
Two cylindrical inclusions were made in the polyacrylamide phantom. Viewed 
from the orientation of the imaging plane, these inclusions were 5 mm in diameter, 
separated by 20 mm, and located 20 mm at depth from the top surface of the 
polyacrylamide. Then, 1 mL of the 1:20 dilution of PFCnDs described previously was 
mixed into 10 mL of ultrasound gel (Sonigel; 3B Scientific) with a 1% (w/v) concentration 
of silica. After removing air bubbles from the gel mixture via 2 minutes of centrifugation 
at 1000 rcf, the 1:200 PFCnD gel mixture was added via syringe to fill one of the empty 
inclusions in the polyacrylamide gel. Each inclusion ultimately contained gel with one of 
the batches of PFCnDs to be analyzed by US/PA imaging, as detailed above. 
Imaging data were processed offline in MATLAB (Mathworks). All images were 
linearly interpolated in two-dimensions by a factor of three for display purposes. 
3.1.4 Results and Discussion 
Nanodroplet Characterization 
We synthesized batches of PFCnDs in one of two cohorts: nanodroplets with a 
10:90 molar ratio of DSPC:DSPE-mPEG2000 and nanodroplets with a more standard 
90:10 molar ratio, hereafter referenced by these defining numeric ratios. We then obtained 
average size measurements via dynamic light scattering (DLS) over the first six hours post-
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synthesis (Figure 2). Initially, the standard formulation produced nanodroplets that were 
relatively large (median: 647 nm) and variable (Interquartile Range [IQR]: 484 nm) in size. 
Nonetheless, the minimum size observed (366 nm) was consistent with reported values 
within seminal PFCnD literature using sonication-based synthesis methods.90 Over the first 
three hours post-synthesis, the average size of the 90:10 nanodroplets trended upward, 
potentially due to Ostwald ripening.91 This hypothesis is further supported by a reduction 
in the inter-quartile range over time (137 nm by hour six). After the third hour post-
synthesis, however, the median droplet size measurement began to decrease (624 nm by 
hour six). This observed phenomenon is likely due to the spontaneous vaporization of 
larger (i.e., 1+ µm) PFCnDs within the solution.78 
 
Figure 2: Average size data for PFCnDs as a function of time post-synthesis. Each box 
represents size data from four batches of lipid-shelled PFCnDs with shells containing a 
molar ratio of 90:10 (red-orange), 50:50 (green), or 10:90 (blue) DSPC:DSPE-mPEG2000. 
For each batch at each time point, the dynamic light scattering instrument yielded three Z-
Average values for average particle size, each Z-Average an average of 10 successive 
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measurements. Samples were kept at room temperature (25°C) during and between 
measurements.76 
By comparison, the initial size of 10:90 nanodroplets was smaller (median: 159 nm) 
and more consistent between batches (IQR: 5 nm). The low variance in size persisted for 
six hours post-synthesis, though the average size measurements did trend upward (median: 
218 nm at 1 hour, 284 at 6 hours) similar to the 90:10 nanodroplets. Again, this 
phenomenon may potentially be due to Ostwald ripening of PFCnDs. Still, nanodroplets 
with an inverted molar ratio of PEGylated phospholipids remain small for an appreciable 
amount of time post-synthesis (median < 250 nm at 2 hours). This is a significant finding 
because downstream PFCnD modification protocols (e.g., bioconjugation) are time-
consuming, and the nanodroplets will grow in size over this time. Many researchers only 
report initial size measurements from their nanodroplets, and these measurements may not 
accurately reflect the ultimate size of PFCnDs used in their in vitro and in vivo experiments. 
We also investigated batches of PFCnDs with an “intermediate” molar ratio of 
DSPC:DSPE-mPEG2000 of 50:50. One might expect that the size data to fall halfway 
between the previous 90:10 and 10:90 batch data. Surprisingly, the intermediate 
nanodroplets behaved far more similarly to the 10:90 nanodroplets than to the 90:10 
nanodroplets. These nanodroplets were initially slightly larger (median: 178 nm) and more 
variable (IQR: 25 nm) than 10:90 nanodroplets. However, such differences in the data 
distributions were small, and the size distributions were effectively the same after the first 
2 hours post-synthesis. These data imply that the relationship between increased lipid shell 
PEGylation and reduced droplet size is nonlinear. It is possible that there is a critical 
concentration of PEG necessary to achieve sufficient steric stabilization such that 
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increasing PEGylation further will not have a demonstrable impact on reducing 
nanodroplet coalescence. Further study is necessary to fully characterize this relationship. 
Much of the differences in size variance at each time point, detailed through the 
interquartile ranges described previously, can be explained by differences in the batch-to-
batch variability of the different formulations tested. Both the 10:90 and 50:50 PFCnDs 
produced nearly identically sized particles batch-to-batch. However, the more traditional 
90:10 PFCnDs were highly variable batch-to-batch, from 366 to 1085 nm immediately 
post-synthesis. More detailed descriptive statistics can be found in APPENDIX A. 
Supplemental Data for Nanodroplet Synthesis Studies It is clear that increasing the molar 
percentage of PEGylated lipid reduces the size of resulting PFCnDs as well as variance 
between synthesized batches. 
This design approach is compatible with other shell modifications that could be 
implemented to further reduce the size and size variability of PFCnDs. Previous studies in 
the literature using “low-boiling point” perfluorocarbons have demonstrated an inverse 
relationship between the acyl chain length of phospholipids in the shell and the median 
sizes of resulting PFCnDs.92 How these design choices are impacted by other factors, such 
as the addition of cholesterol or unsaturated lipids into the shell, remains an active area of 
research. 
Phantom Imaging 
In addition to these sizing studies, combined ultrasound and photoacoustic (US/PA) 
imaging was performed on PFCnDs with varying shell PEGylation. A tissue-mimicking 
phantom was constructed such that two circular inclusions containing diluted batches of 
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90:10 and 10:90 PFCnDs in scattering media were visible within a single US/PA imaging 
plane (Figure 3A). Optical fibers adjacent to the imaging transducer were oriented such 
that both inclusions could simultaneously be evenly illuminated, allowing a more fair 
comparison of the two droplet populations. Because PFCnDs were loaded with a near-
infrared absorbing dye to trigger phase-change events, it was possible to analyze both 





Figure 3: Dual inclusion tissue-mimicking polyacrylamide phantom. This phantom 
was doped with 1% (w/v) silica gel and containing two inclusions with 1:200 stock 
dilutions of “10:90” (left, blue circle; average size: 170 nm at 0 hours post-synthesis) and 
“90:10” (right, red-orange circle; average size: 470 nm at 0 hours post-synthesis) PFCnDs. 
A) Plane-wave B-mode ultrasound image prior to PFCnD laser activation. Three 
successive plane waves (at -3°, 0°, and 3°, respectively) were compounded to create each 
ultrasound image. This image is normalized, interpolated, and displayed using a 40 dB 
dynamic range. Scale bar is 5 mm; B) Absolute differential ultrasound image immediately 
post-laser pulse. Each differential ultrasound image was generated by taking the absolute 
value of the forward-looking difference of the linear ultrasound signal after compounding 
each unique ultrasound frame. This image is interpolated and displayed over a linear scale; 
C) Photoacoustic image immediately post-laser pulse. This image is normalized, 
interpolated, and displayed using a 22 dB dynamic range.76 
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The resulting imaging data were divided into six distinct packets: one without a 
pre-acquisition laser pulse and five with a pre-acquisition near-infrared laser pulse. 
Examining the differential ultrasound signal (Figure 3B) as a function of time reveals 
spikes in intensity within the inclusions immediately after the laser pulse (Figure 4A), 
which are characteristic of the repeatable vaporization-recondensation or “blinking” of 
perfluorohexane nanodroplets.58 This differential signal returns to baseline for both 





Figure 4: Nanodroplet US/PA analysis. A) Absolute linear differential ultrasound signal 
as a function of time for the phantom shown in Figure 3. The differential ultrasound signal 
was integrated across an area-equivalent region of interest containing the “10:90” PFCnDs 
(red-orange), the “90:10” PFCnDs (blue), and a control region centered within the 
polyacrylamide gel background in between the two inclusions (gray). Discontinuities 
within the graph correspond to times when no data are acquired by the US/PA imaging 
sequence; B) Absolute linear differential ultrasound signal post-laser pulse integrated 
across the “10:90” (blue) and “90:10” (red-orange) PFCnD inclusions; C) Linear 




Analyzing the integrated differential ultrasound signal within each inclusion from 
the post-laser-pulse frames, the total signal from 10:90 PFCnDs is 1.5 times the total signal 
from 90:10 PFCnDs (Figure 4B). In plane-wave B-mode ultrasound, the backscattered 
signal (𝑃𝑈𝑆) received from a region of interest containing PFCnDs is proportional to the 
total en face surface area of nanodroplets (𝑛𝑃𝐹𝐶𝑛𝐷𝑠 ∙ 𝑆𝐴𝑃𝐹𝐶𝑛𝐷) encountered by plane waves 
travelling through the region. That is to say, 
𝑃𝑈𝑆 = 𝑃𝑃𝐹𝐶𝑛𝐷𝑠 ∝ 𝑛𝑃𝐹𝐶𝑛𝐷𝑠 ∙ 𝑆𝐴𝑃𝐹𝐶𝑛𝐷 (4) 
Batches of both the 10:90 and 90:10 PFCnDs were synthesized with equivalent molar 
concentrations of perfluorocarbon and surfactant phospholipids. Assuming that the amount 
of surfactant is non-limiting, the number of droplets within each batch should be inversely 
proportional to the cube of the diameter of the PFCnDs because the total volume of 
perfluorocarbon (𝑉𝑃𝐹𝐶) is constant between batches and, 
𝑉𝑃𝐹𝐶 = 𝑛𝑃𝐹𝐶𝑛𝐷𝑠 ∙ 𝑉𝑃𝐹𝐶𝑛𝐷 = 𝑛𝑃𝐹𝐶𝑛𝐷𝑠 ∙ (4 3⁄ )𝜋(𝑑 2⁄ )
3 (5) 
because the surface area of a droplet is proportional to the square of its diameter, combining 
Equations (4) and (5) would imply that the signal from PFCnDs in these experiments 
should be inversely proportional to the corresponding droplet diameter (𝑑). Theoretically, 
this suggests that there should be approximately 2.8 times the signal from the inverted 
PFCnD inclusion than the standard PFCnD inclusion.  
The 1.5-fold enhancement observed is much less than the theoretical one. Because 
the synthesis is sonication-based, it is likely that the total volume of perfluorocarbon is not 
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conserved, as some nanodroplets will be vaporized by the 20 kHz ultrasound during 
sonication, which would lead to a decrease in the observed contrast enhancement. 
Additionally, the quoted droplet diameters were for immediately post-synthesis PFCnDs, 
prior to incorporation into gel mixtures for imaging. It is possible that the nanodroplets 
continued to grow in size, as observed in Figure 2, after synthesis but prior to imaging. 
Since the size of 10:90 nanodroplets trends much larger relative to their initial size, this 
could reduce the size ratio used to predict theoretical signal enhancement. 
As aforementioned, the laser-activated PFCnDs used for imaging also produce a 
photoacoustic signal, which can be visualized independently for contrast enhancement 
(Figure 3C). The photoacoustic signal produced from nanodroplets can be attributed to 
two distinct components.53 The first component is due to the pressure wave created by the 
optical droplet vaporization (ODV) and the resulting volumetric expansion. Because the 
partial derivative of spherical volume in the radial direction is equivalent to surface area, 
the resulting pressure of this component follows the logic of the ultrasound signal 
enhancement detailed previously. 
If volumetric expansion were the only component of the photoacoustic signal 
emitted by PFCnDs, then the signal enhancement for 10:90 nanodroplets should be 
equivalent across ultrasound and photoacoustic imaging. However, experimentally the 
photoacoustic signal enhancement is higher: 2.2 for photoacoustic signal (Figure 4C) 
versus 1.5 for differential ultrasound (Figure 4B). One potential explanation for this 
observation is the photoacoustic signal emitted from the encapsulated photoabsorber, 
which is the second component of laser-activated PFCnD photoacoustic signal.53 A study 
in mixed micelles demonstrated that water-insoluble drugs have increased solubility in 
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DSPE compared to DSPC.93 Similar logic would suggest that inverted nanodroplets, with 
an appreciably higher DSPE shell content, should solubilize more of the water-insoluble, 
near-infrared photoabsorber and may be preferable for encapsulating non-polar 
therapeutics when using PFCnDs for applications in controlled delivery and release. 
In conclusion, we have investigated the effects of variable lipid shell composition 
on the particle and imaging characteristics of lipid-shelled, laser-activated PFCnDs. Our 
results suggest that increasing the molar concentration of PEGylated phospholipid 
compared to standard formulations reduces the size and size variability of nanodroplets. 
Additionally, our imaging studies demonstrate that nanodroplets from batches with an 
inverted molar ratio of lipids produce increased ultrasound and photoacoustic signal 
compared to batches of 90:10 nanodroplets, likely because of increased total surface area 
and dye encapsulation in 10:90 nanodroplets. 
These data confirm that it is possible to produce small-sized, monodisperse 
PFCnDs without the need for more involved synthesis strategies. We also note that the 
strategy of increased shell PEGylation is not mutually exclusive with alternative 
approaches: it could potentially be combined with others (e.g., size separation, 
microfluidics, acyl chain elongation) to further tune PFCnD size or percent yield. Although 
these studies utilized nanodroplets for US/PA imaging, the dynamic contrast of these 
agents could potentially be used with optical coherence tomography,94 magnetic resonance 
imaging,95,96 and other techniques that can use microbubbles or perfluorocarbon for 
contrast generation. Moving forward, we anticipate that the shell-focused strategy for 
PFCnD synthesis will facilitate the use of PFCnDs amongst more investigators in a wide 
array of applications-based research endeavors. 
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3.2 Pulse-Inversion-Based Imaging for Enhanced Imaging Sensitivity to Optically-
Activated Nanodroplets 
Adapted, with permission, from: Zhu, Y.I., Yarmoska, S. K. & Emelianov, S. Y. 
Pulse-Inversion-Based Imaging for Repeatable Optically Activate Phase-Change 
Nanodroplets with Enhanced Sensitivity and Specificity. Submitted. 
Yiying Zhu was responsible for image acquisition and processing. Steven Yarmoska 
was responsible for synthesis and all other primary data generation. 
3.2.1 Abstract 
Optically-activated perfluorohexane nanodroplets (PFHnDs) can vaporize, 
providing ultrasound contrast, and then stochastically recondense into liquid droplets. 
Their repeatable activation and random recondensation enables super-resolution imaging 
and longitudinal contrast-enhanced ultrasound. However, imaging sensitivity and 
specificity are critical for the detection of these small-sized contrast agents. To address this 
challenge, we introduced the method of ultrafast planar pulse-inversion ultrasound imaging 
together with the analysis of PFHnD echogenicity dynamics to improve the detection of 
optically-activated PFHnDs. We demonstrated this imaging method in a tissue mimicking 
phantom and in an in vivo mouse spleen to achieve PFHnD-specific imaging. 
3.2.2 Introduction 
An emerging class of ultrasound contrast agents, perfluorocarbon nanodroplets 
(PFCnDs), has been explored to overcome the size limitations of microbubbles. These 
nanodroplets are synthesized with a liquid perfluorocarbon core and are produced to be in 
 38 
the submicrometer range. Traditional nanodroplets can undergo a one-time activation to 
form gas microbubbles in situ, providing ultrasound contrast after they reach extravascular 
targets.97 Repeatable activated nanodroplets, optically triggered phase-change  
perfluorohexane nanodroplets (PFHnDs),98 have been investigated to provide multiple 
activations per particle. Upon pulsed laser irradiation, photoabsorbers encapsulated within 
the PFHnDs cause localized heating, vaporizing the PFHnDs into gas bubbles. These 
vaporized PFHnDs temporarily behave like microbubbles, providing transient ultrasound 
contrast. Then, within microseconds, vaporized PFHnDs spontaneously recondense to their 
naïve droplet form, ready to be triggered again to serve as contrast agents. PFHnDs are 
theoretically small enough to escape leaky tumor neovasculature and can be targeted to 
extracellular markers that are not expressed on the endothelium. Also, optically-activated 
PFHnDs can produce photoacoustic contrast because of the mechanism used to trigger their 
phase change.99 Additionally, the ability of PFHnDs to be repeatably triggered due to their 
high boiling point perfluorohexane core enables both ultrasound super resolution 
imaging100 and longitudinal tracking by contrast-enhanced ultrasound.101 
One of the greatest challenges in PFHnD-enabled contrast-enhanced ultrasound 
imaging is low imaging sensitivity and low specificity to PFHnDs. These PFHnDs are 
designed to be small for extravasation, which also introduces two major challenges in 
imaging them. First, the backscattered ultrasound signals from PFHnDs are weak compared 
to those of microbubbles, due to their relatively reduced cross-sectional area. This 
challenge demands a high imaging sensitivity to capture the presence of PFHnDs. Second, 
due to their extravascular location, PFHnDs are present in a hyperechoic tissue 
environment. Compared to traditional vascular imaging, in which the background is 
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relatively anechoic, extravascular imaging requires high imaging specificity to differentiate 
PFHnDs from enhanced background signal.   
Fortunately, optically triggered PFHnDs exhibit unique ultrasound echogenicity 
due to their vaporization-recondensation behavior. First, nascent liquid-cored PFHnDs 
weakly scatter ultrasound, appearing hypoechoic in an ultrasound image. Immediately after 
optical activation, however, vaporized PFHnDs become hyperechoic under ultrasound, 
similar to traditional gas microbubbles. Ultrafast ultrasound imaging can capture the 
transient echogenicity associated with PFHnDs that shows an exponential decaying trend, 
which is distinctive from the background. Previously, we have found that the PFHnD 
echogenicity dynamics can be manipulated by the ultrasound imaging sequence.102 
Different phases of the imaging pulse lead to different responses from PFHnDs in 
ultrasound images, including changes in ultrasound signal intensity and echogenicity 
dynamics. Based on these observations, we moved forward to design a new imaging 
method that can image PFHnDs with high sensitivity and specificity. 
Here, we present an imaging method utilizing ultrafast planar pulse-inversion 
ultrasound imaging together with PFHnD echogenicity dynamics to improve the detection 
of optically activated PFHnDs. This method includes the following three components. The 
first is a pulse-inversion imaging sequence with acquisition including both fundamental 
and second-harmonic signals. Specifically, we transmit interleaved pulses with opposite 
phases (i.e., pulse inversion imaging): a pulse with an initial rarefactional phase is 
immediately followed by a pulse with an initial compressional phase.102 The summation of 
echoes from the inverted pulses helps to suppress linearly scattering background. Second, 
we perform differential imaging in the time domain (i.e., subtracting adjacent ultrasound 
 40 
frames) in order to further suppress static background signals. Finally, a PFHnD map is 
created by image processing, resulting in an exponential decay constant map reconstructed 
from exponential fitting for each image pixel over time. We have demonstrated this 
imaging method in a tissue mimicking phantom and an in vivo mouse spleen to achieve 
PFHnD-specific imaging. 
3.2.3 Materials and Methods 
Synthesis of PFHnDs 
The PFHnDs consisted of a perfluorohexane core, a stabilizing lipid shell, and an 
encapsulated dye, and they were synthesized following a protocol adapted from previous 
studies.76,103 Briefly, 1 µmol of DSPC, 18:0 Cy5 PE, and DSPE-mPEG2000 (all from 
Avanti Polar Lipids, Inc.) were isolated in a 1:1:8 molar ratio along with 0.5 mg of near-
infrared-absorbing dye (IR-1048; Sigma-Aldrich) from a chloroform solution using a 
rotary evaporator. After rotary evaporation produced an even cake of lipid and dye, the 
solid isolate was further dried under nitrogen flow in order to evaporate all residual 
chloroform. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and agitated 
using a water bath sonicator to produce a solution of dye-loaded nanomicelles. This 
solution was centrifuged at 300 rcf for 1 minute in order to pellet excess near-infrared dye. 
Then, 900 µL of the nanomicelle-containing supernatant was combined with 100 µL of 
PBS and 50 µL of perfluorohexane. This solution was then probe sonicated (1s on, 15s off, 
5 times) on ice in order to produce a stock solution of PFHnDs, which was stored 
refrigerated in amber glass prior to use. 
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Prior to their use for imaging, 100 µL of PFHnDs were diluted in 2 mL of PBS and 
bath sonicated for 5 minutes. This solution was then centrifugated at 3000 rcf for 5 minutes 
in order to pellet the PFHnDs. The supernatant was removed and the PFHnDs were 
reconstituted in 100 µL of sterile saline for imaging. This protocol produces PFHnDs with 
an average hydrodynamic diameter of 244 nm measured via dynamic light scattering 
(Zetasizer Nano ZS; Malvern Instruments Ltd.) and at a concentration of approximately 
1010 PFHnDs/mL as assessed by nanoparticle tracking analysis (NanoSight NS300; 
Malvern Panalytical). 
Tissue Mimicking Phantom 
A tissue-mimicking phantom containing three hollow cylindrical inclusions was 
fabricated to demonstrate the imaging sequences. To construct this phantom, 150 mL of 
degassed water was mixed with 50 mL of 40% acrylamide (Thermo Fisher Scientific) and 
set to mix on a stir plate at 350 rpm. To this stirring solution, 2 mL of 10% (w/v) ammonium 
persulfate solution (Sigma-Aldrich, St. Louis, MO, USA) and 400 mg of silica particles 
(product number: 717185; Sigma-Aldrich) were added.  Next, 250 μL of N, N, N′, N′-
Tetramethylethylenediamine (Alfa Aesar, Thermo Fisher Scientific) was added to 
crosslink the acrylamide.  The primed solution was allowed to continue stirring for 9 
minutes before being quickly poured into a rectangular 58 x 58 x 78 mm mold. The 
resultant solution polymerized within 60 seconds of being transferred into this mold. 
The three hollow inclusions were filled with ultrasound gel containing either 0.2% 
w/v silica particles, 1% v/v (PFHnDs to gel) of the as-prepared PFHnDs, or a mixture of 
both 0.2% w/v silica particles and 1% v/v of the as-prepared PFHnDs. In order to 
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homogenize the inclusion components, silica and/or PFHnDs were added to de-gassed 
ultrasound gel, vigorously mixed by hand, and then centrifugated at 1000 rcf for 2 minutes. 
The resultant homogenous gel solutions were backfilled into the hollow inclusions using 1 
mL slip tip disposable syringes. 
Mouse Preparation 
All small animal experiments were conducted under the purview of Georgia Tech’s 
Institutional Animal Care and Use Committee (GT IACUC; Protocol A16018). A five-
month-old BALB/c mouse (Strain 028; Charles River Laboratories) was placed under 
general anesthesia with isoflurane (5% induction, 1.5-2% maintenance) prior to the 
following interventions. 
The mouse was placed on a heating pad set to 38°C to help maintain its internal 
body temperature while under general anesthesia. The skin overlying the neck and spleen 
of the mouse was shaved and chemically depilated with calcium hydroxide lotion. The 
mouse was placed in the right lateral decubitus position and its spleen was imaged as 
detailed above. 
After preliminary imaging, the skin of the mouse neck was disinfected and 50 uL 
of PFHnDs, prepared for imaging as described previously, were injected intravenously in 
the right jugular vein. After 20 minutes, the mouse was again placed in the right lateral 
decubitus position and its spleen was imaged a second time. 
After post-injection imaging, the mouse was euthanized via a lethal intraperitoneal 
injection of Euthasol (150 mg/kg; Henry Schein Medical). Following cessation of 
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breathing, the mouse was exsanguinated via perfusion with 6.80 pH PBS and fixed by 
perfusion with 4% paraformaldehyde. After perfusion-fixation, the spleen of the mouse 
was resected, placed into an OCT-filled cryomold (both Sakura Finetek), and flash frozen 
under dry ice. 
Mouse Spleen Histology 
The flash-frozen spleen was sectioned longitudinally and frozen sections were 
stored at -80°C. Prior to confocal imaging, slides were thawed and rehydrated with 7.40 
pH PBS. After incubation with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride; 
Invitrogen, Thermo Fisher Scientific), slides were again washed with PBS, mounted with 
antifade reagent (ProLong Gold Antifade Mountant; Invitrogen), and sealed. 
Mounted sections were imaged on a Zeiss laser scanning microscope consisting of 
an LSM 700 scan head mounted on an AxioObserver Z1 inverted microscope stand with a 
motorized stage. Images were obtained with laser lines at 405 and 639 nm using a 20x / 0.8 
N.A. Plan Apochromat objective lens with a working distance of 0.550 mm. 
Imaging System and Imaging Sequences 
The imaging was performed by an ultrasound linear array transducer CL15-7 
(Advanced Technology Laboratories, Inc.) integrated with an optical fiber bundle (Nanjing 
Chunhui Science & Industrial Co., LTD). The imaging probe was acoustically coupled 
with the imaging object using clear ultrasound gel.  The optical fiber bundle, connected to 
a pulsed laser system (Phocus Mobile; Opotek Inc.) operating at 1064 nm wavelength, was 
used to irradiate the phantom with 5-ns laser pulses at a pulse-repetition rate of 10 Hz.  The 
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estimated fluence at the depth of 5 mm, measured by a laser power meter (Nova II; Ophir-
Spiricon, LLC), was 60 mJ/cm2 (± 5% allowance). To image, the ultrasound transducer 
was driven at a 7 MHz center frequency using a programmable research ultrasound imaging 
system (Vantage 256; Verasonics, Inc.). The full imaging window was 22.8 mm wide and 
25 mm deep. Immediately following each laser pulse, one photoacoustic image was 
captured. Then, 0-degree planar ultrasound waves were transmitted at a pulse repetition 
frequency of 10 kHz for the phantom imaging and 8 kHz for mouse imaging. Two 
ultrasound imaging sequences were used for ultrafast plane-wave imaging.  One, denoted 
as “N-sequence,” had had an initial rarefactional phase followed by a compressional phase. 
The other one, referred to as “NP-sequence,” transmits pulses with opposite phases (i.e., 
pulse inversion imaging): first pulse with an initial rarefactional phase followed by a 
compressional phase and second pulse with an initial compressional phase. The received 
waves were sampled at 56 MHz to include both fundamental and second harmonic 
components of the ultrasound echoes. All data were saved and processed offline in 
MATLAB (MathWorks). 
Image Processing and Quantitative Analysis 
To form contrast-enhanced ultrasound images, the received beamformed images 
were processed as follows. For the N-sequence, the 10 kHz images were subtracted from 
the adjacent frames to get a series of differential images. For the NP-sequence, adjacent 
two ultrasound frames were first summed to form a new series of background-suppressed 
images. This new set of images were subtracted from the adjacent ones to get a series of 
differential images.    
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We processed the first-frame images to compute the signal-to-noise ratio (SNR) 
and PFHnD detection rate to compare the imaging sensitivity from two different imaging 
sequences. Specifically, a PFHnD mask was obtained for each first-frame image by 
identifying the image pixels that had 6 dB higher signal than the averaged background 
noise signal within the inclusion. The SNR was calculated by dividing the average signal 
from the PFHnD mask by the average background noise signal. The PFHnD detection rate 
was defined as the ratio of the pixel number in the PFHnD mask divided by the total pixel 
number within the inclusion, with the assumption that the inclusion was filled with 100% 
PFHnDs.  
The final PFHnD specific imaging was achieved by performing double differential 
ultrafast ultrasound imaging after one laser activation to identify PFHnD related decaying 
behavior. An exponential decay function was fit to the value of each image pixel as a 
function of time. A decay constant map was then constructed for one imaging sequence as 
a PFHnD indicator. The PFHnD map overlaying the conventional B-mode image resulted 
in final PFHnD specified imaging. 
3.2.4 Results and Discussion 
Tissue Mimicking Phantom Imaging 
The first-frame images after optical activation for the silica-only inclusion and the 
inclusion containing both silica and PFHnDs are shown in Figure 5 for both the N-
sequence and NP-sequence. It is clear that the contrast from optically triggered PFHnDs is 
not separable from the scattering background under conventional imaging, but the 
inclusions containing PFHnDs are separable by differential imaging. In differential 
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imaging of the silica and PFHnD containing inclusion, the SNRs are 33.9 dB and 39.2 dB 
with detection rates of 20.5% and 67.9% for the N-sequence and NP-sequence, 
respectively. The NP-sequence detects about three times the number of PFHnDs with 
double the SNR compared to the N-sequence. 
 
Figure 5: N-sequence versus NP-sequence US imaging of a phantom. First-frame 
conventional US images and differential US (δ US) images are shown for the N-sequence 
(A) and NP-sequence (B). Dashed contours indicate the silica-only inclusion (orange) and 
the inclusion filled with a mixture of silica and PFHnDs (green). The NP-sequence 
demonstrates a 5-dB SNR improvement and over triple the PFHnD detection rate of the N-
sequence.  Images are displayed on a 40-dB dynamic range. 
The ultrafast differential ultrasound image series for PFHnDs after one optical 
activation imaged by the NP-sequence shows a unique disappearing behavior (Figure 6). 
Image pixels related to regions containing PFHnDs exhibit exponentially decaying 
ultrasound signals, with an example shown in Figure 7A. PFHnD maps for the PFHnD-
only inclusion and silica-only inclusion are constructed from each ultrasound image series 
after one laser activation and displayed in Figure 7B. 
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Figure 6: Decay in PFHnD signal post-lasing. An ultrafast differential US (δ US) image 
series after one optical activation for the PFHnD-only inclusion (top row) and the silica-
only inclusion (bottom row) using the NP-sequence. Blue and orange contours indicate the 
PFHnD-only and silica-only inclusions, resspectively. PFHnDs show a characteristic 
signal enhancement followed by a rapid decay post-lasing, whereas the silica-only 
background is statically non-enhancing. All images are displayed on a 40-dB dynamic 
range. 
 
Figure 7: An example of US signal decay used for PFHnD mapping. A) Normalized 
intensity over time for representative image pixels from the PFHnD and silica inclusions 
displayed in Figure 6; B) Images of the PFHnD-only and silica-only inclusions from Figure 
6. Blue and orange contours indicate the PFHnD-only and silica-only inclusions, 
respectively. The first column shows conventional US images. The second shows PFHnD 
maps reconstructed from exponential decay constants. The third column overlays these 
maps on the US images. B-mode images are displayed on a 40-dB dynamic range. 
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The unique ultrasound echogenicity decay associated with imaging PFHnDs, as 
shown in Figure 7, grants us opportunities to differentiate them from other scatters via 
differential imaging. Ideally, static linear scatters respond to successive ultrasound imaging 
pulses the same way. Therefore, their signals can be completely cancelled by subtracting 
adjacent ultrasound images. In contrast, the decaying signals from PFHnDs will have 
residual signal remaining after the subtraction of adjacent ultrasound frames. In our ideal 
tissue mimicking phantom, differential imaging could successfully separate PFHnDs from 
background silica. It is worth mentioning that this unique decaying behavior may relate to 
the acoustic interaction with the pulse inversion imaging sequence. More investigation is 
needed to understand the underlying physics of PFHnDs’ recondensation process after 
optical triggering and PFHnDs’ interaction with ultrasound when being imaged. 
By performing differential imaging, either once or multiple times, optically 
triggered PFHnDs can be separated from background, yielding PFHnD contrast enhanced 
imaging. This differential imaging operation can also be easily implemented for real-time 
imaging. It is possible to threshold those images from differential imaging to create PFHnD 
masks. The additional exponential decay constant map we presented imposed one more 
parameter, the decay constant, to isolate PFHnD behavior. For example, in Figure 4, some 
hyperechoic regions in the PFHnD only inclusion are not detected by PFHnD map because 
those regions contain stable gas bubbles, which do not exhibit decaying echogenicity 
dynamics. The imaging application will ultimately dictate the most appropriate method for 
PFHnD contrast enhancement. For example, for real-time PFHnD particle trafficking 
tracking, real-time differential imaging may be more favorable. In contrast, PFHnD drug-
loaded delivery may benefit from decay constant mapping to accurately specify PFHnDs 
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to correlate with drug delivery efficiency. In addition, other than providing ultrasound 
contrast, optically triggered PFHnDs also give photoacoustic signals upon laser activation. 
Photoacoustic imaging is another dimension to explore for optically triggered PFHnD 
related applications. 
Murine Spleen Imaging 
The in vivo imaging of PFHnDs introduces new challenges compared to the ideal 
phantom case. Here, ultrasound refection at the skin layer in the mouse results in residual 
signal after differential imaging (Figure 8A). By introducing second differential imaging 
(i.e., subtracting adjacent differential images the second time), these background signals 
are suppressed, as shown in Figure 8B, while retaining contrast in the spleen. The diffuse 
distribution of PFHnDs in the spleen 20 minutes after IV delivery, as shown in the second 
differential image, is confirmed by histology (Figure 8F). As demonstrated in this proof-
of-concept in vivo experiment, the unique echogenicity decaying feature of PFHnDs may 
be retained after multiple differential operators, allowing improved discrimination versus 
other time-varying signals. It may also be possible to identify PFHnDs with one-time 
differential imaging by comparing pre-injection and post-injection images. 
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Figure 8: Results from the in vivo mouse spleen imaging experiment. Images were 
taken 20 minutes post-IV injection of PFHnDs. A blue contour indicates the spleen on 
images. A) Differential ultrafast US images (δ US) over time; B) second differential 
ultrafast US images (δ2 US) over the same time; C) Corresponding conventional US image 
of the spleen; D) PFHnD map reconstructed from exponential decay constants derived from 
δ2 US data; E) PFHnD map overlaid on the conventional US image; F) Histology of the 
mouse spleen. Blue signal is from DAPI-labeled cells and red signal is from Cy5, which 
tagged the IV-injected PFHnDs. B-mode images are presented on a 40-dB dynamic range. 
In conclusion, we have demonstrated a new method leveraging pulse-inversion 
imaging and differential imaging of PFHnDs to increase sensitivity and take advantage of 
PFHnD echogenicity dynamics for specificity improvement. The pulse-inversion-based 
sequence we presented has higher imaging sensitivity by detecting about three times the 
number of PFHnDs with double the signal to noise ratio compared to conventional one-
pulse imaging. This result has direct implications for background-free contrast-enhanced 
ultrasound imaging of PFHnDs and can be further developed for eventual use with 
molecular imaging involving PFHnDs. 
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CHAPTER 4. PERFLUOROCARBON NANODROPLETS FOR 
LYMPHATIC IMAGING AND THERAPEUTIC APPLICATIONS 
4.1 Longitudinal Imaging of Perfluorohexane Nanodroplets Trafficking Within 
Regional Lymphatics in Breast Cancer 
4.1.1 Abstract 
Optically triggered perfluorocarbon nanodroplets (PFCnDs) are a phase-change 
class of ultrasound and photoacoustic (US/PA) contrast agent that are stable at 
submicrometer sizes. Upon laser irradiation, near-infrared dye encapsulated within the 
PFCnDs absorbs, causing a phase change of the fluoroalkane core to create microbubbles 
in situ. In this way, PFCnDs have the transport characteristics of a small particle while 
retaining the imaging contrast properties of a large particle. One biological system where 
the transport characteristics of PFCnDs are advantageous is the lymphatics. In contrast to 
traditional micrometer-sized gas microbubbles used with US imaging, the submicrometer 
size of these agents means that they are rapidly transported through the lymphatic vessels. 
This makes PFCnDs a more ideal US/PA contrast agent for use in analyzing transport and 
delivery within the lymphatic system. However, more common formulations of PFCnDs 
use low boiling point fluoroalkane cores, such as perfluoropentane, with bulk boiling points 
on the order of or below physiological temperature. These formulations will vaporize into 
stable microbubbles after a single input of energy, which impairs longitudinal imaging of 
a single injected bolus. It also hampers the implementation of PFCnDs in lymphatic 
imaging, because large-animal lymphatic trafficking times are variable and phase-changed 
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PFCnDs have unfavorable transport characteristics. In response to this limitation, we 
developed perfluorohexane nanodroplets (PFHnDs), which can repeatably vaporize and 
recondense at physiological temperatures in response to multiple laser pulses. This feature 
allows PFHnDs to retain the transport characteristics of their submicrometer liquid-cored 
state while supporting US/PA imaging at multiple timepoints. To demonstrate the utility 
of PFHnDs for longitudinal contrast-enhanced US/PA imaging, we imaged naïve and 
tumor-bearing mice longitudinally over 24 hours. We developed a computationally 
straightforward algorithm to leverage ultrafast US dynamics to highlight regions of PA 
contrast with a high probability of containing optically triggered PFHnDs. Our resulting 
imaging data show focal enhancement moving through ipsilateral lymphatics around the 
draining lymph node in both naïve and tumor-bearing animals. Histological data confirm 
the draining path of PFHnDs. We also explored confounding factors in the resulting US/PA 
contrast, and future studies will work to minimize these false-positive results. In total, these 
proof-of-concept data lay the foundation for using PFHnDs to longitudinally monitor 
transport and delivery in a variety of biological applications. 
4.1.2 Introduction 
The lymphatic system is critical in maintaining fluid homeostasis, mounting an 
effective immune response, and absorbing dietary lipids.104 Dysregulation of the 
lymphatics can lead to lymphedema, for which curative clinical interventions are currently 
lacking.105 Modulation of the lymphatics, both in terms of their flow and immune function, 
is also a hallmark of metastasis in most solid tumors.106,107 Sentinel lymph node metastatic 
status offers important prognostic information to patients with breast cancer,108 
melanoma,109 and other solid neoplastic diseases.110,111 Furthermore, since the advent of 
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immunotherapy, tumor-draining lymph nodes (TDLNs) have gained increased interest as 
a control point for training the adaptive immune response on tumor antigens.112 For these 
and other reasons, there is a renewed fervor to investigate both the basic science governing 
and therapeutic interventions within the lymphatic system. 
Much of the basic and translational research within the lymphatic system involves 
analysis of flow and bulk transport through the lymphatics. To date, these analyses have 
been accomplished through the use of near-infrared tracers and histology.113,114 While near-
infrared tracers provide a facile means of tagging and tracking small molecules, their 
fluorescent imaging has limited depth penetration and resolution.115 Histology is a gold-
standard technique, but the use of histology precludes a true longitudinal analysis. 
Additionally, for preclinical research, the interim sacrifice of animals for histology may 
not be a viable strategy to assess transport longitudinally in large-animal models, where 
lymphatic structures are more individually variable.116 To assess lymphatic transport and 
function, it may be necessary to employ other imaging techniques. 
One such technique is ultrasound (US) imaging. Ultrasound is a non-ionizing 
imaging technique with clinical traction in point-of-care settings. Ultrasound can image at 
maximum depths of one to tens of centimeters, depending on transducer hardware. 
Additionally, with the integration of a pulsed laser light source, US systems can also 
perform photoacoustic (PA) imaging. Photoacoustic imaging relies on the photoacoustic 
effect, a phenomenon reminiscent of “lightning and thunder.” Photons of input pulsed laser 
light (“lightning”) are absorbed by chromophores. This causes localized heating and 
thermal expansion, which leads to a pressure wave (“thunder”) that can be detected and 
formed into an image by conventional ultrasound hardware. Photoacoustic images are 
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ultrasound-like images with contrast based not on variations in tissue density but on 
variations in tissue optical absorption. Because US and PA images can be simultaneously 
acquired and co-registered, PA imaging provides complementary information to that 
afforded by traditional ultrasonography. 
In order to analyze flow via imaging, a contrast agent is typically necessary for use 
as a tracer. In US, gas microbubbles are the clinically approved contrast agent of choice. 
These biocompatible agents produce excellent imaging contrast, but their relatively large 
(1+ µm) size makes them ill-suited for draining in the interstitium and lymphatics without 
mechanical assistance.117 In PA imaging, dyes and plasmonic nanoparticles are the most 
prevalent exogenous contrast agents. These agents’ small size means that they are rapidly 
transported through the lymphatics.75 However, agents that are too small will be resorbed 
into the bloodstream,75 and there are lingering concerns about the long-term biological 
clearance of larger plasmonic nanoparticles from the body. An ideal contrast agent for 
lymphatic imaging with US would leverage both the imaging contrast and biocompatibility 
of microbubbles and the transport characteristics of smaller particles. 
Perfluorocarbon nanodroplets (PFCnDs) are a preclinical phase-change class of 
ultrasound and photoacoustic (US/PA) contrast agent that were developed to satisfy these 
design constraints.41,53 Nanodroplets utilize the same biocompatible shell components as 
gas microbubbles, but they substitute the gas core material for one of fluoroalkane. The 
submicrometer size of PFCnDs keeps the fluoroalkane core in a liquid state at physiologic 
temperatures.51 In this nascent liquid-cored state, PFCnDs produce imperceptible US 
contrast. However, when exposed to a pulse of acoustic or optical energy, the fluoroalkane 
core vaporizes.53,86 This vaporization event effectively transforms the PFCnDs into 
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microbubbles in situ.41 If the vaporization was triggered via laser irradiation, then this event 
also produces PA contrast.53 
Traditional PFCnD formulations utilize a “low-boiling point” (e.g., 
perfluoropentane; BP: 28°C) perfluorocarbon core.41,118,119 When these agents change 
phase in situ, the phase-change is permanent, as the resulting microbubbles are stable at 
physiologic temperatures. This precludes longitudinal imaging of a single injected bolus. 
It also stymies the implementation of PFCnDs in lymphatic imaging. Large-animal 
lymphatic architecture and trafficking times are variable, and phase-changed PFCnDs have 
unfavorable transport characteristics. To address these shortcomings, we propose the use 
of optically triggered perfluorohexane nanodroplets (PFHnDs).58 These PFHnDs change 
phase in response to pulses of near-infrared laser light. However, because they have a core 
of perfluorohexane (BP: 56°C), PFHnDs will stochastically recondense into their original 
liquid-cored state after the laser pulse ends.57 A single PFHnD can repeatedly change phase 
in response to a train of laser pulses, facilitating longitudinal imaging of these nanodroplets. 
Additionally, the optical trigger allows for the generation of PA contrast, which can be 
leveraged for enhanced imaging sensitivity compared to US-only acquisition. 
The goal of these studies was to demonstrate the feasibility of longitudinal imaging 
with optically triggered PFHnDs. Here, we image these agents in tumor-draining and naïve 
murine lymphatics over 24 hours. Histology is utilized in order to confirm the draining path 
of the PFHnD bolus. Post-processing algorithms for the resulting contrast-enhanced 
US/PA data are implemented in order to improve the detection of PFHnD-generated signal, 
and confounding factors are discussed. Our proof-of-concept studies lay the foundation for 
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in vivo longitudinal imaging of phase-change US/PA contrast agents and may facilitate 
compelling image-guided applications-based research in the lymphatics. 
4.1.3 Materials and Methods 
Perfluorocarbon Nanodroplet Synthesis 
One micromole (10−6 mol) of DSPC, 18:0 Cy5 PE, and DSPE-mPEG2000 (all 
from Avanti Polar Lipids, Inc.) in a 1:1:8 molar ratio was extracted from chloroform 
aliquots and added to a 10 mL pear-shaped flask (Aldrich). To this isolate, 0.5 mg of near-
infrared-absorbing dye (IR-1048; Sigma-Aldrich) from a 5 mg/mL chloroform aliquot 
were added. An additional 200 µL of HPLC-grade chloroform were added to the flask to 
ensure the formation of an even lipid cake. The pear-shaped flask was covered in aluminum 
foil and placed into a rotary evaporator with a water bath (R-215, V700, and V-855 with 
B-491; Buchi) and water-cooled condenser and evaporated for 30 minutes, adhering to the 
“20/40/60” rule. After this, the solid isolate was further dried under nitrogen flow for a 
minimum of 20 minutes in order to evaporate all residual chloroform in the lipid cake. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and homogenized 
using a water bath sonicator (1800 Series Ultrasonic Cleaner; Branson) for 5 minutes at 
room temperature to produce a solution of dye-loaded nanomicelles. This solution was 
centrifuged at 300 rcf for 1 minute in order to pellet excess near-infrared dye. Then, 900 
µL of the nanomicelle-containing supernatant was combined with 100 µL of PBS and 50 
µL of perfluorohexane (FluoroMed, L.P.) in a 2-dram glass scintillation vial (VWR). The 
glass vial was placed into an ice bath and allowed to rest for 5 minutes. Then, the solution 
was probe sonicated in the ice bath with a 1/8” microtip (QSonica) at 1% power (1s on, 
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15s off, 5 times) in order to produce a stock solution of PFCnDs, which was stored at 4°C 
in amber glass prior to use. 
Prior to their use for imaging, 100 µL of PFCnDs were diluted in 2 mL of PBS and 
bath sonicated for 2 minutes. This solution was then centrifugated at 3000 rcf for 5 minutes 
in order to pellet the PFCnDs. The supernatant was removed and the PFCnDs were 
reconstituted in 200 µL of sterile saline for imaging. This protocol produces PFCnDs with 
an average hydrodynamic diameter of 225-258 nm measured via dynamic light scattering 
(Zetasizer Nano ZS; Malvern Instruments Ltd.) and at a concentration of approximately 
1010 PFCnDs/mL as assessed by nanoparticle tracking analysis (NanoSight NS300; 
Malvern Panalytical). 
All of the previously described synthesis steps were performed in darkness to 
minimize photobleaching of the Cy5 fluorophore. 
4T1 Cell Line 
4T1 triple negative breast carcinoma cells (ATCC), passage 11-16, were cultured 
in RPMI plus L-Glutamine (Corning) supplemented with 10% FBS (Corning) and 1% 
penicillin-streptomycin (Sigma-Aldrich). Cells were maintained within T-75 flasks 
(CELLSTAR; Greiner Bio One, VWR) at 37°C in a humidified incubator with 5% CO2. 
 To passage cells, all media was aspirated from the T-75 flask and replaced by 5 mL 
of sterile PBS without calcium or magnesium (VWR). The PBS was swirled around the 
bottom of the flask a minimum of 15 times in order to wash any residual media from the 
cells. The PBS was then aspirated and replaced by 2 mL of 0.25% Trypsin/2.21 mM EDTA 
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in HBSS without sodium bicarbonate, calcium, or magnesium (Corning), enough volume 
to cover the entire bottom of the T-75. The flask was placed back into the incubator for 3 
minutes and then removed. After gently agitating the flask and visually inspecting for signs 
of cell detachment, 8 mL of pre-warmed RPMI media, prepared as described above, was 
added to the flask to bring the total volume to 10 mL. This solution was used to wash the 
bottom of the flask five times, dislodging any residually adhering cells. Then, the solution 
was vigorously pipetted up-and-down five times in order to form a single-cell suspension. 
Lastly, 50 to 1000 µL of this solution was used to seed the new flask pre-filled with fresh 
warmed media to ultimately reach a total final volume of 20 mL. 
Mice 
All animal studies were conducted under the oversight of the Georgia Tech 
Institutional Animal Care and Use Committee (IACUC) under protocol A100281. Four-
week-old female BALB/cJ mice were purchased from The Jackson Laboratory (Stock No.: 
000651). Upon receipt, mice were allowed a minimum of five days to acclimate to the 
housing facility at the Georgia Institute of Technology. Mice were housed with their 
littermates, with a maximum of four mice per cage, until administration of perfluorohexane 
nanodroplets, at which point the dosed mouse would be housed in isolation prior to 
reaching the experimental endpoint. Cages within the housing facility contain 100% corn 
cobb bedding and enrichment in the form of a mouse igloo, wood gnawing block, and 
rodent nesting sheets (all Bio-Serv; Fisher Scientific). The facility operates on a 12-hour 
day-night cycle, with “daytime” occurring from 06:00-18:00 UTC-5. Mice had access to 
food and water ad libitum throughout all phases of the study. 
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Murine Anesthesia 
In order to achieve general anesthesia, mice were placed into a non-primed 
induction chamber, which was then filled with 5% isoflurane in oxygen at a flow rate of 
400 mL/min. After mice lost their righting reflex and their sympathetic response to 
isoflurance abated to yield a respiration rate of at most 100 breaths per minute (bpm), the 
isoflurane was lowered to 2%. 
Once their respiration rate reduced to between 60-80 bpm, mice were transferred 
onto a temperature-controlled stage (Visualsonics) heated to 40°C. The isoflurane flow rate 
was raised to 600 mL/min for the initial transfer but was slowly lowered back to 400 
mL/min during positioning on the stage. For procedures under general anesthesia 
scheduled to last longer than 30 minutes, sterile petrolatum ophthalmic ointment (Puralube; 
Dechra Phramaceuticals) was applied to the eyes of mice immediately post-transfer using 
a 6” wood-handled cotton-tip applicator (Puritan Medical). 
Throughout general anesthesia sessions, the isoflurane was gradually lowered to 
between 1.25-1.5% maintenance in order to consistently maintain murine respiration 
between 60-80 bpm. If after two hours mice respired slower than 60 bpm, isoflurane was 
lowered to 1% or 0.75% as necessary to maintain the appropriate respiration rate. 
After non-terminal procedures, mice were returned to pre-warmed cages and 
monitored until they regained consciousness and resumed normal behavior. A heat lamp 
was applied if this process did not occur within 15 minutes. 
4T1 Syngeneic Model of Breast Cancer 
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Prior to inoculation, 4T1 cells were trypsinized (Corning), pelleted at 300 rcf for 5 
minutes, and resuspended in sterile PBS without calcium (Corning) at a final concentration 
of 2 × 106 cells per mL. Cells were counted prior to pelleting using 10 µL of solution on 
a hemocytometer. The count from the central grid of the hemocytometer was used to 
estimate the number of cells in the pellet prior to resuspension. The final cell solution was 
stored on ice prior to inoculation. 
Five- or six-week-old BALB/cJ mice were placed under general anesthesia per the 
previously detailed protocol. The skin overlying the right fourth mammary fat pad was 
shaved with an electric-powered shaver (BravMini+; Wahl). The area was then chemically 
depilated with Nair calcium hydroxide lotion (Church & Dwight). Nair was dabbed with a 
cotton-tipped applicator into the hair roots and allowed to sit on the skin for 60 seconds. 
After this, the Nair lotion was removed by sequential, unidirectional wiping with first moist 
and then dry gauze pads. 
The shaved and depilated area was then disinfected with a 2% chlorhexidine 
gluconate solution (Dermachlor; Henry Schein Animal Health) applied with a gauze pad 
and allowed to air dry prior to further manipulation of the animal. Then, 50 µL of the 4T1 
cell solution (105 cells) were injected subcutaneously in the anterolateral aspect of the right 
fourth mammary fat pad using a 31-Gauge diabetic syringe (Ultra Fine II™ U-100; BD). 
For non-tumor mice, a solution of sterile PBS was used as a sham inoculation. 
US/PA System and Imaging Sequence 
Imaging was performed using a linear array ultrasound transducer (CL15-7; 
Advanced Technology Laboratories, Inc.) integrated with a 2-to-1 optical fiber bundle 
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(CBGL-8-1/2-2500; Nanjing Chunhui Science & Industrial Co., LTD). The optical fiber 
bundle was connected to an Nd:YAG pulsed laser (Phocus Mobile; Opotek Inc.) operating 
at the fundamental 1064 nm wavelength. The split end of the fiber bundle was mechanically 
fixed to the transducer via a custom 3D-printed holder. These fiber outputs allowed for 
irradiation of imaged tissue, which was performed with 5-ns laser pulses at a pulse 
repetition frequency (prf) of 10 Hz. The estimated fluence at the depth of fiber intersection 
within the imaging plane (12-14 mm) was measured to be 85±5 mJ/cm2 with a power meter 
(Nova II; Ophir-Spiricon, LLC). For US imaging, the transducer was driven at a 12.5 MHz 
center frequency using a programmable research US imaging system (Vantage 256; 
Verasonics, Inc.). The full imaging window in each plane was 22.8 mm wide and 25 mm 
deep. The imaging probe and optical fiber outputs were acoustically coupled with the 
subject using clear ultrasound gel (Sonigel; 3B Scientific). 
For the imaging sequence at each imaging plane, a traditional line-by-line B-mode 
acquisition was first captured to record the underlying anatomy. Next, the tissue was 
irradiated with six successive laser pulses. A packet of US/PA data was acquired after each 
pulse. Each packet begins with 40 ultrafast pulse inversion (UFPI) frames at 8 kHz with 
alternating compressional or rarefactional phase as described in 3.2.3. After these “pre-
laser” frames, the tissue is irradiated by a laser pulse. This pulse is immediately followed 
by a receive-only acquisition to capture PA signal and 40 “post-laser” UFPI frames at 8 
kHz. Idle time fills the time between US/PA packets to synchronize with the 10 Hz prf of 
the pulsed laser. The first three US/PA packets use UFPI sequences with transmits that 
have an initial rarefactional phase, as described previously. The last three invert this order 
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and use transmits beginning with an initial compressional phase. All of the received waves 
were sampled at 56 MHz. 
After all images in the US/PA imaging sequence at a plane were saved in system 
memory, a motor controller (Model ESP301; Newport Corporation) translated a motorized 
linear stage (Model UTS150PP; Newport Corporation) 0.3 mm in the direction 
perpendicular to the imaging. In this new imaging plane, the US/PA imaging sequence was 
again acquired and saved in memory. This process repeats to acquire 35 imaging planes, 
spanning a total distance of 10.2 mm, for each volumetric acquisition. After completing a 
volumetric acquisition, the software returns the motor stage to its original position at the 
first imaging plane. 
All data were saved and processed offline in MATLAB (MathWorks). For 
displaying post-processed volumetric images, line-by-line B-mode and post-processed PA 
images at each imaging plane were linearly interpolated by a factor of 5 in two dimensions 
and saved as JPEGs. These co-registered JPEG stacks were imported into Amira (Thermo 
Fisher Scientific) and rendered in three-dimensional space. The B-mode layer was made 
translucent at 𝛼 = 0.15 to highlight the co-registered PA signal. Amira software adjusted 
the dynamic range of its display colormap in order to match the range of the post-processed 
PA signal for each individually rendered volume. 
US/PA Imaging Protocol 
Mice were placed under general anesthesia per the previously described protocol. 
If necessary, the skin overlying the abdomen, upper pelvis, and right back (hip to scapula) 
was shaved with an electric-powered shaver. These areas were then chemically depilated 
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with Nair calcium hydroxide lotion. For the first pre-injection imaging session, the Nair 
was left on the skin for a full 60 seconds. However, for downstream imaging timepoints 
where the mice had already been depilated, regions of regrown or residual hair in the 
imaged regions only received exposure of 30 seconds or less to the depilatory lotion. This 
protocol ensured no unnecessary irritation of the skin within the imaged regions. 
After the mice were sufficiently depilated for imaging, a rectangular cut-out of 
hunter green felt (Walmart) was slid underneath mice and fixed to the imaging stage. The 
felt prevents reverberation artifacts in ultrafast imaging by attenuating plane waves 
reflected off the imaging stage and does not absorb residual 532-nm light from the laser 
source, which could produce potential photoacoustic artifacts. Once the felt was in place, 
mice were placed into the left lateral decubitus position, and their limbs were fixed to the 
imaging stage with adhesive tape (ZONAS® Porous Tape; Johnson & Johnson). Acoustic 
coupling gel (Sonigel; 3B Scientific), which was previously centrifugated for 5 minutes at 
10,000 rcf to remove bubbles and UV-sterilized, was applied to the depilated skin surface 
using a 5-mL disposable slip-tip syringe (BD). The transducer was lowered until coupled 
with the gel, and real-time B-mode imaging on the Verasonics Vantage system was used 
to appropriately position the mouse. The 3-axis motor stage was used to translate the 
transducer through the imaging volume of interest. A 1-mL disposable slip-tip syringe 
(BD) was used to remove any bubbles remaining in the gel from this imaging volume. 
Following initial positioning, acoustic coupling gel was used to couple the laser 
fiber bundles to the mouse skin surface. The motor stage was again translated through the 
volume of interest both to ensure no additional bubbles entered the volume and to ensure 
gel coupling of the fibers throughout the entire motion of the transducer setup through the 
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imaging volume. Bubbles were removed and more gel was added as necessary. Once 
quality coupling of the transducer and fibers was assured, two sequential US/PA volumes 
were acquired by the system. The first was a volume beginning cranially and ending 
caudally after the ipsilateral inguinal lymph node. The second volume started with the 
inguinal lymph node and proceeded caudally to the primary tumor or mid-4th mammary fat 
pad (naïve mice). 
After volumetric US/PA acquisitions, a quality assurance (QA) code was executed 
in MATLAB (MathWorks) to quickly assess B-mode, PA, ultrafast pulse-inversion US, 
and initial differential US images across the imaging volume. If the QA code suggested 
issues in US coupling, laser light illumination, or malpositioning, then these issues were 
addressed, and the corresponding volume was reacquired. 
Once high-quality volumetric scans were acquired in the left lateral decubitus 
position, the imaging stage was moved from under the transducer and excess gel was 
removed from the mice. Tape was removed from the four limbs of the mice, and they were 
repositioned and re-taped in the supine position. The imaging stage was re-positioned under 
the transducer 180° rotated compared to before, and additional gel was added to couple the 
transducer. After bubbles were removed from the imaging volume, more gel was again 
added to couple the laser fiber bundles. Following the same positioning workflow as 
before, two sequential US/PA volumes were acquired by the system. The first began 
caudally near the primary tumor and ended cranially. The second volume proceeded 
cranially in a non-overlapping fashion (i.e., 0.3 mm cranial to the final plane in the first 
acquisition). 
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Each volumetric acquisition takes approximately 8 minutes to acquire and save the 
data. The entire imaging workflow, from induction of anesthesia to regaining of 
consciousness or euthanasia, requires between 120 to 150 minutes, on average, to execute. 
Perfluorocarbon Nanodroplet Injection 
Mice were manually restrained without general anesthesia by scruffing. Then, the 
skin overlying the right fourth mammary fat pad was disinfected with a 70% isopropyl 
alcohol swab (BD). Next, a 31-Gauge diabetic syringe was used to perform a subcutaneous 
injection of 100 µL of 1010 particles/mL solution of perfluorocarbon nanodroplets in the 
anterolateral aspect of the right fourth mammary fat pad, superior to any primary tumors. 
Mice were immediately returned to the animal housing facility after the injection procedure 
and before any downstream imaging. A cage change was performed for each injected 
mouse during the injection protocol in order to encourage movement to circulate fluid from 
the injected bolus prior to post-injection imaging. 
If mice displayed overly aggressive behavior during the manual restraint attempt 
(i.e., attempted biting or jumping out of cage), mice were sedated with “twilight” isoflurane 
exposure, which entails 5% isoflurane exposure at 400 mL/min flow rate until the loss of 
righting reflex, to facilitate injection. 
Euthanasia 
Mice were sacrificed via a primary lethal intraperitoneal injection of Euthasol (150 
mg/kg; Henry Schein Medical) contralateral to the primary tumor. After cessation of 
breathing, mice were exsanguinated during the perfusion-fixation procedure, which served 
as secondary euthanasia. In brief, a transverse incision through the skin and underlying 
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fascia was made immediately inferior to the sternum. Vertical incisions were made 
superiorly on either side of the primary incision, transecting the ribs in the process, in order 
to expose the diaphragm. The diaphragm was transected laterally, and the rib cage was 
separated and reflected superiorly, exposing the heart. A 27-Gauge butterfly needle (Surflo 
Winged Infusion Set; Terumo) was inserted into the left ventricle of the ideally still-beating 
heart and the right auricle was lanced vertically in order to convert the circulatory system 
into an open circuit. At this stage, 20 mL of 6.90 pH PBS was pumped through the 
circulatory system at a rate of 5 mL/min using a syringe pump (Legato 200; KD Scientific) 
attached to the butterfly needle setup. Next, the PBS syringe was replaced by one with a 
solution of 4% paraformaldehyde (reagent grade; Sigma-Aldrich) in 6.90 pH PBS, and 20-
25 mL of this solution was pumped through the mice at a rate of 5 mL/min. Successful 
perfusion-fixation was confirmed by palpation of the mouse extremities to assess rigor. 
 After perfusion-fixation, both the ipsi- and contralateral popliteal, inguinal, and 
proper axillary lymph nodes were resected. These nodes were placed into OCT-filled 
cryomolds (both Sakura Finetek), flash frozen under dry ice, and stored at -80°C to be 
sectioned for downstream histological analysis. 
Lymph Node Histology 
Prior to confocal imaging, slides were thawed, DAPI-stained, and sealed. All of 
these steps were performed in darkness to minimize photobleaching of fluorophores within 
the sections. First, frozen slides were thawed at room temperature for 20 minutes. Next, 
slides were rehydrated with 7.40 pH PBS for another 20 minutes. After this, excess PBS 
was tapped off slides, and the hydrated tissues were incubated with a 1:25000 (1:1000, then 
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10:250) PBS dilution of DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride; 
Invitrogen, Thermo Fisher Scientific) from an aliquot of 5 mg/mL in dimethylformamide 
(DMF). After 10-12 minutes of DAPI incubation, the DAPI solution was tapped off slides. 
Then, the slides were washed three times with PBS, allowing PBS to hydrate the sample 
for 5 minutes before being tapped off for the next wash. After the last wash, slides were 
mounted with antifade reagent (ProLong Gold Antifade Mountant; Invitrogen). Two to 
three drops of mountant were dropped evenly across the slide, in between tissue, and a 
glass coverslip (VWR) was slowly and evenly pressed down over the slide to distribute the 
mountant across the glass without disrupting the tissue. Lastly, clear nail polish was twice 
applied to all four edges of the coverslip to seal it to the slide, allowing at least 30 minutes 
for the first application to dry before adding the second. Mounted and sealed slides were 
stored in the dark at 4°C, at minimum overnight, until their scheduled time to be imaged 
on the confocal. 
Mounted sections were imaged on a Zeiss laser scanning microscope consisting of 
an LSM 700 scan head mounted on an AxioObserver Z1 inverted microscope stand with a 
motorized stage. Images were obtained with laser lines at 405 and 639 nm using a 20x / 0.8 
N.A. Plan Apochromat objective lens with a working distance of 0.550 mm. Tiled confocal 
images were rendered as JPEGs using Zen Black software (Carl Zeiss AG). The dynamic 
range of the Cy5 channel was set as the minimal level to suppress all signal in the right 
popliteal lymph node. 
Statistical Analysis 
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Statistical analyses were performed in R (R Core Team). A two-way ANOVA with 
repeated measures was performed on the data to assess the effects of measurement 
timepoint and animal model on the masked PA signal. 
4.1.4 Results and Discussion 
We elected to use BALB/c mice as a model small animal for our longitudinal 
studies of the lymphatic drainage of optically triggered PFHnDs. These mice have 
relatively static lymphatic organization,120 and the background supports various syngeneic 
models of cancer, including the 4T1 model of metastatic triple-negative breast cancer.121 
The 4T1 syngeneic model is actively used in the scientific community for studies of cancer-
induced lymphangiogenesis and lymphatic metastasis.106,122-124 Thus, this animal model is 
a logical starting point for our proof-of-concept studies. 
 
Figure 9: Schema for the inoculation and US/PA imaging of lymphatics in BALB/c 
mice. 
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The animal imaging protocol used for these imaging studies is shown in Figure 9. 
The timing and technique of our tumor inoculation is based on methods established by a 
prominent group of lymphatic researchers.122 It does not produce overt lymphatic 
metastases over the course of our longitudinal US/PA imaging, but it should induce 
lymphovascular remodelling in the tumor-draining lymph node (TDLN).122 We perform 
three sessions of US/PA imaging per mouse: one prior to PFHnD injection to establish a 
baseline, another 6 hours after PFHnD injection, and a final session at 24 hours prior to the 
experimental endpoint. 
Each US/PA imaging volume is the result of sequential 2D acquisitions across the 
imaging span. Representative images from one such 2D plane can be seen in Figure 10. 
First, the US/PA imaging sequence acquires a traditional line-by-line B-mode US image 
(Figure 10A) in order to visualize the underlying anatomy. Next, after an emitted laser 
pulse, the sequence receives the generated PA signal, which can be reconstructed into a PA 
image (Figure 10B). Absorption at the skin surface and within other endogenous 
structures, as well as imaging artifacts, can produce PA signals that confound the signal 
produced by optically triggered PFHnDs. To more specifically isolate signal from the 
PFHnDs, it is necessary to leverage the transient US contrast generated by these repeatably 
vaporizable agents. In 3.2, we demonstrated the ability of an ultrafast pulse inversion 
(UFPI) sequence to enhance US signal from PFHnDs relative to background. We 
implement the same paradigm here, as well. By performing differential imaging (i.e., 
taking the first difference of the imaging data with respect to time), we can highlight the 
rapidly decaying ultrasound contrast produced by recondensing PFHnDs vaporized by the 
preceding laser pulse. To maintain methodological consistency with the previous study, we 
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utilize the second differential (i.e., first difference of the first difference) UFPI (δ2 UFPI) 
data to analyze the dynamics of recondensing PFHnDs. Qualitatively, the differential UFPI 
(δ UFPI) and δ2 UFPI data are similar (see APPENDIX B, Figure 27), and either could 
theoretically be used for analysis. 
The first image in the δ2 UFPI time series in our representative 2D dataset can be 
seen in Figure 10C. Although a region of draining PFHnDs, highlighted by the dashed 
yellow box, is easily perceived within this plane, there are also areas of nonspecific 
enhancement from an endogenous hyperechoic structure and the animal imaging stage. To 
better reject areas of nonspecific enhancement, it is necessary to examine the temporal 
dynamics of these signals. The absolute value of the median δ2 UFPI signal from the boxed 
region of interest in Figure 10C is shown in Figure 10D as a function of time. This signal 
displays a high-magnitude exponential decay that is commonly observed from optically-
triggered PFHnDs upon recondensation.76,102,103 
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Figure 10: Representative 2D US/PA imaging data from a tumor-draining lymph 
node. A) Traditional B-mode imaging of the tumor-draining lymph node (light blue 
outline), displayed on a 40 dB dynamic range; B) The corresponding PA image, displayed 
on a 40 dB dynamic range; C) The second differential ultrafast pulse inversion (δ2 UFPI) 
image acquired immediately post-laser pulse, displayed on a 20 dB dynamic range; D) A 
plot of the median linear δ2 UFPI signal within the region of interest highlighted in C) by 
the dashed yellow box; E) The mask based on the δ2 UFPI that will be applied to the PA 
data for display; F) Final merged US/PA image with the δ2 UFPI masked PA data. Scale 
bar is 5 mm. 
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To date, both internally and in conference presentations, our group has explored a 
variety of post-processing options based on this exponential decay phenomenon for 
highlighting optically triggered PFHnDs. Many of these methods have involved fitting the 
linear time-series data to an exponential decay function and thresholding the data based on 
the resulting model coefficients. However, these methods are computationally intensive 
and scale poorly to the amount of data collected in these longitudinal studies. In order to 
efficiently process these data, we applied a pixelwise threshold to the δ2 UFPI data with 
logical masking based on quantitative measures intended to approximate an exponential 
decay fit. These criteria are listed below in Table 1. 
Table 1: Criteria for Thresholding δ2 UFPI Imaging Data 
Logical Mask Criteria 
• 20 log10(𝛿
2 UFPI[1]) − 20 log10(𝑚𝑎𝑥(𝛿
2 UFPI)) ≥ −20 
• 𝛿2 UFPI[1] > 𝛿2 UFPI[2] 
• 𝛿2 UFPI[2] > 𝛿2 UFPI[20] 
• 𝛿2 UFPI[1] > 2 × 𝛿2 UFPI[20] 
Applying these criteria to the pixelwise δ2 UFPI data generates a logical mask at 
each plane, like the one shown in Figure 10E. After adjusting for variable time delay in 
the Verasonics Vantage receive-only acquisition relative to the laser Q-switch, the δ2 UFPI 
mask is applied to the corresponding PA frame to generate a masked PA image (Figure 
10F), whose retained contrast has a higher probability of corresponding to optically 
triggered PFHnDs. We perform this post-processing algorithm for all six laser pulses at 
each frame and then take the median result for the final masked PA image at the frame. 
When performed on each plane across the volume, this workflow generates volumetric 
imaging data like that shown in Figure 11 for a representative syngeneic 4T1 mouse. 
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Figure 11: Processed US/PA volumes from a 4T1 syngeneic mouse. This mouse 
received a 100 µL subcutaneous injection of PFHnDs at 0 hours. A) Cartoon showing the 
left lateral decubitus position of the mouse for imaging. The yellow dashed lines 
approximate the volumes shown. Lymph nodes are false colored in light blue; B) Masked 
PA signal (red-orange) overlaid with the corresponding US volume 48 hours before 
PFHnD injection; C) Masked PA signal overlaid with US obtained 6 hours after PFHnD 
injection; D) Masked PA signal overlaid with US obtained 24 hours after PFHnD injection. 
Scale bars are approximately 5 mm. 
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The left lateral decubitus position of the mouse for the imaging volumes shown is 
displayed in Figure 11A, with the approximate region of interest boxed in dashed yellow 
lines. At baseline (Figure 11B), there is some nonspecific enhancement, but none adjacent 
to the TDLN. However, 6 hours after ipsilateral peritumoral injection of PFHnDs (Figure 
11C), a large bolus of PA enhancement can be seen immediately adjacent to this lymph 
node. By 24 hours post-injection (Figure 11D), this bolus has cleared the region. Histology 
obtained after the 24-hour imaging timepoint (Figure 12) confirms that PFHnDs drained 
to the tumor-draining right inguinal (RI) lymph node and that they even reached the 
downstream right axillary (RA) lymph node. No enhancement from Cy5 included within 
the PFHnD construct was observed within the upstream right popliteal (RP) lymph node, 
which drains unidirectionally towards the RI lymph node. 
The enhancement observed from Cy5-doped PFHnDs on histology of the RI and 
RA lymph nodes is focal and largely restricted to the exterior region of the nodes. Previous 
research has demonstrated that the vast majority of transport through lymph nodes occurs 
through the “peripheral pathway” through the subcapsular sinus and medulla, which sit on 
the periphery of the node.125 Additionally, while the PFHnDs used in this study are small 
in their relationship to traditional US contrast agents, they are still relatively large in a 
biological sense. Therefore, it is unsurprising that only a small percentage of injected 
PFHnDs would be able to traverse the conduit network into the more central regions of the 
nodes. The number of retained functional PFHnDs in the RI TDLN may be below the 
detection threshold of our US/PA system, and more upstream locations in the lymphatic 
drainage pathway (i.e., near the RA) should be imaged at later timepoints in future studies. 
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Figure 12: Representative fluorescent histology of draining PFCnDs in 4T1 syngeneic 
mice. Mice have a primary tumor (PT) in the right fourth mammary fat pad. Histology 
sections were obtained from the right popliteal (RP), right inguinal (RI), and right axillary 
(RA) lymph nodes post-perfusion at 24 hours post-injection. Sections are stained with 
DAPI (blue). PFCnDs (Cy5; red) can be seen on the periphery of the RI and RA lymph 
nodes, ipsilateral to the peritumoral injection site (red in lower left inset cartoon). All signal 
from the Cy5 channel is displayed on the same dynamic range. Yellow and green insets 
show magnified regions from the RI and RA lymph nodes, respectively. Scale bar for top 
row is 200 µm. Scale bar for bottom row insets is 50 µm. 
Returning to the initial US/PA imaging volume, it is odd that there are still a few 
regions of focal enhancement after post-processing the data. In particular, the large region 
of enhancement at the cranial edge of the volume is suspicious, as it is deep to the skin 
surface and unlikely an artifact. Upon further investigation, it appears the large and focal 
enhancement in this region may be due to absorption from bowel contents. We 
subsequently performed volumetric US/PA imaging of resected large intestines from mice 
fed standard (Figure 13A) and non-fluorescent (Figure 13B) diets, and both showed 
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similar focal enhancement in regions containing fecal matter. Although absorption 
measurements of homogenized feces from mice on standard (Figure 13C) and non-
fluorescent (Figure 13D) diets do not reveal high absorption at 1064 nm, the optical density 
of absorbers within the feces is likely high enough to create the photoacoustic effect on 
display within in vivo volumes containing the abdomen. 
 
Figure 13: US/PA imaging of ex vivo murine intestines post-perfusion. Ex vivo large 
intestines show appreciable enhancement from post-processed PA images in mice fed both 
standard (A) and non-fluorescent (B) diets. Absorbance measurements were also obtained 
on homogenized murine fecal pellets from mice fed standard (C) and non-fluorescent (D) 
diets. Although the spectra are dominated by scattering, the high density of absorbers 
within the pellets may explain the confounding enhancement on US/PA imaging of the 
abdomen. Scale bars are approximately 5 mm. 
 77 
Similar volumes from other 4T1 syngeneic mice that we imaged under this same 
protocol can be found in APPENDIX B. Supplemental Data for Imaging of 
Perfluorocarbon Nanodroplets Trafficking in Lymphatics. In addition to tumor-inoculated 
mice, we also imaged naïve BALB/c mice using the same protocol. A representative series 
of US/PA volumes from one of these naïve mice is shown in Figure 14. Again, at baseline 
(Figure 14B), there is some focal contrast enhancement in the abdomen, possibly due to 
feces in the large intestine. However, there is minimal enhancement surrounding the RI 
lymph node. Conversely, there is large focal enhancement near the draining RI lymph node 
(Figure 14C) 6 hours after PFHnDs are injected subcutaneously over the ipsilateral fourth 
mammary fat pad. By 24 hours post-injection (Figure 14D), most of this enhancement has 
dissipated, although some small regions of contrast remain caudal to the lymph node and 
upstream of it within the imaged volume. Due to the presence of minor artifacts throughout 
the longitudinally collected volumes, it is impossible to say with certainty whether these 
are also artifacts or whether they correspond to small foci of PFHnDs within regional 
lymphatics. 
Similar to the 4T1 inoculated case, histology from naïve mice collected after the 
24-hour timepoint (Figure 15) shows enhancement from the Cy5 fluorophore incorporated 
within PFHnDs retained within the ipsilateral RI and RA lymph nodes downstream of the 
injection site. No PFHnD-related fluorescence is noted in the upstream RP lymph node or 
in contralateral left popliteal or inguinal lymph nodes. US/PA volumes from other naïve 
mice imaged under this protocol, which qualitatively resemble the representative ones 
displayed here, can be found in APPENDIX B. Supplemental Data for Imaging of 
Perfluorocarbon Nanodroplets Trafficking in Lymphatics. 
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Figure 14: Processed US/PA volumes from a naïve BALB/c mouse. This mouse 
received a 100 µL subcutaneous injection of PFHnDs at 0 hours. A) Cartoon showing the 
left lateral decubitus position of the mouse for imaging. The yellow dashed lines 
approximate the volumes shown. Lymph nodes are false colored in light blue; B) Masked 
PA signal (red-orange) overlaid with the corresponding US volume 48 hours before 
PFHnD injection; C) Masked PA signal overlaid with US obtained 6 hours after PFHnD 
injection; D) Masked PA signal overlaid with US obtained 24 hours after PFHnD injection. 
Scale bars are approximately 5 mm. 
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Figure 15: Representative fluorescent histology of draining PFCnDs in naïve BALB/c 
mice. Sections were taken from the left popliteal (LP), right popliteal (RP), left inguinal 
(LI), right inguinal (RI), and right axillary (RA) lymph nodes post-perfusion at 24 hours 
post-injection. Sections are stained with DAPI (blue). PFCnDs (Cy5; red) can be seen 
focally on the periphery of the RI and RA lymph nodes, ipsilateral to the injection site (red 
in upper right inset cartoon). All signal from the Cy5 channel is displayed on the same 
dynamic range. Scale bar is 200 µm. 
Quantitative masked PA data from planes centered at the draining lymph nodes in 
all imaged mice are shown in Figure 16. The data were manually curated to exclude the 
third of each imaging plane containing the dorsal aspect of the mouse. This step represents 
an attempt to exclude surface artifacts and to focus on signal from PFHnDs draining 
through regional lymphatics near the RI lymph node. Masked PA signal in the remaining 
volumes centered around the RI lymph node (15 planes, 4.2 mm) was integrated, producing 
a single value of total PA signal at each timepoint for each mouse. This quantitative 
analysis shows an increase in the magnitude and variance of the total PA signal at 6 hours 
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compared to preliminary imaging, which then generally decreases back to baseline by 24 
hours. However, a two-way ANOVA with repeated measures did not find significant 
differences in the masked PA signal as a function of time (p=0.101) or animal model 
(p=0.319), nor did it find a difference in the temporal behavior of PA signal as a function 
of animal model (p=0.339). The effect as a function of time is trending towards 
significance, and it is likely that a larger sample would be sensitive to changes, particularly 
at the 6-hour timepoint. A higher statistically powered sample size and more precise, 
artifact-free processing will be necessary to generate a better estimate of how PFHnD 
drainage varies by time and small animal model. 
One might expect to observe differences between the trafficking of PFHnDs in 
naïve and tumor-draining lymphatics. In breast cancer, metastasis is partially mediated by 
the production of vascular endothelial growth factor C (VEGF-C), which induces 
lymphangiogenesis.126 4T1 cells have been previously shown to produce VEGF-C in this 
syngeneic model of breast cancer.127 Still, the VEGF-C induced lymphangiogenesis in 
murine models of breast cancer has been observed within intratumoral lymphatics.126 Our 
observations of bulk PFHnD transport may imply that this effect does not extend to 
extratumoral lymphatics. However, our imaging approach may also be insensitive to subtle 
changes in trafficking that would be better investigated at shorter timepoints and possibly 
with an intratumoral, not peritumoral, bolus. In any case, further refinement of our imaging 
technique and post-processing will be necessary to examine smaller and more sparse 




Figure 16: Curated total masked PA signal at the draining lymph node in imaged 
mice. Volumes centered around the draining lymph node were analyzed, and the dorsal 
third aspect of each plane was excluded. Data show an increase in signal in the region at 6 
hours that generally dissipated by 24 hours. Two-way ANOVA with repeated measures did 
not find significant differences between animal models (p=0.319) or timepoints (p=0.101), 
but the timepoint data are trending towards significance. 
Residual PA signal after post-processing represents a large confounding factor 
precluding more precise quantitative analysis of these results. As previously discussed, 
some of this confounding signal is due to endogenous strong absorbers, such as feces in 
the large intestines. Other residual signal is likely the result of the threshold-based post-
processing technique failing to appropriately reject all other nonspecific signal. The 
 82 
imaging sequences and processing techniques to best isolate the transient enhancement 
from optically triggered PFHnDs are still active areas of research. 
In conclusion, we have generated evidence of the ability to track PFHnDs 
longitudinally in vivo. We developed an imaging sequence and post-processing techniques 
to leverage both the US and PA imaging data in order to highlight areas with increased 
probability of containing optically triggered PFHnDs. Using tumor-draining and naïve 
murine lymphatics as a test case, we imaged subcutaneously delivered PFHnDs over a 
period of 24 hours. Our US/PA imaging results show focal enhancement around the 
draining lymph node at 6 hours, with enhancement becoming weaker and more diffuse by 
24 hours. Histological data obtained at 24 hours suggests that PFHnDs may have drained 
to even more distal lymphatics, and future imaging studies should include more cranial 
lymphatics to assess the complete extent of drainage. These studies lay the foundation for 
additional US/PA research in the lymphatics and for other biological applications that 
require longitudinal monitoring of transport and delivery. 
4.2 Adjuvant-Containing Perfluorohexane Nanodroplets for Image-Guided 
Immunotherapy 
4.2.1 Abstract 
Immunotherapy has fundamentally changed the treatment approach to a variety of 
solid tumors. By harnessing the adaptive immune system to combat tumor growth, 
immunotherapeutics, such as checkpoint inhibitors, offer an avenue for treatment that has 
the potential for fewer off-target effects than traditional exogenous agents and approaches. 
Still, systemically administered immunotherapeutics can produce off-target effects in the 
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form of autoimmunity. To address this limitation, researchers have explored methods for 
the focal delivery of immunotherapeutics, including nanoparticle formulations. Imaging of 
these nanoparticles is critical to monitor their successful delivery to either primary tumors 
or tumor-draining lymph nodes. Many immunotherapeutic nanoparticles have not been 
developed with the ability for imaging with platforms that can scale from small to large 
animal imaging in translational studies. Ultrasound is one such scalable, non-ionizing 
imaging modality that has gained increasing utilization in point-of-care settings. However, 
gas microbubbles, the traditional contrast agents for use with ultrasound, have 
unfavourable transport characteristics in the extravascular space and are thus ill-suited for 
use as an immunotherapeutic vehicle. Perfluorocarbon nanodroplets are an emerging, 
phase-change contrast agent for ultrasound and photoacoustic imaging that have improved 
transport characteristics due to their submicrometer size prior to user activation for 
imaging. Here, we develop and present a class of perfluorocarbon nanodroplets for focal 
adjuvant delivery and demonstrate their ability to stimulate antigen presenting cells in vitro. 
These studies lay the foundation for the future advancement of ultrasound image-guided 
immunotherapy into the preclinical arena. 
4.2.2 Introduction 
The implementation of checkpoint inhibitors has revolutionized the treatment of 
solid tumors,128-137 and the researchers who contributed seminal work to this approach were 
jointly awarded the Nobel Prize in Medicine in 2018.138 Prior to the use of checkpoint 
inhibition as a therapeutic strategy, cancer patients relied solely upon exogenous methods 
for tumor destruction: surgical resection, radiotherapy, or cytotoxic chemotherapeutic and 
biologic agents. Checkpoint inhibitors disrupt a “molecular brake” imposed by certain solid 
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tumors on cytotoxic T lymphocytes (CTLs), allowing the body to mount an adaptive 
immune response to tumor antigens.139 Checkpoint-based immunotherapeutic methods 
have shown clinical efficacy in patients with lung,136 genitourinary,129,131,132,137 and other 
cancers.128,133-135 
 Checkpoint inhibition and other immunomodulatory approaches in cancer seek to 
leverage the molecular specificity of the adaptive immune response to avoid the 
morbidities associated with exogenous cytotoxic and otherwise destructive methods. 
However, systemically administered immunotherapeutics still produce off-target effects 
(i.e., autoimmunity) by upregulating T cells outside the tumor microenvironment. One 
avenue for avoiding these side effects is to focally deliver the immunotherapeutic payload, 
either directly into the primary tumor or to tumor-draining lymph nodes (TDLNs).140 By 
only upregulating tumor-resident T cells or T cells within a TLDN, this greatly increases 
the probability that CTLs train on tumor antigen instead of autoantigens. 
 Other groups have previously used an array of vehicles, from metallic nanoparticles 
to liposomes,112,141-143 to focally deliver immunotherapeutics. Many of these approaches 
lack the ability to confirm delivery in vivo via concomitant imaging. Confirmation of 
appropriate local delivery without the need for ex vivo techniques, such as biopsy, will be 
highly desired for any downstream clinical scale-up of these approaches. Current 
formulations with the potential for image tracking, such as gold and iron oxide 
nanoparticles, are not without challenges. Gold nanoparticles, compatible with optical and 
photoacoustic (PA) imaging, have lingering concerns over their long-term biocompatibility 
and clearance that have stymied their implementation for any in vivo clinical application. 
Conversely, iron oxide nanoparticles are commonly paired with magnetic resonance 
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imaging (MRI), a paradigm that has clinically flourished with widespread use. However, 
MRI is a non-portable technique that is often not available in resource-limited and point-
of-care settings, and its use incurs a large expense on both the patient and provider. 
 Ultrasound is a cost-effective, portable imaging paradigm with widespread 
implementation in both academic and community clinical settings. Contrast-enhanced 
ultrasound typically utilizes microbubbles, which are gas-cored, micrometer-sized 
constructs, that can be functionalized for molecular-specific diagnosis or therapeutic 
delivery.25 Previous groups have adapted microbubbles to deliver genetic material as part 
of an ultrasound-guided therapeutic regime.144,145 However, microbubbles have short (i.e., 
minutes-long) biostability and are thus ill-suited to imaging endocytosed vehicle and the 
ensuing cell-mediated transport of immunotherapeutic. Perfluorocarbon nanodroplets 
(PFCnDs) are an emerging class of phase-change contrast agents for use with ultrasound 
and photoacoustic imaging.41,53,90,101 These PFCnDs utilize the same biocompatible shell 
components as microbubbles but replace the gas core with one of liquid fluoroalkane. In 
response to a pulse of either acoustic or optical energy, the fluoroalkane core vaporizes to 
effectively create a microbubble in situ. Our group has previously demonstrated that 
PFCnDs are biologically stable for at least 72 hours when trafficking within antigen 
presenting cells (APCs) and that they can be imaged within TDLNs at this timepoint.146 
 Here, we present a new class of immunotherapeutic PFCnDs: poly(I:C) 
perfluorocarbon nanodroplets (pICnDs). These pICnDs are coated with 
polyinosinic:polycytidylic acid (commonly abbreviated poly(I:C)), a molecule that is 
structurally similar to double-stranded RNA. When endocytosed by APCs, poly(I:C) 
stimulates intracellular TLR3 receptors within endosomes.147 Within certain APCs, such 
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as dendritic cells (DCs) and macrophages (Mφs), TLR3 agonism leads to signalling 
cascades that mobilize adaptive immune cells, enact a TH1 response, and ultimately result 
in cell-mediated immunity.148 The CTL response associated with cell-mediated immunity 
has been shown to have robust anti-tumor activity.149,150 The TH1 response leads to 
upregulation of APC endocytosis, which can prime TDLN APCs to ingest locally 
metastatic tumor cells and present their antigens to T cells. This can train T cells to attack 
cancer cells, indirectly eliciting a CTL response. In addition, TH1 cells can directly induce 
a CTL response through the production of cytokines, such as IL-2.151 Furthermore, TH1 
cells may also directly kill cancer cells through the production of cytokines that initiate cell 
death.149 Depending on the PD-L1 status of the tumor, poly(I:C) can serve as either a 
standalone immunotherapeutic or as a complement to checkpoint inhibition. 
 The overarching goals of these studies are to characterize these pICnDs, their 
imaging response, and their ability to elicit an immune response from APCs. To this end, 
we utilized RAW 264.7 Mφs as a model organism for evaluating the APC response. RAW 
264.7 Mφs are an established in vitro platform for probing Mφ cell signaling. Moreover, 
due to the variety of syngeneic models available on a BALB/c background, these BALB/c-
originating Mφs are a logical starting point for downstream preclinical scale-up of this 
image-guided therapeutic platform. The studies that follow demonstrate the ability of 
pICnDs to stimulate APCs, which could ultimately initiate widespread anti-tumor activity 
if pICnDs are focally delivered to either primary tumors or TDLNs. 
4.2.3 Materials and Methods 
Poly(I:C) Perfluorocarbon Nanodroplet Synthesis 
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One micromole (10−6 mol) of DSPC, 18:1 TAP (DOTAP), and 18:1 (Δ9-Cis) PE 
(DOPE) (all from Avanti Polar Lipids, Inc.) in a 2:9:9 molar ratio was extracted from 
chloroform aliquots and added to a 10 mL pear-shaped flask (Aldrich). To this isolate, 0.5 
mg of near-infrared-absorbing dye (IR-1048; Sigma-Aldrich) from a 5 mg/mL chloroform 
aliquot were added. An additional 325 µL of HPLC-grade chloroform were added to the 
flask to ensure the formation of an even lipid cake. The pear-shaped flask was placed into 
a rotary evaporator with a water bath (R-215, V700, and V-855 with B-491; Buchi) and 
water-cooled condenser and evaporated for 30 minutes, adhering to the “20/40/60” rule. 
After this, the solid isolate was further dried under nitrogen flow for a minimum of 20 
minutes in order to evaporate all residual chloroform in the lipid cake. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and homogenized 
using a water bath sonicator (1800 Series Ultrasonic Cleaner; Branson) for 5 minutes at 
room temperature to produce a solution of dye-loaded nanomicelles. This solution was 
centrifuged at 300 rcf for 1 minute in order to pellet excess near-infrared dye. Then, 900 
µL of the nanomicelle-containing supernatant was combined with 100 µL of PBS and 50 
µL of perfluorohexane (FluoroMed, L.P.) in a 2-dram glass scintillation vial (VWR). The 
glass vial was placed into an ice bath and allowed to rest for 5 minutes. Then, the solution 
was probe sonicated in the ice bath with a 1/8” microtip (QSonica) at 1% power (1s on, 
15s off, 5 times) in order to produce a stock solution of PFCnDs, which was stored at 4°C 
in amber glass prior to use. 
Lyophilized polyinosinic-polycytidylic acid (poly(I:C)) (Sigma-Aldrich) was 
dissolved in sterile 7.40 pH PBS without calcium or magnesium (VWR) at a concentration 
of 10 mg/mL and frozen at -20°C in 100 µL aliquots. Before adjuvant loading, poly(I:C) 
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from aliquot was reannealed to ensure appropriate reconstitution. To achieve this, frozen 
aliquots were taken from -20°C and placed into a 60°C water bath for 20 minutes to thaw 
the solution and denature poly(I:C) strands. Then, the aliquots were removed from the bath 
and left to rest at room temperature for 20 minutes to allow for poly(I:C) strands to 
reanneal. 
To coat PFCnDs with adjuvant, the stock solution was first reconstituted by vortex 
pulsing the solution 10 times and then by water bath sonicating the stock for 1 minute at 
room temperature. From this reconstituted solution, 100 µL of PFCnDs were diluted in 2 
mL of PBS and bath sonicated for 2 minutes. This solution was then centrifugated at 3000 
rcf for 5 minutes in a low-adhesion microcentrifuge tube (2 mL; USA Scientific) in order 
to pellet the PFCnDs. The supernatant was removed and the PFCnDs were reconstituted in 
1 mL of 3.00 pH PBS in order to protonate DOPE groups on the shell. Of this positively 
charged PFCnD solution, 200 µL were added to a sterile low adhesion microcentrifuge 
tube with either 100 µL of 10 mg/mL poly(I:C) or 100 µL of sterile 7.40 pH PBS without 
calcium or magnesium (negative control). The tubes containing the PFCnDs were then 
placed into an ice bath on a shaker plate for thirty minutes to allow for anion exchange on 
the positively charged phospholipid surface of the PFCnD shell. 
After the thirty minutes, an additional 700 µL of sterile 7.40 pH PBS was added to 
each microcentrifuge tube, and the tubes were again spun down at 3000 rcf for 5 minutes 
to pellet the PFCnDs. The supernatant was removed and the PFCnDs were reconstituted in 
1 mL of phenol-free DMEM plus 4.5 g/L glucose, L-glutamine, and HEPES (Gibco, 
Thermo Fisher Scientific) supplemented with 10% FBS (Corning) and 1% penicillin-
streptomycin (Sigma-Aldrich). 
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Zeta Potential Measurements 
Nanodroplets were prepared as described in the synthesis section above. After the 
thirty-minute incubation step, 700 µL of 7.40 pH PBS were added to each sample to bring 
the total volume to 1.0 mL. Measurements of zeta potential were obtained by a standard 
DLS instrument (Zetasizer Nano ZS; Malvern Instruments Ltd.) using a folded capillary 
zeta cell (DTS1070; Malvern Instruments Ltd.). Samples were diluted 1:100 in 7.40 pH 
PBS prior to being loaded into the capillary cell. Each reported measurement is the average 
of ten successive zeta potential measurements, and three measurements were obtained for 
each sample. 
RAW 264.7 Cell Line 
RAW 264.7 BALB/c macrophages (ATCC), passage 7-8, were cultured in DMEM 
plus 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Corning) supplemented with 10% 
FBS (Corning) and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were maintained 
within T-75 flasks (CELLSTAR; Greiner Bio One, VWR) at 37°C in a humidified 
incubator with 5% CO2. 
To passage cells, the media was aspirated and replaced with 5 mL of fresh, 37°C -
warmed media. A sterile cell scraper with 25-cm handle (bioWORLD) was used to 
physically dislodge adherent cells from the bottom of the flask using serial, downward, 
squeegee-like strokes. After rinsing the scraper in the cell-rich media, an additional 5 mL 
of warmed media was added to the flask. Using a motorized pipette, the 10 mL of cell-rich 
media was first used to wash the base of the flask five times to dislodge any remaining 
adherent cells and then used to pipette the solution up-and-down vigorously five times in 
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order to form a single cell suspension. Finally, 50 to 1000 µL of this solution was used to 
seed the new flask pre-filled with fresh warmed media to ultimately reach a total final 
volume of 20 mL. 
RAW 264.7 cells resuspended from frozen aliquot were passed a minimum of one 
time in flask prior to being used to seed 96-well plates for in vitro experiments. 
Poly(I:C) Perfluorocarbon Nanodroplet Griess Assay 
 Starting with RAW 264.7 cells in a T-75 flask, the media was aspirated and 
replaced by 5 mL of sterile PBS without calcium or magnesium (VWR). The PBS was 
swirled around the bottom of the flask a minimum of 15 times in order to wash any residual 
phenol-containing media from the cells. This PBS was aspirated and replaced with 5 mL 
of pre-warmed phenol-free DMEM plus 4.5 g/L glucose, L-glutamine, and HEPES (Gibco, 
Thermo Fisher Scientific) supplemented with 10% FBS (Corning) and 1% penicillin-
streptomycin (Sigma-Aldrich). Cells were manually scraped and formed into a single-cell 
suspension, as detailed above, utilizing this phenol-free media. Next, the cells were pelleted 
at 400 rcf for 5 minutes and resuspended in phenol-free DMEM at a final concentration of 
5 × 105 cells per mL. 
 From this cell suspension, 100 µL (5 × 104 cells) were added to wells of a sterile 
96 well TC-treated black microplate (Cellstar, product number 655090; Greiner Bio-One), 
which was placed into an incubator for 24 hours. After the 24-hour period, 100 µL of 
particle-containing media were added to each well of RAW 264.7 cells. The four particle 
incubation conditions were as follows: pICnDs, blank pICnDs (no adjuvant), free 
poly(I:C), and phenol-free DMEM. Nanodroplets were prepared for incubation as detailed 
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previously. The free adjuvant solution was prepared by adding 100 µL of reannealed 10 
mg/mL poly(I:C) to 900 µL of phenol-free media, which results in a 500 µg/mL 
concentration of poly(I:C) per well. After bringing all well volumes to 200 µL, the 96-well 
plate was returned to the incubator for 12 hours. 
After the first 12 hours of particle incubation, the 96-well plate was removed from 
the incubator, and half of the wells were lased using a custom well-plate lasing 
system.152,153 This system integrates a 10 Hz nanosecond pulsed Nd:YAG laser (Vibrant; 
Opotek, Inc.) with a three-axis motorized stage (three 100mm Precision Ball Screw 
Positioner Table/Linear Actuator Stage 404XR; Parker Hannifin Corporation) and power 
meter (Nova II; Ophir Photonics) in order to lase individual wells of the 96-well plate in a 
controlled manner. The system is driven by LabVIEW 2016 software (National 
Instruments) that can control the number and intensity of laser pulses per well, modulating 
the energy via an external Q-switch delay triggered to the laser via a coupled function 
generator (AFG3022C; Tektronix, Inc.). The well-plate lasing system was used to lase half 
of the wells with 10 pulses of 1064-nm laser light at 10 Hz. Each laser pulse was 20±1 mJ 
with a beam profile approximately matched to the cross-section of the well, yielding an 
optical fluence of roughly 62.5 mJ/cm2. The lid of the 96-well plate was removed during 
the lasing procedure. The plate spent no more than 10 minutes outside of the incubator for 
the duration of this lasing step, and it was returned to the incubator immediately at the 
conclusion of lasing. 
Another 12 hours after the lasing step, the 96-well plate was again removed from 
the incubator. At this time, 100 uL of supernatant was removed from each well and placed 
into the corresponding well of a non-sterile 96 well TC-treated black microplate. A 
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volume-matched ladder of sodium nitrite (50 µM by twos to 0.78 µM and then 0 µM) in 
phenol-free DMEM was created in triplicate in the first three columns of this non-sterile 
well plate. A 40 mg/mL solution of modified Griess reagent (product number G4410; 
Sigma-Aldrich) was created in deionized water, and 100 µL of this solution was added to 
each sample well in the new 96-well plate. The preceding transfer and incubation steps 
were performed in darkness as to minimize light exposure to the colorimetric Griess 
reagent. 
After allowing the Griess reagent to incubate with the samples for 10 minutes in 
darkness, the well-plate was placed into a microplate reader (Synergy HT; BioTek 
Instruments) for quantitative absorbance measurements. Using the standard plate reader 
software (Gen5; BioTek Instruments), an absorbance spectrum from 500 to 650 nm in 2-
nm steps was acquired for each sample well. These spectra were exported to an Excel 
spreadsheet and processed in MATLAB (MathWorks). For each well, the absorbance at 
baseline (650 nm) was subtracted from the absorbance at the peak of the modified Griess 
reagent (546 nm). These adjusted absorbance values were arranged in a matrix and 
exported in a plain Excel spreadsheet. Processed data were ultimately plotted in R (R Core 
Team) using the ggplot2 data visualization package. A linear regression of the ladder data 
was used to convert absorbance data to moles of nitrite detected. 
Statistical Analysis 
Statistical analyses were performed in R (R Core Team). A two-way ANOVA was 
performed on the data to assess the factors of particle incubation and lasing on nitrite 
production, as assessed by adjusted absorbance. For factors with a significant impact on 
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the adjusted absorbance, a post hoc Tukey’s test was performed to assess all pairwise 
differences in the adjusted absorbance means for groups within the factor. 
4.2.4 Results and Discussion 
The conserved TLR3 domain recognizes double-stranded RNA because this 
antigen is typically of viral origin in a biological setting. When internalized by Mφs or 
DCs, pI:C leads to a TH1 response via TLR3 agonism.
147 This is because pI:C is structurally 
similar to double-stranded RNA and can thus serve as a double-stranded RNA mimic. 
Because of this structural similarity, particle design modifications developed for the 
delivery of genetic material should also prove efficacious for delivering pI:C. Liposomes 
and other gas-filled, ultrasound responsive agents have previously been used for gene 
delivery.154-156 In these formulations, cationic lipids were utilized within the shell to load 
genetic material onto the particle surface via electrostatic interaction between the cationic 
particle exterior and the highly anionic phosphate backbone of DNA or RNA. 
In the poly(I:C) perfluorocarbon nanodroplets (pICnDs) presented here, we based 
our formulation on that of cationic liposomes. We elected to use DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane) as our cationic lipid and DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) as a “helper” lipid.157 Under acidic conditions, the head group of 
DOPE is also protonated, and both DOPE and DOTAP can participate in electrostatic 
interactions with phosphate groups in poly(I:C) during adjuvant incubation. To test 
whether this formation allowed for adherence of poly(I:C) to the nanodroplet surface, we 
performed zeta potential measurements of particles resuspended in 7.40 pH PBS following 
incubation with either poly(I:C) adjuvant or a volume equivalent of 7.40 pH PBS under 
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acidic conditions. Zeta potential is proportional to the surface charge of particles in 
solution.158 After incubation and resuspension, the zeta potential of pICnDs was -11.16 mV 
as compared to the -4.54 mV measured from “blank” nDs incubated without adjuvant 
(Table 2). The more negative zeta potential of pICnDs indicates that poly(I:C) is 
appropriately adhering to the particles’ surface, as its phosphate backbone makes poly(I:C) 
molecules anionic. 
Table 2: Zeta Measurements for Loaded and Unloaded pICnDs 








Blank nDs -4.54±0.47 0.00±0.00 -0.3577±0.0373 15.0±0.4 
pICnDs -11.16±1.72 0.00±0.00 -0.8788±0.1357 14.8±0.3 
After obtaining preliminary evidence of adjuvant adherence to the nanodroplet 
surface in our pICnD formulation, we proceeded to conduct a functional in vitro assay of 
our immunotherapeutic particles. We elected to use BALB/c-derived RAW 264.7 Mφs as 
a model APC line. This cell line was utilized to demonstrate canonical TLR3 agonism by 
poly(I:C).147 Additionally, there are a variety of syngeneic models of cancer that utilize a 
BALB/c background, which would increase the import of these in vitro results for 
downstream in vivo immunotherapeutic studies. Cells were seeded in a 96-well plate and 
incubated for 24 hours to give them sufficient time to recover from the stress of passaging 
and re-enter a log growth phase. Following this seeding period, wells were incubated with 
either pICnDs, PBS-incubated “blank” nDs, free poly(I:C) (positive control), or media 
(negative control). 
Twelve hours after particle incubation with RAW 264.7 Mφs, cells were irradiated 
with pulse near-infrared laser light at 1064 nm using a custom well-plate lasing system. 
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The wait step prior to laser irradiation gives sufficient time for free particles to be 
endocytosed by Mφs within the wells. For lased wells, the lasing sequence was designed 
to mimic the effect of an acute US/PA imaging session. Here, the concern is not thermal 
deposition from the laser but mechanical effects from the repeated vaporization and 
recondensation of intracellular PFHnDs. During vaporization, PFHnDs expand between 3-
5 times in diameter,119,159 which corresponds to a two or three order-of-magnitude 
volumetric expansion. It is possible that repeated vaporization and recondensation of 
PFCnDs may impact either positively impact Mφ response to adjuvant by mechanically 
releasing adjuvant from the pICnD surface or negatively impact Mφ response to adjuvant 
by damaging its internal organelles. 
Another twelve hours after true or sham laser irradiation, supernatant from the wells 
was isolated for a Griess assay. This is an established assay that utilizes a colorimetric 
reagent that detects the presence of nitrite ions in solution.160-162 Nitrite is a stable 
breakdown product of nitric oxide,163 and it can be used as a surrogate for nitric oxide 
production.164 Macrophages produce nitric oxide in response to TLR agonism,165 and nitric 
oxide from activated Mφs produces a variety of downstream effects, from antimicrobial 
activity to adaptive immune modulation.166,167 The results of the Griess assay for our in 
vitro studies of RAW 264.7 Mφs are shown in Figure 17 below. 
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Figure 17: In vitro Griess assay of RAW 264.7 macrophages. Nitrite is a stable 
breakdown product of nitric oxide, which is produced by macrophages after adjuvant 
stimulation. The production nitrite in wells incubated with media or naïve PFCnDs is 
marginal, whereas nitrite production is elevated in wells incubated with pICnDs and free 
pI:C: adjuvant. Two-way ANOVA was performed with post hoc Tukey’s test between 
incubation conditions. * p<1×10-7. 
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A two-way ANOVA revealed significant differences between incubation 
conditions but not between lasing conditions. In terms of the particle incubations, wells 
incubated with media or unloaded “blank” nDs produced minimal nitrite, with responses 
below the working range of the modified Griess reagent. Wells incubated with pICnDs 
displayed a significantly increased nitrite production compared to these negative controls. 
However, the average nitrite production from pICnD-incubated wells, 1.8 µM, was nearly 
an order-of-magnitude lower than that observed from free adjuvant incubation, 13.1 µM. 
It is worth noting that the selected free adjuvant incubation, 500 µg/mL, is well in excess 
of what is reported in the literature for positive controls.160,168 Thus, the levels of nitrite 
observed likely represent the maximal potential response of RAW 264.7 Mφs to poly(I:C) 
stimulation. Still, more work is necessary to optimize the loading and delivery of adjuvant 
to APCs via pICnDs. 
Ongoing studies will seek to improve the loading efficiency of poly(I:C) to cationic 
nDs in order to improve Mφ activation. We will explore increasing the molar percentage 
of cationic lipids within the shell, altering the pH of adjuvant incubation, and using a 
different subset of helper lipids. Of note, the helper lipid DOPE has been used in gene 
delivery to facilitate endosomal escape by destabilizing the endosomal membrane.157,169,170 
Although this phenomenon is beneficial for traditional gene delivery, poly(I:C) produces 
its effects at TLR3, which is located within the endosome. Endosomal escape may account 
for some of the attenuated nitrite production observed in pICnD wells in our in vitro study, 
but further work is necessary to characterize this effect. The PEGylated lipid within the 
preliminary pICnD formulation already affords some steric stabilization to the nDs.76 As 
 98 
such, it is possible that future iterations of pICnDs can replace DOPE with additional 
cationic lipid without destabilizing the construct. 
In conclusion, we have developed a new class of PFCnDs capable of focally 
delivering adjuvant. These particles have the potential to facilitate US/PA image-guided 
immunotherapy. Our preliminary studies support the ability to adhere poly(I:C) to the 
cationic shell surface of PFCnDs, and in vitro studies show that these particles are capable 
of eliciting an immune response from APCs. We have shown that this response is 
unaffected by the mechanical effects induced by the repeated laser-activated vaporization 
and recondensation of PFCnDs, which is necessary for contrast-enhanced US/PA imaging 
of these contrast agents. Future studies will optimize the ability of these particles to retain 
and deliver adjuvant, increasing the probability of eliciting and effective immune response 
in vivo. The in vivo implementation of adjuvant-delivering particles will require additional 
optimization, as it is dependent upon the complex interplay between innate and adaptive 
immune cells that in vitro methods, such as co-culture, do not always faithfully 
recapitulate. Nonetheless, the proof-of-concept studies presented here lay the groundwork 
for a timely and bold new direction in therapeutic contrast-enhanced US research. 
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CHAPTER 5. ASSESSING PERFLUOROCARBON 
NANODROPLET EXTRAVASATION WITHIN PRIMARY BREAST 
TUMORS 
5.1 Antibody-Functionalized Perfluorohexane Nanodroplets for Molecularly 
Specific Ultrasound Imaging in Cancer 
5.1.1 Abstract 
The molecular makeup of solid tumors plays an integral role in their diagnosis, 
prognosis, and therapy. Standard-of-care methods for sampling tissue for histological 
analysis of molecular markers, such as biopsy, may be contraindicated based on anatomical 
location or patient comorbidities and can be subject to sampling error. Molecular imaging 
techniques provide one avenue for real-time, non-invasive analysis of entire lesions as 
either an adjunct to or replacement for these techniques. Ultrasound is one such non-
invasive, non-ionizing imaging modality that can provide molecular information through 
the use of functionalized contrast agents. However, gas microbubbles, which are the 
standard contrast agents used clinically with ultrasound, are too large to extravasate 
through fenestrations in leaky tumor vasculature to bind cancer markers when delivered 
systemically. Perfluorocarbon nanodroplets (PFCnDs) are a phase-change class of 
ultrasound contrast agents that are submicrometer sized prior to on-demand user activation 
into microbubbles in situ. These PFCnDs are small enough to extravasate after 
intravascular delivery, and these agents can be functionalized to afford molecular 
specificity. In this proof-of-principle study, we demonstrate one such functionalization 
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strategy: the conjugation of monoclonal antibodies to the PFCnD surface via thiol 
chemistry. After synthesizing targeted PFCnDs through this methodology, we then apply 
these PFCnDs to an assay of cancer cells in vitro. We demonstrate that PFCnDs targeted 
to breast cancer markers preferentially adhere to the surface of cancer cells that express 
this marker and that it is the molecularly specific binding of the antibodies that is 
responsible for this interaction. This study builds the foundation for the use of targeted 
PFCnDs in whole-organism studies of solid tumors. 
5.1.2 Introduction 
Diagnosis of solid tumors, such as breast cancer, typically involves histological 
analysis of samples obtained via biopsy. After sectioning the sample, a pathologist can 
assess the tissue morphology and molecular makeup in order to diagnose and sub-type the 
potential tumor. Different tumor subtypes dictate different courses of treatment for the 
patient. In breast cancer, for example, tumor subtypes are delineated by the relative 
expression of three cellular receptors: estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (HER2). Each of these receptors has a 
corresponding treatment that will affect cells overexpressing them; for example, tamoxifen, 
a selective estrogen receptor modulator, is often prescribed to ER-positive patients. 
Molecular markers play a role throughout the clinical work-up: from diagnosis to 
therapy. However, the biopsy process used to sample tissue for molecular analysis is not 
without drawbacks. Biopsy is prone to sampling error and has the potential for morbidity 
due to the presence of nearby arteries, lymphatic vessels, and nerves in common locations 
for solid tumors. Therefore, non-invasive methods of assessing the molecular composition 
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of tumors are of high clinical interest. Imaging techniques, such as ultrasound, have the 
potential to be used to assist or potentially even supplant biopsy. However, an exogenous 
contrast agent with molecular specificity is necessary to facilitate molecular-specific 
imaging. 
Molecular targeting provides a means by which contrast agents, such as PFCnDs, 
can attain disease-state specificity. Several groups have reported surface coating of 
liposomes and perfluorocarbon-based particles with targeting ligands.171-174 In this study, 
we seek to demonstrate disease-state specificity by conjugating PFCnDs to monoclonal 
antibodies (mAbs). Our in vitro assay demonstrates that conjugation to mAbs for 
extracellular cellular moieties causes PFCnDs to focally adhere to cancer cells and that this 
interaction is molecularly specific. 
5.1.3 Materials and Methods 
Targeted Perfluorocarbon Nanodroplet Synthesis 
Prior to synthesis of the nanodroplet stock solution, monoclonal antibodies to either 
HER2 (ab16901 lot # GR3215414-5; abcam) or Gamma-sarcoglycan (H-60 lot # 
SC515128; Santa Cruz Biotechnology) were modified with Traut’s reagent (2-
iminothiolane hydrochloride; Sigma-Aldrich) to create sulfhydryl groups from primary 
amine groups on the antibodies. Maleimide groups on the surface of the nanodroplets from 
stock can then react with these sulfhydryl groups to tether monoclonal antibodies to the 
nanodroplet surface. One microliter of a 1:20 PBS dilution of 2 mg/mL Traut’s reagent in 
PBS was added to each of three antibody aliquots (10 µL; 1 mg/mL) after thawing them at 
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room temperature. These aliquots were allowed to incubate for one hour at room 
temperature, during which time the stock solution of nanodroplets was synthesized. 
One micromole (10−6 mol) of DSPC, DSPE-PEG2000 Maleimide, and DSPE-
mPEG2000 (all from Avanti Polar Lipids, Inc) in a 1:2:7 molar ratio was extracted from 
chloroform aliquots and added to a 10 mL pear-shaped flask (Aldrich). To this isolate, 330 
µg of DiI (Invitrogen) from a 3 mg/mL chloroform aliquot were added. The pear-shaped 
flask was covered in aluminum foil and placed into a rotary evaporator with a water bath 
(R-215, V700, and V-855 with B-491; Buchi) and water-cooled condenser and evaporated 
for 30 minutes, adhering to the “20/40/60” rule. After this, the solid isolate was further 
dried under nitrogen flow for a minimum of 20 minutes in order to evaporate all residual 
chloroform in the lipid cake. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and homogenized 
using a water bath sonicator (1800 Series Ultrasonic Cleaner; Branson) for 5 minutes at 
room temperature to produce a solution of dye-loaded nanomicelles. This solution was 
centrifuged at 300 rcf for 1 minute in order to pellet excess DiI. Then, 900 µL of the 
nanomicelle-containing supernatant was combined with 100 µL of PBS and 50 µL of 
perfluorohexane (FluoroMed, L.P.) in a 2-dram glass scintillation vial (VWR). The glass 
vial was placed into an ice bath and allowed to rest for 5 minutes. Then, the solution was 
probe sonicated in the ice bath with a 1/8” microtip (QSonica) at 1% power (1s on, 15s off, 
5 times) in order to produce the stock solution of PFCnDs, which was stored at 4°C in 
amber glass prior to incubation with antibodies. 
 103 
After the one-hour Traut’s reagent incubation, 1 µL of a 1:10 PBS dilution of a 
quenching solution of 1 mg/mL glycine (Invitrogen UltraPure; Thermo Fisher Scientific) 
in PBS was added to each of the three antibody aliquots. The quenched antibody solutions 
were allowed to rest for 5-10 minutes prior to incubation with nanodroplets. 
Prior to antibody incubation, 100 µL of the PFCnD stock solution was diluted in 1 
mL of PBS and bath sonicated for 2 minutes. All three quenched antibody aliquots (12 µL 
each; 36 µL total) were added to this diluted nanodroplet stock and left to incubate in the 
dark within an ice bath on a shaker plate for two hours, replacing ice in the water bath at 
the one-hour mark. After the two-hour incubation, 1 µL of 1-butanethiol (Acros Organics; 
Thermo Fisher Scientific) was added to the solution to quench all unreacted maleimide 
groups. This quenched solution was allowed to rest for 5-10 minutes prior to resuspension. 
 After quenching, the targeted PFCnD solution was centrifugated at 3000 rcf for 5 
minutes in order to pellet the PFCnDs. The supernatant was removed and the PFCnDs were 
reconstituted in 1 mL of sterile PBS. This solution was then diluted 1:10 in pre-warmed 
DMEM media, described below, for incubation with cells. 
SK-BR-3 Cell Line 
SK-BR-3 HER2+ breast adenocarcinoma cells (ATCC), passage 5-10, were 
cultured in DMEM plus 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Corning) 
supplemented with 10% FBS (Corning) and 1% penicillin-streptomycin (Sigma-Aldrich). 
Cells were maintained within T-75 flasks (CELLSTAR; Greiner Bio One, VWR) at 37°C 
in a humidified incubator with 5% CO2. 
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 To passage cells, all media was aspirated from the T-75 flask and replaced by 5 mL 
of sterile PBS without calcium or magnesium (VWR). The PBS was swirled around the 
bottom of the flask a minimum of 15 times in order to wash any residual media from the 
cells. The PBS was then aspirated and replaced by 2 mL of 0.25% Trypsin/2.21 mM EDTA 
in HBSS without sodium bicarbonate, calcium, or magnesium (Corning), enough volume 
to cover the entire bottom of the T-75. The flask was placed back into the incubator for 3 
minutes and then removed. After gently agitating the flask and visually inspecting for signs 
of cell detachment, 8 mL of pre-warmed DMEM media, prepared as described above, was 
added to the flask to bring the total volume to 10 mL. This solution was used to wash the 
bottom of the flask five times, dislodging any residually adhering cells. Then, the solution 
was vigorously pipetted up-and-down five times in order to form a single-cell suspension. 
Lastly, 50 to 1000 µL of this solution was used to seed the new flask pre-filled with fresh 
warmed media to ultimately reach a total final volume of 20 mL. 
MDA-MB-231 Cell Line 
 MDA-MB-231 triple-negative breast adenocarcinoma cells (ATCC), passage 10-
15, were cultured in DMEM plus 4.5 g/L glucose, L-glutamine, and sodium pyruvate 
(Corning) supplemented with 10% FBS (Corning) and 1% penicillin-streptomycin (Sigma-
Aldrich). Cells were maintained within T-75 flasks (CELLSTAR; Greiner Bio One, VWR) 
at 37°C in a humidified incubator with 5% CO2. 
To passage cells, all media was aspirated from the T-75 flask and replaced by 5 mL 
of sterile PBS without calcium or magnesium (VWR). The PBS was swirled around the 
bottom of the flask a minimum of 15 times in order to wash any residual media from the 
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cells. The PBS was then aspirated and replaced by 2 mL of 0.25% Trypsin/2.21 mM EDTA 
in HBSS without sodium bicarbonate, calcium, or magnesium (Corning), enough volume 
to cover the entire bottom of the T-75. The flask was placed back into the incubator for 3 
minutes and then removed. After gently agitating the flask and visually inspecting for signs 
of cell detachment, 8 mL of pre-warmed DMEM media, prepared as described above, was 
added to the flask to bring the total volume to 10 mL. This solution was used to wash the 
bottom of the flask five times, dislodging any residually adhering cells. Then, the solution 
was vigorously pipetted up-and-down five times in order to form a single-cell suspension. 
Lastly, 50 to 1000 µL of this solution was used to seed the new flask pre-filled with fresh 
warmed media to ultimately reach a total final volume of 20 mL. 
In vitro Cell Targeting Assay 
Cells, either SK-BR-3 or MDA-MB-231, were trypsinized as detailed previously, 
pelleted at 300 rcf for 5 minutes, and resuspended in fresh, pre-warmed media at a 
concentration of 5 × 103 cells per mL. Then, 3 mL of media (1.5 × 104 cells) were added 
to each well of a sterile, glass-bottomed 6-well plate (Chemglass). The seeded 6-well plate 
was kept in the incubator for 2-3 days prior to the start of the assay. 
On the day of the assay, DiI-labelled, maleimide functionalized PFCnDs were 
synthesized as described above. These PFCnDs were either targeted (anti-HER2), 
mistargeted (anti-Gamma-sarcoglycan), or untargeted (1-butanethiol backfill only). The 
media in each well was aspirated and replaced with 2 mL of PFCnD-containing media. The 
6-well plate was then returned to the cell incubator for 2 hours, with brief, manual agitation 
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of the plate every 10 minutes to prevent the negatively buoyant PFCnDs from completely 
sinking during this time. 
After the 2-hour incubation with PFCnDs, the wells were washed to remove 
unbound PFCnDs. The media in each well was aspirated and replaced by fresh, pre-
warmed, PFCnD-free media a total of three times. Next, 1.5 µL of 10 mM Green CMFDA 
Dye (CellTracker™; Invitrogen) in DMSO was added to each well and allowed to incubate 
for 45 minutes. After incubation with this dye, the well plate was immediately imaged 
under confocal microscopy. 
Confocal imaging was performed within the Optical Microscopy Core in the Petit 
Institute for Bioengineering and Bioscience at Georgia Tech. Cells were imaged on a Zeiss 
laser scanning microscope consisting of an LSM 700 scan head mounted on an 
AxioObserver Z1 inverted microscope stand with a motorized stage. Images were obtained 
with laser lines at 488 and 555 nm using a 10x / 0.3 N.A. Plan Apochromat objective lens 
with a working distance of 5.20 mm. 
5.1.4 Results and Discussion 
The use of Traut’s reagent is common to create sulfhydryl groups from primary 
amine groups on antibodies. Sulfhydryl groups can then be used for antibody conjugation 
via a thiol chemistry-based approach. Here, we utilize a maleimide linker on the PFCnD 
shell in order to achieve bioconjugation of antibodies to the nanodroplet surface. However, 
antibodies have primary amine groups throughout their structure. As such, it is possible 
that antibodies can be attached to PFCnDs in an orientation where the antigen-binding sites 
are not outwardly facing. It is also possible, even with appropriate directional conjugation, 
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that the Traut’s reagent may convert additional primary amines to sulfhydryl groups within 
the antigen-binding site itself. Depending on the resulting conformational change induced 
such a substitution, the Traut’s reagent may inadvertently inactivate some antibodies in 
solution. As such, it is important to assess this synthesis strategy to ensure that it affords 
sufficient functional antibody attachment to be used in downstream in vivo studies that 
require a molecularly specific agent. 
Prior to any in vitro assays, the PFCnDs in this protocol were coarsely assessed for 
successful bioconjugation via average size measurements using DLS. Figure 18 shows the 
size measurements of PFCnDs before and after incubation with thiolated antibodies. The 
large increase in hydrodynamic diameter from 268 to 423 nm, far more than would be 
expected from Ostwald ripening alone,76 suggests that the Traut’s reagent bioconjugation 
protocol successfully attaches antibodies to the PFCnDs’ surface. After this coarse 
assessment, we proceeded to a more relevant in vitro assay to assess the binding of 
bioconjugated PFCnDs to their intended molecular targets. 
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Figure 18: Average PFCnD size data before and after anti-HER2 antibody 
incubation. Data demonstrate an increase in Z-Average in excess of what would be 
expected from Ostwald ripening over the incubation time period, suggesting successful 
antibody conjugation. 
We hypothesize that targeted PFCnDs will focally adhere to cancer cells as a result 
of the molecularly specific binding of bioconjugated antibodies on the nanodroplet shell to 
their corresponding extracellular targets on the cancer cell surface. This molecular 
interaction is necessary to accumulate PFCnDs within tumors to permit diagnostic contrast-
enhanced US/PA imaging with these agents. As such, we performed a controlled in vitro 
assessment of this binding by incubating cancer cells of different receptor status with 
fluorescently labelled PFCnDs and assessing their binding via confocal imaging. 
Representative data from this assay can be seen in Figure 19. 
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Figure 19: Representative confocal images from the in vitro PFHnD targeting assay. 
HER2-positive SK-BR-3 cells (A, B, C) or HER2-negative MDA-MB-231 cells (D, E, F) 
incubated with untargeted (A, D), mistargeted (B, E), or targeted (C, F) PFHnDs. After 
washing, only C) shows appreciable enhancement from PFHnD fluorescent signal. 
As mentioned, human breast cancer is often classified by the expression levels of 
ER, PR, and HER2 within tumor tissue samples. Of these three classically assessed 
receptors, only HER2 is constitutively present on the extracellular membrane where it can 
interact with extracellular contrast agents. For this reason, we elected to conduct our in 
vitro assay of breast cancer cells with HER2 as the molecular target of interest. We utilized 
two established cell lines of HER2-positive (SK-BR-3) and HER2-negative (MDA-MB-
231) breast cancer. 
To adequately assess the impact of binding from the PFCnDs’ perspective, we 
employed three distinct control populations. First, as a negative control, we incubated 
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maleimide-group containing PFCnDs without antibodies and only performed a 1-
butanethiol backfill to cap all maleimide groups. Second, we performed a mistargeted 
control by incubating PFCnDs with Traut’s reagent functionalized monoclonal antibodies 
to Gamma-sarcoglycan. Gamma-sarcoglycan is expressed within the cell membranes of 
striated muscle,175 and therefore, it should not be expressed in breast cancer cells of 
epithelial origin. Lastly, we included PFCnDs incubated with Traut’s reagent 
functionalized monoclonal antibodies to HER2, our target of interest. After incubating cells 
with particles in these groups, the media in the wells was aspirated and replaced with 
PFCnD-free media three times in order to wash out unbound PFCnDs remaining in solution 
prior to imaging. 
As shown in the representative data, the highest focal retention of PFCnD fluorescent 
signal was observed for the molecularly appropriate targeted group (Figure 19C). For cells 
with the appropriate HER2 target, untargeted (Figure 19A) and mistargeted (Figure 19B) 
PFCnDs only exhibited minor residual adhesion to cells. Given the homogenously colored 
appearance of isolated cells in each of the SK-BR-3 incubation wells, it is also possible 
that some of the retained fluorescence may be due to the nonspecific transfer of DiI from 
PFCnDs into the cell membranes of cancer cells upon contact,176,177 although this 
phenomenon is rare. 
Similar to the negative controls in the HER2-positive cell case, the HER2-negative 
cell conditions show minimal (Figure 19D) or absent (Figure 19E, Figure 19F) PFCnD 
fluorescent signal after washing wells. This is an important finding, as along with the 
mistargeted PFCnD control data it precludes the possibility of an unknown surface protein 
interaction that could lead to confounding appreciable accumulation of targeted PFCnDs 
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at the cancer cell surface. Taken together, these in vitro data suggest that PFCnDs targeted 
to extracellular cell markers will focally adhere to these markers due to the molecularly 
specific interaction of bioconjugated antibodies on the particle surface. The results are 
encouraging for the advancement of PFCnDs towards in vivo molecular US/PA imaging. 
In conclusion, we have developed a facile method of bioconjugating antibodies to 
the surface of PFCnDs. We have then utilized this method to demonstrate that HER2 
targeted PFCnDs focally adhere to HER2-positive breast cancer cells in vitro and that this 
interaction is molecularly specific. Our ongoing research efforts with these particles will 
move towards applying them to the molecularly specific imaging of HER2-positive tumors 
in vivo. More generally, these methods open up the possibility for the molecularly-specific 
imaging of a wide array of surface markers, both epithelial and endothelial, with US/PA 
imaging. 
5.2 Imaging of Intravascularly Delivered Perfluorohexane Nanodroplets in 
Primary Breast Tumors 
5.2.1 Abstract 
To accommodate their growing metabolic demands, many solid tumors recruit 
blood vessels via the secretion of pro-angiogenic cytokines. The resulting aberrant 
angiogenesis produces neovasculature that is torturous and “leaky,” with large gaps 
between endothelial cells. These endothelial fenestrations provide an opportunity, 
however, for the delivery of diagnostic or therapeutic particles that are small enough to be 
transported through them. Many preclinical researchers have utilized the combination of 
fenestrated vasculature and impaired lymphatic outflow to deliver particles to primary 
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tumors through what is known as the enhanced permeability and retention effect. The 
ability to image particles delivered to tumors is critical for providing real-time diagnoses 
and confirming therapeutic delivery. In ultrasound imaging, the diagnostic contrast agent 
used clinically is gas microbubbles. Unfortunately, microbubbles are too large to 
extravasate from through fenestrations into the tumor stroma when they are delivered 
systemically. In response to this limitation, perfluorocarbon nanodroplets (PFCnDs) were 
developed. PFCnDs are submicrometer agents that can be triggered to vaporize into 
microbubbles in situ, affording ultrasound and photoacoustic contrast in the process. The 
overarching goal was to be able to deliver the submicrometer form of PFCnDs 
intravascularly, allow them to be transported into the tumor stroma, and then trigger them 
for extravascular contrast-enhanced ultrasound imaging. However, researchers have yet to 
show that PFCnDs extravasate in a realistic small animal model of primary cancer. To this 
end, we investigated the use of PFCnDs for ultrasound and photoacoustic (US/PA) imaging 
in two immunocompetent, orthotopic models of primary breast cancer. We also 
implemented a drug regimen to attempt to increase PFHnD delivery in these models. Our 
preliminary results, while inconclusive, lay the groundwork to obtain results that will be 
scalable to human neoplastic disease. 
5.2.2 Introduction 
All neoplastic diseases are the result of genetic mutations that result in a pro-growth 
phenotype within cells. This occurs either by the upregulation of growth pathways (proto-
oncogenes) or by the disruption of pathways that keep aberrant growth in check (tumor-
suppressor genes). If this rampant growth occurred in isolation, then all neoplastic growths 
would be self-limited, as their metabolic demands would rapidly outpace the local 
 113 
availability of metabolic resources. However, the metabolic demands of the tumor, 
specifically the ensuing local hypoxia, create a selective pressure for the secretion of pro-
angiogenic cytokines.178 This induces local angiogenesis to supply oxygen and other 
nutrients to support the continued growth and eventual metastasis of the neoplasm. 
Tumor vessels grow through the same mechanisms of angiogenesis as in embryonic 
development: sprouting or intussusception from existing vascular networks.179 Circulating 
endothelial precursor cells may also play a role in tumor angiogenesis.180,181 A diverse array 
of molecular pathways contribute towards the formation of cancer neovasculature. Chief 
among these are members of the vascular endothelial growth factor (VEGF) and 
angiopoietin (Ang) pathways.178 The molecular regulators of angiogenesis are not as well 
coordinated in tumor angiogenesis as in physiological angiogenesis. Consequently, tumor 
neovasculature is structurally abnormal as compared to physiological vasculature. Tumor 
blood vessels are often tortuous and dilated with excessive communicating shunts. This 
disorganization leads to localized chaotic blood flow,182 which results in hypoxic and acidic 
regions within tumors.183 Additionally, the underlying structure of tumor blood vessels is 
abnormal. Tumor neovessels are “leaky.”69,70,184 The vascular walls are porous, owing to 
endothelial fenestrae, vesicles, and transcellular holes in addition to widened 
interendothelial junctions.178 The endothelial pore size in leaky tumor neovasculature has 
been reported to be between 380 to 780 nm;69-71 however, these estimates were likely 
biased towards the larger side of what is observed clinically in human solid tumors.72 
The hyperpermeability of tumor neovasculature coupled with defective lymphatic 
drainage in neoplastic tissue can result in the penetration and retention of both 
nanoparticles and small molecules into the tumor stroma.71,185,186 This phenomenon is 
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referred to as the enhanced permeability and retention (EPR) effect, and it has been 
championed by biomedical researchers for decades as a mechanism to passively target 
diagnostic and therapeutic agents to tumors following intravascular administration.72,187 
Although EPR shows promise in preclinical xenograft models,188 vascular leakiness has 
been shown to be heterogeneous across time and space as well as in response to 
treatment.189 Therefore, translational efforts should employ adjunct strategies, such as 
active targeting and pharmacological vascular remodeling, to achieve appreciable delivery 
through EPR.72,190-192 
For years, researchers in the ultrasound contrast agent community have promised 
that PFCnDs could be used as extravascular contrast agents in tumors due to their size and 
the EPR effect.59,77,118,119,193 However, little meaningful progress has been made towards 
rigorously proving that this phenomenon occurs. Several groups have shown signal 
enhancement in primary tumors inoculated non-orthotopically in the flank,194 but these 
tumor models bear no resemblance to known human disease. 
The goal of these studies was to investigate the potential for PFCnD extravasation 
in a realistic model of breast cancer. We performed US/PA imaging before, immediately 
after, and 24 hours after intravenous PFCnD administration. We then compared the results 
of US/PA imaging to histology. Additionally, we utilized a regimen of angiotensin receptor 
blocker microdosing in an attempt to decrease tumor solid stress and improve particle 
delivery. These efforts represent a critical reframing of the biological application that has 
justified the development of phase-change US agents for the last two decades, and they 
highlight lingering challenges in ongoing efforts to conclusively demonstrate PFCnD 
extravasation. 
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5.2.3 Materials and Methods 
Targeted Perfluorocarbon Nanodroplet Synthesis 
Prior to synthesis of the nanodroplet stock solution, monoclonal antibodies to Erbb2 
(ab16901 lot # GR3215414-5 or GR3283213-2; abcam) or polyclonal antibodies to 
EpCAM (ab71916 lot # GR3292991-1; abcam) were modified with Traut’s reagent (2-
iminothiolane hydrochloride; Sigma-Aldrich) to create sulfhydryl groups from primary 
amine groups on the antibodies. Maleimide groups on the surface of the nanodroplets from 
stock can then react with these sulfhydryl groups to tether monoclonal antibodies to the 
nanodroplet surface. One microliter of a 1:20 PBS dilution of 2 mg/mL Traut’s reagent in 
PBS was added to each of three antibody aliquots (10 µL; 1 mg/mL) after thawing them at 
room temperature. These aliquots were allowed to incubate for one hour at room 
temperature, during which time the stock solution of nanodroplets was synthesized. 
One micromole (10−6 mol) of DSPC, 18:0 Cy5 PE, DSPE-PEG2000 Maleimide, 
and DSPE-mPEG2000 (all from Avanti Polar Lipids, Inc) in a 2:2:5:11 molar ratio was 
extracted from chloroform aliquots and added to a 10 mL pear-shaped flask (Aldrich). To 
this isolate, 0.5 mg of near-infrared-absorbing dye (IR-1048; Sigma-Aldrich) from a 5 
mg/mL chloroform aliquot were added. An additional 400 µL of HPLC-grade chloroform 
were added to the flask to ensure the formation of an even lipid cake. The pear-shaped flask 
was covered in aluminum foil and placed into a rotary evaporator with a water bath (R-
215, V700, and V-855 with B-491; Buchi) and water-cooled condenser and evaporated for 
30 minutes, adhering to the “20/40/60” rule. After this, the solid isolate was further dried 
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under nitrogen flow for a minimum of 20 minutes in order to evaporate all residual 
chloroform in the lipid cake. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and homogenized 
using a water bath sonicator (1800 Series Ultrasonic Cleaner; Branson) for 5 minutes at 
room temperature to produce a solution of dye-loaded nanomicelles. This solution was 
centrifuged at 300 rcf for 1 minute in order to pellet excess near-infrared dye. Then, 900 
µL of the nanomicelle-containing supernatant was combined with 100 µL of PBS and 50 
µL of perfluorohexane (FluoroMed, L.P.) in a 2-dram glass scintillation vial (VWR). The 
glass vial was placed into an ice bath and allowed to rest for 5 minutes. Then, the solution 
was probe sonicated in the ice bath with a 1/8” microtip (QSonica) at 1% power (1s on, 
15s off, 5 times) in order to produce the stock solution of PFCnDs, which was stored at 
4°C in amber glass prior to incubation with antibodies. 
After the one-hour Traut’s reagent incubation, 1 µL of a 1:10 PBS dilution of a 
quenching solution of 1 mg/mL glycine (Invitrogen UltraPure; Thermo Fisher Scientific) 
in PBS was added to each of the three antibody aliquots. The quenched antibody solutions 
were allowed to rest for 5-10 minutes prior to incubation with nanodroplets. 
Prior to antibody incubation, 100 µL of the PFCnD stock solution was diluted in 1 
mL of PBS and bath sonicated for 2 minutes. All three quenched antibody aliquots (12 µL 
each; 36 µL total) were added to this diluted nanodroplet stock and left to incubate in the 
dark within an ice bath on a shaker plate for two hours, replacing ice in the water bath at 
the one-hour mark. After the two-hour incubation, 1 µL of 1-butanethiol (Acros Organics; 
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Thermo Fisher Scientific) was added to the solution to quench all unreacted maleimide 
groups. This quenched solution was allowed to rest for 5-10 minutes prior to resuspension. 
After quenching, the targeted PFCnD solution was centrifugated at 3000 rcf for 5 
minutes in order to pellet the PFCnDs. The supernatant was removed and the PFCnDs were 
reconstituted in 150-300 µL of sterile saline for imaging. This protocol produces PFCnDs 
with a hydrodynamic diameter of 400-600 nm measured via dynamic light scattering 
(Zetasizer Nano ZS; Malvern Instruments Ltd.). 
4T1 Cell Line 
4T1 triple negative breast carcinoma cells (ATCC), passage 11-16, were cultured 
in RPMI plus L-Glutamine (Corning) supplemented with 10% FBS (Corning) and 1% 
penicillin-streptomycin (Sigma-Aldrich). Cells were maintained within T-75 flasks 
(CELLSTAR; Greiner Bio One, VWR) at 37°C in a humidified incubator with 5% CO2. 
To passage cells, all media was aspirated from the T-75 flask and replaced by 5 mL 
of sterile PBS without calcium or magnesium (VWR). The PBS was swirled around the 
bottom of the flask a minimum of 15 times in order to wash any residual media from the 
cells. The PBS was then aspirated and replaced by 2 mL of 0.25% Trypsin/2.21 mM EDTA 
in HBSS without sodium bicarbonate, calcium, or magnesium (Corning), enough volume 
to cover the entire bottom of the T-75. The flask was placed back into the incubator for 3 
minutes and then removed. After gently agitating the flask and visually inspecting for signs 
of cell detachment, 8 mL of pre-warmed RPMI media, prepared as described above, was 
added to the flask to bring the total volume to 10 mL. This solution was used to wash the 
bottom of the flask five times, dislodging any residually adhering cells. Then, the solution 
 118 
was vigorously pipetted up-and-down five times in order to form a single-cell suspension. 
Lastly, 50 to 1000 µL of this solution was used to seed the new flask pre-filled with fresh 
warmed media to ultimately reach a total final volume of 20 mL. 
Mice 
All animal studies were conducted under the oversight of the Georgia Tech 
Institutional Animal Care and Use Committee (IACUC) under protocol A100281. Three-
to-four-week-old female transgenic mice (Stock No.: 002376) and four-week-old female 
BALB/cJ mice (Stock No.: 000651) were purchased from The Jackson Laboratory. Upon 
receipt, mice were allowed a minimum of five days to acclimate to the housing facility at 
the Georgia Institute of Technology. Mice were housed with their littermates, with a 
maximum of five mice per cage, until administration of perfluorohexane nanodroplets, at 
which point the dosed mouse would be housed in isolation prior to reaching the 
experimental endpoint. Cages within the housing facility contain 100% corn cobb bedding 
and enrichment in the form of a mouse igloo, wood gnawing block, and rodent nesting 
sheets (all Bio-Serv; Fisher Scientific). The facility operates on a 12-hour day-night cycle, 
with “daytime” occurring from 06:00-18:00 UTC-5. Mice had access to food and water ad 
libitum throughout all phases of the study. 
MMTVneu Genetically Engineered Mouse Model 
 This is a genetically engineered mouse model (GEMM) of neu overexpression 
(FVB/N-Tg(MMTVneu)202Mul/J; The Jackson Laboratory).195,196 This model results in 
the expression of unactivated neu (Erbb2) protein under the direction of the MMTV long 
terminal repeat, which leads to the spontaneous development of mammary tumors. Tumors 
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first appear around four months of age, with a median incidence of 205 days. These tumors 
are focal in the mammary gland, and tumors overexpress HER2. 
 Mice in this GEMM were purchased from the vendor at 3-to-4 weeks of age. At 6-
to-7 weeks of age, mice were placed under general anesthesia and their ears were punched 
for longitudinal identification. During this anesthesia session, and monthly thereafter, the 
entire mammary crests of the mice were shaved and chemically depilated, as described 
previously, in order to facilitate tumor screening. Weekly thereafter, mice were manually 
restrained via scruffing in order to visually inspect and palpate the mammary crests to 
monitor for the development of tumors. 
Murine Anesthesia 
In order to achieve general anesthesia, mice were placed into a non-primed 
induction chamber, which was then filled with 5% isoflurane in oxygen at a flow rate of 
400 mL/min. After mice lost their righting reflex and their sympathetic response to 
isoflurance abated to yield a respiration rate of at most 100 breaths per minute (bpm), the 
isoflurane was lowered to 2%. 
Once their respiration rate reduced to between 60-80 bpm, mice were transferred 
onto a temperature-controlled stage (Visualsonics) heated to 40°C. The isoflurane flow rate 
was raised to 600 mL/min for the initial transfer but was slowly lowered back to 400 
mL/min during positioning on the stage. For procedures under general anesthesia 
scheduled to last longer than 30 minutes, sterile petrolatum ophthalmic ointment (Puralube; 
Dechra Phramaceuticals) was applied to the eyes of mice immediately post-transfer using 
a 6” wood-handled cotton-tip applicator (Puritan Medical). 
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Throughout general anesthesia sessions, the isoflurane was gradually lowered to 
between 1.25-1.5% maintenance in order to consistently maintain murine respiration 
between 60-80 bpm. If after two hours mice respired slower than 60 bpm, isoflurane was 
lowered to 1% or 0.75% as necessary to maintain the appropriate respiration rate. 
After non-terminal procedures, mice were returned to pre-warmed cages and 
monitored until they regained consciousness and resumed normal behavior. A heat lamp 
was applied if this process did not occur within 15 minutes. 
4T1 Syngeneic Model of Breast Cancer 
Prior to inoculation, 4T1 cells were trypsinized (Corning), pelleted at 300 rcf for 5 
minutes, and resuspended in sterile PBS without calcium (Corning) at a final concentration 
of 2 × 106 cells per mL. Cells were counted prior to pelleting using 10 µL of solution on 
a hemocytometer. The count from the central grid of the hemocytometer was used to 
estimate the number of cells in the pellet prior to resuspension. The final cell solution was 
stored on ice prior to inoculation. 
Five- or six-week-old BALB/cJ mice were placed under general anesthesia per the 
previously detailed protocol. The skin overlying the right fourth mammary fat pad was 
shaved with an electric-powered shaver (BravMini+; Wahl). The area was then chemically 
depilated with Nair calcium hydroxide lotion (Church & Dwight). Nair was dabbed with a 
cotton-tipped applicator into the hair roots and allowed to sit on the skin for 60 seconds. 
After this, the Nair lotion was removed by sequential, unidirectional wiping with first moist 
and then dry gauze pads. 
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The shaved and depilated area was then disinfected with a 2% chlorhexidine 
gluconate solution (Dermachlor; Henry Schein Animal Health) applied with a gauze pad 
and allowed to air dry prior to further manipulation of the animal. Then, 50 µL of the 4T1 
cell solution (105 cells) were injected subcutaneously in the anterolateral aspect of the right 
fourth mammary fat pad using a 31-Gauge diabetic syringe (Ultra Fine II™ U-100; BD). 
Losartan Potassium Microdosing 
 Lyophilized solid losartan potassium (99% by TLC; BioVision) was dissolved 8 
mg/mL in non-sterile PBS (VWR). The resulting solution was drawn up into a 10-mL Leur 
lock syringe, taken into a sterile biohood, and sterile-filtered through a 0.20 um 
polyethersulfone membrane (Part Number 431229; Corning). The resulting sterile losartan 
solution was divided into 1 mL aliquots and stored at -20°C prior to use. All of the previous 
steps were performed in darkness to protect the light-sensitive losartan. 
 Frozen aliquots were thawed in darkness at room temperature for a minimum of 30 
minutes prior to injection. In a sterile biohood, a 40 mg/kg dose of the 8 mg/mL solution 
was drawn into a sterile 30-Gauge diabetic syringe. Mice were placed under general 
anesthesia as detailed previously. After being placed into the supine position, the mice 
received the 40 mg/kg dose of losartan via an intraperitoneal injection contralateral to the 
side of the tumor side. The general anesthesia session for each losartan injection lasted no 
more than 5 minutes, unless accompanied by concomitant US/PA imaging. 
US/PA System and Imaging Sequence 
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Imaging was performed using a linear array ultrasound transducer (CL15-7; 
Advanced Technology Laboratories, Inc.) integrated with a 2-to-1 optical fiber bundle 
(CBGL-8-1/2-2500; Nanjing Chunhui Science & Industrial Co., LTD). The optical fiber 
bundle was connected to an Nd:YAG pulsed laser (Phocus Mobile; Opotek Inc.) operating 
at the fundamental 1064 nm wavelength. The split end of the fiber bundle was mechanically 
fixed to the transducer via a custom 3D-printed holder. These fiber outputs allowed for 
irradiation of imaged tissue, which was performed with 5-ns laser pulses at a pulse 
repetition frequency (prf) of 10 Hz. The estimated fluence at the depth of fiber intersection 
within the imaging plane (12-14 mm) was measured to be 85±5 mJ/cm2 with a power meter 
(Nova II; Ophir-Spiricon, LLC). For US imaging, the transducer was driven at a 12.5 MHz 
center frequency using a programmable research US imaging system (Vantage 256; 
Verasonics, Inc.). The full imaging window in each plane was 22.8 mm wide and 25 mm 
deep. The imaging probe and optical fiber outputs were acoustically coupled with the 
subject using clear ultrasound gel (Sonigel; 3B Scientific). 
For the imaging sequence at each imaging plane, a traditional line-by-line B-mode 
acquisition was first captured to record the underlying anatomy. Next, the tissue was 
irradiated with six successive laser pulses. A packet of US/PA data was acquired after each 
pulse. Each packet begins with 40 ultrafast pulse inversion (UFPI) frames at 8 kHz with 
alternating compressional or rarefactional phase as described in 3.2.3. After these “pre-
laser” frames, the tissue is irradiated by a laser pulse. This pulse is immediately followed 
by a receive-only acquisition to capture PA signal and 40 “post-laser” UFPI frames at 8 
kHz. Idle time fills the time between US/PA packets to synchronize with the 10 Hz prf of 
the pulsed laser. The first three US/PA packets use UFPI sequences with transmits that 
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have an initial rarefactional phase, as described previously. The last three invert this order 
and use transmits beginning with an initial compressional phase. All of the received waves 
were sampled at 56 MHz. 
After all images in the US/PA imaging sequence at a plane were saved in system 
memory, a motor controller (Model ESP301; Newport Corporation) translated a motorized 
linear stage (Model UTS150PP; Newport Corporation) 0.3 mm in the direction 
perpendicular to the imaging. In this new imaging plane, the US/PA imaging sequence was 
again acquired and saved in memory. This process repeats to acquire 35 imaging planes, 
spanning a total distance of 10.2 mm, for each volumetric acquisition. After completing a 
volumetric acquisition, the software returns the motor stage to its original position at the 
first imaging plane. 
All data were saved and processed offline in MATLAB (MathWorks). For 
displaying post-processed volumetric images, line-by-line B-mode and post-processed PA 
images at each imaging plane were linearly interpolated by a factor of 5 in two dimensions 
and saved as JPEGs. These co-registered JPEG stacks were imported into Amira (Thermo 
Fisher Scientific) and rendered in three-dimensional space. The B-mode layer was made 
translucent at 𝛼 = 0.15 to highlight the co-registered PA signal. Amira software adjusted 
the dynamic range of its display colormap in order to match the range of the post-processed 
PA signal for each individually rendered volume. 
US/PA Imaging Protocol 
 Mice were placed under general anesthesia per the previously described protocol. 
If necessary, the skin surrounding the primary tumor was shaved with an electric-powered 
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shaver. The area was then chemically depilated with Nair calcium hydroxide lotion. For 
the first pre-injection imaging session, the Nair was left on the skin for a full 60 seconds. 
However, for downstream imaging timepoints where the mice had already been depilated, 
regions of regrown or residual hair in the imaged regions only received exposure of 30 
seconds or less to the depilatory lotion. This protocol ensured no unnecessary irritation of 
the skin within the imaged regions. 
After the mice were sufficiently depilated for imaging, a rectangular cut-out of 
hunter green felt (Walmart) was slid underneath mice and fixed to the imaging stage. Once 
the felt was in place, mice were placed into the anatomically appropriate position for 
viewing the primary tumor, and their limbs were fixed to the imaging stage with adhesive 
tape (ZONAS® Porous Tape; Johnson & Johnson). Acoustic coupling gel (Sonigel; 3B 
Scientific), which was previously centrifugated for 5 minutes at 10,000 rcf to remove 
bubbles and UV-sterilized, was applied to the depilated skin surface using a 5-mL 
disposable slip-tip syringe (BD). The transducer was lowered until coupled with the gel, 
and real-time B-mode imaging on the Verasonics Vantage system was used to 
appropriately position the mouse. The 3-axis motor stage was used to translate the 
transducer through the imaging volume of interest. A 1-mL disposable slip-tip syringe 
(BD) was used to remove any bubbles remaining in the gel from this imaging volume. 
Following initial positioning, acoustic coupling gel was used to couple the laser 
fiber bundles to the mouse skin surface. The motor stage was again translated through the 
volume of interest both to ensure no additional bubbles entered the volume and to ensure 
gel coupling of the fibers throughout the entire motion of the transducer setup through the 
imaging volume. Bubbles were removed and more gel was added as necessary. Once 
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quality coupling of the transducer and fibers was assured, US/PA volumes were acquired 
by the system. 
After volumetric US/PA acquisitions, a quality assurance (QA) code was executed 
in MATLAB (MathWorks) to quickly assess B-mode, PA, ultrafast pulse-inversion US, 
and initial differential US images across the imaging volume. If the QA code suggested 
issues in US coupling, laser light illumination, or malpositioning, then these issues were 
addressed, and the corresponding volume was reacquired. 
Each volumetric acquisition takes approximately 8 minutes to acquire and save the 
data. The entire imaging workflow, from induction of anesthesia to regaining of 
consciousness or euthanasia, requires between 90 to 120 minutes, on average, to execute. 
Perfluorocarbon Nanodroplet Injection 
Mice were placed under general anesthesia per the previously described protocol. 
When transferred to the temperature-controlled stage, mice were placed in the supine 
position. An electric-powered shaver was used to shave the skin overlying the neck down 
to the manubrium. This area was then chemically depilated with Nair calcium hydroxide 
lotion, which was dabbed with a cotton-tipped applicator into the hair roots and allowed to 
sit on the skin for 60 seconds prior to removal via sequential, unidirectional wiping with 
first moist and then dry gauze pads. 
After preparing the skin, the mice were optimally positioned for injection into the 
jugular vein. Mice were moved from the center to the upper edge of the temperature-
controlled stage. A 1-mL disposable syringe was placed underneath the mouse at the level 
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of the scapula. Then, the breathing tube was positioned such that the mouse head hangs off 
and slightly below the stage. The result of these manipulations is the mouse positioned with 
its neck in extension and its shoulders abducted and extended. 
After positioning the mice, the depilated skin on the neck was disinfected with a 
70% isopropyl alcohol swab. A 30-Gauge diabetic syringe was filled with 70 µL of a 1010 
particles/mL solution of perfluorocarbon nanodroplets. Then, this needle was inserted 
suprasternally in the medial aspect of the pectoral muscle at an approximate angle of 30° 
from the skin surface and pointed towards the ipsilateral mouse ear. The needle was 
inserted into the mouse such that the needle tip enters the widest part of the jugular vein, 
which appears as the darkest aspect of the vein as seen through the skin. To confirm needle 
positioning, the entire syringe was elevated no more than 1 mm in order to better visualize 
the needle. After the needle was positioned correctly, the syringe plunger was slightly 
withdrawn to generate a flash of blood in order to confirm placement of the needle tip 
within the jugular vein. Once a flash was generated, the syringe plunger was slowly 
depressed in a sawtooth motion in order to deliver the full 70 µL volume intravascularly 
while confirming placement of the needle tip throughout the course of the injection via 
flashes on pullback. 
Euthanasia 
Mice were sacrificed via a primary lethal intraperitoneal injection of Euthasol (150 
mg/kg; Henry Schein Medical) contralateral to the primary tumor. After cessation of 
breathing, mice were exsanguinated during the perfusion-fixation procedure, which served 
as secondary euthanasia. In brief, a transverse incision through the skin and underlying 
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fascia was made immediately inferior to the sternum. Vertical incisions were made 
superiorly on either side of the primary incision, transecting the ribs in the process, in order 
to expose the diaphragm. The diaphragm was transected laterally, and the rib cage was 
separated and reflected superiorly, exposing the heart. A 27-Gauge butterfly needle (Surflo 
Winged Infusion Set; Terumo) was inserted into the left ventricle of the ideally still-beating 
heart and the right auricle was lanced vertically in order to convert the circulatory system 
into an open circuit. At this stage, 20 mL of 6.90 pH PBS was pumped through the 
circulatory system at a rate of 5 mL/min using a syringe pump (Legato 200; KD Scientific) 
attached to the butterfly needle setup. Next, the PBS syringe was replaced by one with a 
solution of 4% paraformaldehyde (reagent grade; Sigma-Aldrich) in 6.90 pH PBS, and 20-
25 mL of this solution was pumped through the mice at a rate of 5 mL/min. Successful 
perfusion-fixation was confirmed by palpation of the mouse extremities to assess rigor. 
After perfusion-fixation, both the primary tumor and spleen were resected. These 
specimens were placed into OCT-filled cryomolds (both Sakura Finetek), flash frozen 
under dry ice, and stored at -80°C to be sectioned for downstream histological analysis. 
Histology 
Prior to confocal imaging, slides were thawed, DAPI-stained, and sealed. All of 
these steps were performed in darkness to minimize photobleaching of fluorophores within 
the sections. First, frozen slides were thawed at room temperature for 20 minutes. Next, 
slides were rehydrated with 7.40 pH PBS for another 20 minutes. After this, excess PBS 
was tapped off slides, and the hydrated tissues were incubated with a 1:25000 (1:1000, then 
10:250) PBS dilution of DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride; 
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Invitrogen, Thermo Fisher Scientific) from an aliquot of 5 mg/mL in dimethylformamide 
(DMF). After 10-12 minutes of DAPI incubation, the DAPI solution was tapped off slides. 
Then, the slides were washed three times with PBS, allowing PBS to hydrate the sample 
for 5 minutes before being tapped off for the next wash. After the last wash, slides were 
mounted with antifade reagent (ProLong Gold Antifade Mountant; Invitrogen). Two to 
three drops of mountant were dropped evenly across the slide, in between tissue, and a 
glass coverslip (VWR) was slowly and evenly pressed down over the slide to distribute the 
mountant across the glass without disrupting the tissue. Lastly, clear nail polish was twice 
applied to all four edges of the coverslip to seal it to the slide, allowing at least 30 minutes 
for the first application to dry before adding the second. Mounted and sealed slides were 
stored in the dark at 4°C, at minimum overnight, until their scheduled time to be imaged 
on the confocal. 
Mounted sections were imaged on a Zeiss laser scanning microscope consisting of 
an LSM 700 scan head mounted on an AxioObserver Z1 inverted microscope stand with a 
motorized stage. Images were obtained with laser lines at 405 and 639 nm using a 20x / 0.8 
N.A. Plan Apochromat objective lens with a working distance of 0.550 mm. Tiled confocal 
images were rendered as JPEGs using Zen Black software (Carl Zeiss AG). The dynamic 
range of the Cy5 channel was set as the minimal level to suppress all signal from the spleen 
in a saline injected MMTVneu mouse. 
5.2.4 Results and Discussion 
The MMTVneu GEMM of HER2-overexpressing breast cancer is a logical choice 
for investigating the IV delivery of PFCnDs to primary tumors. Breast cancer is a highly 
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prevalent cancer of significant public health relevance,1 and HER2 is overexpressed in 
approximately 13% of cases.197 This spontaneous model of HER2-overexpressing breast 
cancer is also compatible with the targeted PFHnDs developed in 5.1. Previous 
nanoparticle delivery studies in small animal models have only shown appreciable primary 
tumor retention after vascular delivery when specific molecular targeting is 
implemented.198-201 Thus, we elected to exclusively use targeted PFHnDs for our primary 
tumor studies. 
To investigate PFHnD extravasation in the MMTVneu model, we performed 
volumetric US/PA imaging of the primary tumor using a similar workflow and equivalent 
data processing to what was detailed in 4.1.4. We performed baseline imaging 48 hours 
prior to injection, imaging immediately after IV injection of targeted PFHnDs, and terminal 
imaging 24-hour after IV injection, at which point we perfused the mouse and resected its 
primary tumor and spleen for histological processing. Volumetric US/PA data for an 
MMTVneu mouse imaged under this protocol can be seen below in Figure 20. 
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Figure 20: US/PA imaging volumes from an MMTVneu mouse injected with targeted 
PFHnDs. This mouse received an IV injection of anti-HER2 PFHnDs. A) Cartoon showing 
the primary tumor (PT) location and supine position of the mouse for imaging. The yellow 
dashed lines approximate the volumes shown; B) Masked PA signal (red-orange) overlaid 
with the corresponding US volume 48 hours before targeted PFHnD injection; C) Masked 
PA signal overlaid with US obtained 40 minutes after targeted PFHnD injection; D) 
Masked PA signal overlaid with US obtained 24 hours after targeted PFHnD injection. All 
volumes show minimal PA enhancement. Scale bars are approximately 5 mm. 
Unfortunately, the primary tumor volumes obtained after image processing show 
no enhancement within the tumor stroma and only minimal masked PA signal in focal spots 
on the tumor surface. Because this sparse enhancement is at the level of the skin and can 
also be seen at baseline, it is likely an artifact nonspecific to any injected PFHnDs. To 
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further analyze the delivery within this mouse, we performed confocal imaging of 
histological sections of the primary tumor and spleen. The injected PFHnDs were doped 
with a Cy5 fluorophore, which should produce enhancement on confocal imaging. The 
results from this mouse can be seen in Figure 21. 
 
Figure 21: Representative histology from an MMTVneu mouse 24 hours after IV 
injection of HER2-targeted PFHnDs. This mouse received no pre-treatment. Sections 
were stained with DAPI (blue). A) Cartoon diagram of primary tumor location in the right 
first mammary fat pad; B) Section of the spleen showing focal enhancement from the Cy5 
channel (red; absent); C) Section of the primary tumor with sparse enhancement from the 
Cy5 channel; D) Inset of the region in C) denoted with a yellow dashed line. The focal 
enhancement could correspond to Cy5-tagged PFHnDs; E) Second view of a primary 
tumor section showing minimal Cy5 enhancement; F) Inset of the region in E) denoted 
with a green dashed line. Enhancement from background connective tissue underscores the 
low SNR of the Cy5 channel. Scale bar for B), C), and E) is 200 µm; 25 µm for insets. 
The spleen of this mouse shows focal, low-intensity enhancement from the Cy5 
channel (Figure 21B). This may indicate successful IV delivery, as the spleen is one of the 
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major reticuloendothelial organs responsible for clearing PFHnDs from circulation. 
However, because of the low SNR of the Cy5 channel, it is also possible that this signal is 
a false positive due to noise. The dynamic range of the Cy5 channel was set in relation to 
the results of a saline-injected control mouse (see APPENDIX D, Figure 39). Sections of 
the primary tumor are largely devoid of Cy5 signal (Figure 21C), although there are sparse 
foci of signal that may correspond to retained PFHnDs (Figure 21D). The primary tumor 
tissue displays some perivascular Cy5 enhancement (Figure 21E). However, upon closer 
inspection (Figure 21F), this appears to be nonspecific enhancement from endothelial 
connective tissue. 
It is apparent that strategies in addition to particle targeting will need to be employed 
in order to successfully increase delivery to the primary tumor stroma. One complementary 
approach to particle modification is modulation of the tumor microenvironment. Previous 
studies have shown that administering a subclinical dose of angiotensin receptor blocker 
(i.e., too low a dose to reduce systemic blood pressure) leads to a reduction of tumor solid 
stress through collagen remodelling within primary tumor neovasculature.190-192 By 
reducing an unfavourable pressure gradient for particles attempting to traverse into the 
stroma, this microdosing regimen increases the efficiency of nanoparticle delivery.190 
For all downstream small animal experiments investigating PFCnD extravasation, 
we implemented a 7-day losartan potassium microdosing regimen prior to IV delivery of 
PFHnDs (see APPENDIX D, Figure 37). To increase the throughput of our tumor 
extravasation studies, we elected to pursue imaging in the 4T1 syngeneic mouse model of 
breast cancer in addition to the MMTVneu model. The MMTVneu model has a median 
incidence of 205 days, whereas 4T1 tumors can be generated on-demand and imaged 
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within a week of inoculation. However, 4T1 tumors are triple-negative, meaning that HER2 
targeting will be ineffective in this model. As such, for 4T1 studies we implemented 
PFHnDs targeted against epithelial cell adhesion molecule (EpCAM). EpCAM is a cell-
cell adhesion molecule that is typically expressed in the basolateral membrane of normal 
epithelial cells.202 In many cancers of epithelial cell origin, EpCAM is upregulated.203 The 
4T1 cell line demonstrates high EpCAM expression throughout the entire cell membrane 
within primary tumor cells,204 and it has been used previously as a molecular target for 
US/PA nanoparticle targeting of 4T1 cells.205 
The volumetric imaging results for a successful IV injection of anti-EpCAM 
PFHnDs in a losartan microdosed 4T1 syngeneic mouse can be seen in Figure 22. Prior to 
injection (Figure 22B), there is only sparse residual PA enhancement on the skin overlying 
the tumor surface. However, immediately after injection (Figure 22C), a “Y-shaped” 
region of PA enhancement can be seen converging at the tumor, which is suggestive of 
PFHnDs in a large feeding vessel. Figure 22D shows an alternate view of this volume, 
where the curvature of the primary tumor in the mouse pelvis is more evident. Still, there 
is no obvious PA enhancement within the tumor, suggesting that particles have not 
appreciably accumulated within the stroma during this early timepoint. Unfortunately, this 
mouse expired shortly after the post-injection imaging session, and so 24-hour US/PA 
imaging could not be performed. After veterinary consultation, our working hypothesis is 
that the PFHnD injection within this mouse was too concentrated. 
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Figure 22: US/PA imaging volumes from a targeted PFHnD injected 4T1 syngeneic 
mouse. This mouse was microdosed with 40 mg/kg losartan for 7 days prior to IV injection 
with anti-EpCAM PFHnDs. A) Cartoon showing the primary tumor (PT) location and 
supine of the mouse for imaging. The yellow dashed lines approximate the volumes shown; 
B) Masked PA signal (red-orange) overlaid with the corresponding US volume 48 hours 
before targeted PFHnD injection; C) Masked PA signal overlaid with US obtained 45 
minutes after targeted PFHnD injection along with an alternate view (D). These post-
injection volumes show subepidermal enhancement in a channel running towards the 
tumor, possibly corresponding to a feeding vessel. This mouse expired 2 hours after post-
injection imaging. Scale bars are approximately 5 mm. 
 Figure 23 shows histology obtained from non-perfused tissue that was immediately 
resected and flash frozen after the 4T1 mouse from Figure 22 expired. Again, PFHnDs 
were doped with Cy5 fluorophore. The representative section of the spleen in Figure 23B 
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shows high enhancement from the Cy5 channel surrounding structures that resemble 
follicles in what should thus be the periarteriolar lymphoid sheaths. It is unclear whether 
the circular lesions noted throughout the spleen are due to PFHnD bioeffects or artifacts of 
the sample preparation. Though the spleen histology confirms successful systemic 
administration of the PFHnD bolus, the primary tumor histology lacks appreciable Cy5 
enhancement (Figure 23C). Given the short timepoint of organ collection, it remains 
unclear whether this lack of tumor enhancement is due to lack of sufficient time for particle 
accumulation or inability of particles to traffic into the tumor stroma through endothelial 
fenestra in tumor neovessels. 
 
Figure 23: Representative histology from a 4T1 syngeneic mouse 2 hours after IV 
injection of EpCAM-targeted PFHnDs. This mouse received 7 days of 40 mg/kg losartan 
microdosing prior to PFHnD injection. Sections were stained with DAPI (blue). A) Cartoon 
diagram of the primary tumor location in the right fourth mammary fat pad; B) Section of 
the spleen showing strong enhancement in the Cy5 channel surrounding structures 
resembling follicles. The full dynamic range was used for displaying the Cy5 channel; C) 
Section of the primary tumor showing minimal enhancement from the Cy5 channel. Scale 
bar is 200 µm. 
Data from other unsuccessful attempts to generate appreciable PFHnD extravasation, 
likely due to poor delivery, can be found in APPENDIX D. Supplemental Data for 
Nanodroplet Extravasation Studies. Ongoing studies will seek to achieve more consistent 
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IV delivery of PFHnDs and to optimize the injected dose. It is also likely that to promote 
extravasation, we will need to redouble efforts to reduce the average diameter of targeted 
particles. After bioconjugation, the targeted PFHnDs used in these preliminary studies 
ranged from 400 to 600 nm in average diameter, as measured by DLS. This size range may 
be too large to extravasate, even with reduction of tumor solid stress. Estimates of the pore 
cutoff size in 4T1 tumors, for example, are on the order of 250 nm.206 
For the time being, PFCnD extravasation remains the “White Whale.” Nonetheless, 
the animal models and drug regimens that we have implemented here chart a path forward 
towards addressing this experimental challenge in a good-faith way that will have clear 
translational potential, unlike the efforts in non-orthotopic graft models that have predated 
our preliminary studies. We hope that with further refinements in PFHnD synthesis, 
detection, and imaging along with greater experience in these animal models, we will 
continue to make progress in this defining experimental application within the field of 
phase-change contrast agent research. 
5.3 On-Particle Fluorescence Resonance Energy Transfer to Assess Tissue for 
Intact Perfluorocarbon Nanodroplets 
5.3.1 Abstract 
Perfluorocarbon nanodroplets (PFCnDs) are a class of phase-change contrast 
agents for use in contrast-enhanced ultrasound and photoacoustic (US/PA) imaging. These 
agents were initially designed to overcome the chief barrier preventing gas microbubbles, 
the main contrast agent in US, from being used for contrast-enhanced imaging in the 
extravascular space: the relatively large (i.e., 1 µm+) size of these particles. Prior to user-
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initiated activation into microbubbles in situ, PFCnDs are stable at submicrometer sizes. 
Therefore, contrast-enhanced US/PA imaging marries the biological diffusion 
characteristics of a small particle with the imaging contrast enhancement afforded by a 
large particle. Amongst researchers in imaging science, the hope was that these combined 
properties would facilitate the use of PFCnDs for contrast-enhanced imaging of primary 
solid tumors. An intravascular bolus of submicrometer PFCnDs could theoretically 
extravasate through fenestra in tumor neovasculature prior to activation for imaging within 
the tumor stroma. However, despite two decades of research, researchers have failed to 
conclusively demonstrate that PFCnDs accumulate in the tumor stroma in a realistic model 
of orthotopic neoplastic disease. One of the many challenges in this endeavor is 
conclusively proving that intact PFCnDs are spatially located in the intravascular space. 
Histology is the gold standard interrogating the tumor microarchitecture, and fluorescent 
tags can be incorporated into PFCnDs to visualize them on histology. Unfortunately, 
fluorescent tags are a secondary marker of PFCnDs, at best. Confocal microscopy of a 
fluorescent tag cannot differentiate intact PFCnDs from either digested PFCnD 
components or residual in situ nanomicelles. In response to this challenge, we have 
developed a new class of dual-labelled PFCnDs that exhibit on-particle fluorescence 
resonance energy transfer. Because the donor and acceptor fluorophore are spatially 
isolated within different layers of the nanodroplet, these particles should only exhibit 
resonance transfer in an intact state. As such, FRET signal on confocal microscopy can be 
used as a sensitive marker of intact PFCnDs on histology. Here, we demonstrate successful 
resonance transfer in dual-labelled particles compared to matched controls. These 
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characterization studies pave the way for the implementation of this dual-labelled PFCnD 
platform in the assessment of PFCnD biodistribution in models of cancer and beyond. 
5.3.2 Introduction 
Gas microbubbles are the clinically approved and predominantly used contrast 
agents for contrast-enhanced ultrasound imaging. Although microbubbles are strong US 
reflectors, and thus efficient US contrast agents, their relatively large (i.e., 1 µm+) size 
effectively prohibits their use in extravascular imaging. Microbubbles are too large to 
extravasate through endothelial fenestrations in cancer neovasculature, and they are too 
large to traffic within lymphatic vessels or the interstitium in times permissive of clinical 
imaging. In response to the size restrictions of microbubbles in these biological 
applications, perfluorocarbon nanodroplets (PFCnDs) were developed.41,42,53,59,77,78,81,86,118 
Perfluorocarbon nanodroplets are structurally similar to gas microbubbles, but they contain 
a fluoroalkane core that is maintained in a liquid state at physiological temperatures.51,118 
As such, PFCnDs are stable in the liquid-cored state at submicrometer sizes, which affords 
them enhanced biological stability and superior transport characteristics compared to 
microbubbles. Liquid-cored PFCnDs do not produce perceptible enhancement on US 
imaging. However, when exposed to a pulse of acoustic or optical energy, the core of the 
PFCnD undergoes a phase transition to the vapor state, effectively creating microbubbles 
in situ.41,53 These vaporized PFCnDs provide contrast in a similar manner to traditional 
microbubbles. Further, if the phase transition was initiated by a laser pulse, then the initial 
vaporization event of the particles also generates contrast on photoacoustic imaging.53 
Optically-activated PFCnDs have been used for super-resolution57,100 and molecular 
contrast-enhanced ultrasound and photoacoustic (US/PA) imaging,57,146 and they have been 
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used to highlight transport phenomena within lymphatics,58,77,146 post-blood-brain-barrier 
brain,207,208 and the reticuloendothelial system.53,77,103,146 Still, the “White Whale” of 
PFCnD research remains the imaging of nanodroplet extravasation in primary tumors. 
Historically, PFCnDs were developed to facilitate US imaging of intravascularly 
delivered particle accumulation within the tumor stroma. After systemic administration, 
the submicrometer size of PFCnDs should theoretically allow them to extravasate through 
the relatively large inter-endothelial cell gaps in cancer neovessels. However, despite over 
two decades of active investigation, imaging researchers have yet to conclusively to 
demonstrate the aforementioned paradigm in a realistic, orthotopic model of primary 
cancer. Recently, one group demonstrated retention of fluorescent signal within a primary 
tumor in the mouse flank 48-hours.194 However, this study demonstrates critical flaws that 
have continued to propagate within PFCnD extravasation research to date. First, it utilizes 
a contrived animal model, a nude glioblastoma multiforme flank xenograft, that does not 
recapitulate the presentation of known human neoplastic disease. Glioblastoma multiforme 
is innately hypervascular,209 but it almost never metastasizes outside of the central nervous 
system.210 Second, this study relies on fluorescent signal from a secondary tag to serve as 
a proxy reporter of PFCnD accumulation. Although fluorescence on histology is a gold 
standard for assessing PFCnD biodistribution, it can fall victim to inherent confounding. 
Because the fluorescent tag on the PFCnDs is a secondary marker, it can report false 
positive results. This is because the read-out of fluorescence is agnostic to the underlying 
structure of the particle containing the fluorescent tag. Fluorophores contained within intact 
PFCnDs, digested or non-functional PFCnDs, perfluorocarbon-less residual nanomicelles, 
and free fluorophores all appear equivalent on both IVIS imaging and confocal imaging of 
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tissue sections. Even super resolution microscopy does not have sufficient spatial 
resolution to distinguish amongst these functionally unique, submicrometer entities. 
To address the absence of a gold standard to identify intact PFCnDs, we propose a 
novel dual-labelled PFCnD construct. This particle contains two fluorophores in unique 
spatial locations: one within the hydrophobic layer of the phospholipid shell and the other 
within the fluoroalkane core. The spectral characteristics of these two fluorophores are such 
that they can exhibit on-particle fluorescence resonance energy transfer (FRET). When a 
fluorophore absorbs a photon, it enters an excited energy state, after which it returns back 
to the “ground” state and emits a photon in return. However, due to energy lost as heat 
during this process, the emitted photon has a longer, “red-shifted” wavelength. [Consider 
E=hv eqn] If another fluorophore in close proximity has an absorption spectrum containing 
this second photon, then the photon could be absorbed by this second fluorophore. The 
fluorescent process would then begin again, resulting in the emission of an even further 
red-shifted photon. This describes the process of FRET sensitized emission.211 
Because the two fluorophores in our construct occupy unique locations within the 
particle, we should only observe FRET sensitized emission if the particle is intact. All 
FRET phenomena are highly dependent upon close spatial proximity of the “donor” and 
“acceptor” fluorophores. The “Förster distance” at which efficient FRET is possible is 
defined by the spectral overlap of the donor and acceptor molecules as well as their 
molecular orientation,212 and this distance is typically on the order of 1-10 nanometers.213  
In our construct, the acceptor fluorophore is soluble within the fluoroalkane core. Any 
construct without fluoroalkane, such as a nanomicelle or digested PFCnD, would not be 
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capable of sensitized emission. Therefore, the FRET sensitized emission is an indirect 
functional marker of intact particle status. 
Here, we present proof-of-principle studies that characterize the developed FRET 
nanodroplets. We demonstrate the on-particle sensitized emission phenomenon and 
compare these nanodroplets to a control complement. These results lay the groundwork for 
ongoing efforts to use on-particle FRET nanodroplets to characterize particle distribution 
within histological sections and whole organ preparation. 
5.3.3 Materials and Methods 
SQ650 Dye Synthesis 
 The squarylium dye, SQ650, was synthesized by Vadakkancheril S. Jisha, Ph.D. In 
brief, squaric acid (0.34 g, 6 mmol) and 2,3,3-trimethylindolenine (1.9 g, 5.9 mmol) were 
heated under reflux for 3 hours in a mixture of 60 ml of n-butanol/toluene (4:1, v:v) 
containing 1.5 ml of quinoline. Water was removed azeotropically using a Dean-Stark trap. 
The reaction mixture was then cooled to room temperature. The precipitated crude products 
were separated by filtration and washed with n-hexane. The product was further 
characterized by 1H NMR and 13C NMR. 
Fluorescent Nanodroplet Synthesis 
 One micromole (10−6 mol) of DSPC and DSPE-mPEG2000 (both from Avanti 
Polar Lipids, Inc.) in a 1:9 molar ratio was extracted from chloroform aliquots and added 
to a 10 mL pear-shaped flask (Aldrich). For Cy3-positive batches, 30 µL of Cy3 carboxylic 
acid (Lumiprobe) from a 1 mg/mL chloroform aliquot were added. An additional 400 µL 
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of HPLC-grade chloroform were added to the flask to ensure the formation of an even lipid 
cake. The pear-shaped flask was covered in aluminum foil and placed into a rotary 
evaporator with a water bath (R-215, V700, and V-855 with B-491; Buchi) and water-
cooled condenser and evaporated for 30 minutes, adhering to the “20/40/60” rule. After 
this, the solid isolate was further dried under nitrogen flow for a minimum of 20 minutes 
in order to evaporate all residual chloroform in the lipid cake. 
Next, the solid reagents were hydrated with 1 mL of 7.40 pH PBS and homogenized 
using a water bath sonicator (1800 Series Ultrasonic Cleaner; Branson) for 5 minutes at 
room temperature to produce a solution of dye-loaded nanomicelles. This solution was 
centrifuged at 300 rcf for 1 minute and 900 µL of the nanomicelle-containing supernatant 
was combined with 100 µL of PBS in a 2-dram glass scintillation vial (VWR). To this 
solution, 50 µL of either pure perfluorohexane (FluoroMed, L.P.) or, for SQ650-positive 
batches, a 1:1 homogenized mixture of perfluorohexane (PFH) to trifluorotoluene (TFT) 
was added. To make the 1:1 PFH:TFT mixture, 10 mg of SQ650 dye was dissolved in 1 
mL of α,α,α,-trifluorotoluene (Sigma-Aldrich). An equal volume (1 mL) of PFH was added 
to this solution, and the mixture was vortexed until homogenous prior to use. 
The glass vial containing the 50-µL fluoroalkane bolus and nanomicelles was 
placed into an ice bath and allowed to rest for 5 minutes. Then, this solution was probe 
sonicated in the ice bath with a 1/8” microtip (QSonica) at 1% power (1s on, 15s off, 5 
times) in order to produce a stock solution of fluorescent PFCnDs, which was stored at 4°C 
in amber glass prior to use. 
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Prior to their use, 100 µL of the fluorescent PFCnD stock were diluted in 2 mL of 
PBS and bath sonicated for 2 minutes. This solution was then centrifugated at 3000 rcf for 
5 minutes in order to pellet the fluorescent PFCnDs. The supernatant was removed and the 
PFCnDs were reconstituted in 1 mL of PBS. 
All of the previously described synthesis steps were performed in darkness to 
minimize photobleaching of the fluorophores. 
Fluorimetry 
 Fluorimetry was performed using a Fluorolog-3 Model FL3-21 spectrofluorometer 
(Horiba Instruments Incorporated) housed within the Center for the Science and 
Technology of Advanced Materials and Interfaces (STAMI) at the Georgia Institute of 
Technology. After allowing the Peltier cooling element for the detector to reach -20°C, 1 
mL of fluorescent PFCnD sample, prepared as described previously, was added to a four-
walled glass cuvette and diluted with 2 mL of PBS. Measurements of free fluorophores 
were performed with chloroform as both solvent and diluent. 
FluorEssence software was used to optimize the acquisition parameters and correct 
the measured fluorescent spectrum. Slit widths on the spectrofluorometer were adjusted to 
achieve a minimum count per second rate of 105 at the detector. Typically, the slit widths 
at excitation and detection wavelengths were set equally between 3 and 5 nm. 
Samples were excited at either 540 nm or 640 nm, as denoted in the results, and 
emission spectra began acquiring at a minimum of 20 nm red-shifted from the excitation 
center wavelength. 
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OPJ files containing the fluorescent spectra were downloaded for offline analysis. 
Files were opened in Origin Viewer (OriginLab), tabular spectra were converted into CSV 
format, and these spectra were ultimately plotted for display in R (R Core Team) using the 
ggplot2 data visualization package. 
5.3.4 Results and Discussion 
One of the canonical donor-acceptor pairs for FRET sensitized emission is Cyanine 
3 (Cy3) and Cyanine 5 (Cy5). For our on-particle FRET nanodroplets, we have elected to 
replace the acceptor Cy5 with the squarylium dye, SQ650. This class of dye has 
demonstrated biocompatibility for image-guided in vivo applications, such as 
photodynamic therapy.214,215 The SQ650 dye has similar absorption and fluorescent 
emission characteristics to Cy5 and is thus a reasonable substitute to couple with Cy3 for 
these FRET nanodroplets (see APPENDIX E, Figure 47). 
In order for the FRET sensitized emission in these particles to be a true reporter of 
their intact state, the donor and acceptor must occupy two spatially unique locations within 
the particle that will not associate upon particle destruction. Within PFCnDs, the two main 
components that occupy distinct locations are the fluoroalkane core and the amphipathic 
surfactant shell. Fluoroalkanes have poor solubility in both hydrophobic and hydrophilic 
materials, and thus they should not associate with shell components upon particle 
destruction. In order to incorporate a fluorophore within the shell of phospholipid shelled 
PFCnDs, the most logical design choice is to increase its hydrophobicity such that it 
preferentially associates with the hydrophobic fatty acid tails. Cyanine 3 carboxylic acid 
(Cy3CA) is non-reactive and hydrophobic, making it an ideal candidate to incorporate into 
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the lipid shell of PFCnDs. Being dissolved into phospholipid does not affect the ability of 
Cy3CA to fluoresce (Figure 24). 
To incorporate a second fluorophore into the fluoroalkane core of PFCnDs is a more 
challenging proposition. Previous studies have shown that dyes must be highly fluorinated 
relative to their total mass (50%+ wt% F) in order to be soluble in fluoroalkanes.216,217 The 
SQ650 dye is not fluorinated, though ongoing efforts are working to modify the indolyl 
groups with linear fluoroalkanes in order to reach the critical percentage weight of fluorine 
to achieve standalone solubility. In the interim, a double emulsion is necessary in order to 
achieve a PFCnD construct with core-soluble SQ650. Trifluorotoluene (TFT) is a 
hydrofluorocarbon in which SQ650 is readily soluble. When mechanically homogenized 
with perfluorohexane (PFH), TFT forms a stable emulsion that can serve as a proxy for the 
pure typically PFH used in PFHnD synthesis. Additionally, the TFT:PFH emulsion does 
not compromise the ability of SQ650 to fluoresce, as shown in Figure 24. 
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Figure 24: Fluorimetry of individual fluorophores used in FRET particles. Cyanine 3 
carboxylic acid (Cy3CA) containing nanomicelles (pink) dilute in PBS were measured 
using 3-nm excitation and emission slit widths. Free SQ650 dye in a 1:1 (v:v) emulsion of 
trifluorotoluene and perfluorohexane was measured using 5-nm excitation and emission 
slit widths. Excitation wavelengths for each measurement were as noted in the legend. The 
excitation lines at 540 and 640 nm are noted on the fluorescence spectrum with dashed and 
dotted lines, respectively. Each spectrum was normalized to its own maximum value. 
A major potential source of confounding in a FRET sensitized emission setup is 
nonspecific activation of the acceptor fluorophore from the donor excitation wavelength. 
The SQ650 dye only marginally absorbs within the region of wavelengths that would be 
used to excite the Cy3CA donor. Nonetheless, because of the high local fluences generated 
by confocal microscopy, it is still prudent to assess nonspecific donor activation for this 
FRET implementation. Indeed, fluorimetry of SQ650 within a 1:1 TFT:PFH emulsion 
exhibits qualitative nonspecific activation when excited at 540 nm (Figure 24). However, 
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it is important to note that fluorimetry of free dye in bulk emulsion is likely not indicative 
of the response of dye within the proposed nanodroplet construct. 
To perform a more fair assessment of the nonspecific activation of SQ650, we 
obtained fluorimetry measurements on PFCnDs containing SQ650 in the core of the 
construct. Using the same PFCnD population, we recorded fluorescence emission spectra 
after both specific (640 nm) and nonspecific (540 nm) excitation. As displayed in Figure 
25, nonspecific activation is approximately an order of magnitude weaker than specific 
activation from excitation within the main absorbance spectrum of SQ650. 
 
Figure 25: Fluorimetry of SQ650-containing nanodroplets. Nanodroplets were diluted 
in PBS and excited for measurements as noted in the legend. The excitation lines at 540 
and 640 nm are noted on the fluorescence spectrum with dashed and dotted lines, 
respectively. Both measurements were performed on the same sample using 5-nm 
excitation and emission slit widths. The spectra were normalized to the maximum value 
from the 640-nm excitation spectrum. 
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Next, we assessed the fluorescence emission spectrum of PFCnDs containing both 
Cy3CA in the particle shell and SQ650 in the core (Figure 26A). First, we assessed 
excitation at 540 nm, well within the donor excitation spectrum of Cy3CA. The resulting 
emission spectrum displays the characteristic shouldered emission spectrum of Cy3CA, 
meaning that the excitation of the donor is not fully quenched by the encapsulated SQ650 
acceptor. However, this emission spectrum does contain the characteristic emission peak 
of SQ650. In comparison to the emission observed upon excitation by 640 nm, the 540-nm 
induced SQ650 emission is roughly one-third that observed on specific activation of the 
acceptor. Although we cannot rule out some nonspecific activation of the acceptor, this 
ratio of peak acceptor emission signal, versus the ratio observed in Figure 25, implies that 
some FRET sensitized emission is occurring within the dual-labelled PFCnDs. 
We also compared the emission spectrum of FRET nanodroplets to spectra of 
single-fluorophore and no-fluorophore controls (Figure 26B). The Cy3CA-only PFCnDs 
do not display a peak in the region of the SQ650 acceptor, ruling out any nonspecific 
contributions from the emission of the donor in the dual-fluorophore PFCnD results. 
Additionally, the SQ650-only PFCnDs display a lower peak fluorescence emission than 
the dual-fluorophore PFCnDs when excited at 540 nm, providing further evidence of 
sensitized emission from the dual-fluorophore particles. Lastly, PFCnDs without any 
encapsulated fluorophores emit only marginal signal upon fluorimetry. 
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Figure 26: Fluorimetry of FRET nanodroplets and controls. A) Fluorescence spectrum 
from Cy3CA and SQ650-containing nanodroplets diluted in PBS and excited with 540-nm 
(purple) and 640-nm (light purple) light. The excitation lines at 540 and 640 nm are noted 
on the fluorescence spectrum with dashed and dotted lines, respectively. The dual-
fluorophore particles display evidence of resonance transfer; B) Fluorescence spectra of 
FRET nanodroplets as well as single and no-fluorophore nanodroplet controls. The 
excitation line at 540 is noted on the spectra with a dashed line. All spectra were acquired 
with 5-nm excitation and emission slit widths and were normalized to the maximum value 
from the FRET nanodroplet spectrum, except for the Cy3CA nanodroplet spectrum, which 
was acquired using 3-nm excitation and emission slit widths and self-normalized. 
The dual-labelled PFCnDs reported here demonstrate sensitized emission upon 
donor excitation. However, more work is necessary to enhance this phenomenon so that it 
is reliable enough to be utilized in applications involving confocal and gross fluorescence 
imaging. It is possible that the double emulsion necessary to synthesize the PFCnDs 
presented here is restricting donor fluorophores from absorbing photons emitted from 
acceptor fluorophores. Efforts to solubilize SQ650 in PFH via fluoroalkane conjugation 
will allow the creation of dual-labelled PFCnDs via a single emulsion synthesis method. 
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This will allow for a greater amount of SQ650 acceptor fluorophore to be dissolved within 
the core of these PFCnDs, and the use of pure PFH in the core will impose less spatial 
restriction on the acceptor fluorophores. Sensitized emission will only occur within the 
Förster distance of the donor-acceptor pair, which should restrict this phenomenon to the 
outer core of the PFCnDs near the surfactant shell. Upon ideal donor synthesis, additional 
optimization of the donor-acceptor ratio will also be necessary to assure quality sensitized 
emission. 
The class of on-particle FRET PFCnDs presented within this study could eventually 
be used to report on the intact state of the nanodroplets in tissue for both tumor delivery as 
well as other applications that require knowledge of functional biodistribution and 
clearance. FRET sensitized emission could be detected in whole organs in vivo or ex vivo 
via IVIS or fluorescence tomographic imaging, given an appropriate filter set. Many 
commercial confocal systems also include spectral unmixing software to facilitate high 
resolution FRET measurements on histology sections, as well.218,219 Knowledge of intact 
particle distribution is critical for successfully developing US/PA image-guided diagnostic 
and therapeutic approaches using PFCnDs, the in vivo characteristics of which remain 
largely understudied. This class of dual-labelled PFCnDs provide a compelling avenue for 
addressing this critical gap in the field of phase-change contrast agent development.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Optimization of Synthesis and Detection 
In Aim 1, we developed a new approach to synthesize small, monodisperse PFHnDs. 
By increasing the amount of PEGylated lipid within the phospholipid shell of PFHnDs, we 
were able to achieve a stable size reduction over time courses relevant to incubation steps 
that are necessary for the diagnostic and therapeutic functionalization of these particles. In 
phantom studies, we determined that increased PEGylation also increases the observed 
US/PA contrast as compared to equivalent stock dilutions of PFHnDs from a more 
traditional low-PEG formulation. Furthermore, we implemented a new imaging sequence 
based on ultrafast pulse inversion imaging to enhance the detection of US contrast created 
by optically triggered PFHnDs. We then demonstrated the advantages of this sequence 
relative to traditional ultrafast plane wave imaging both in phantoms and in vivo in a murine 
spleen. 
From our synthesis studies, it remains unclear if the ratio of lipids in the stock, either 
per particle or per injected bolus, is equivalent to the initial bulk ratio. Providing 
quantitative evidence for this is further complicated by the fact that mass spectrometry 
techniques are confounded by the ionized solvents necessary to form stable lipid particles. 
Additionally, our data showed a non-linear effect of shell PEGylation on size reduction, 
but we did not completely characterize this phenomenon or establish a critical point where 
this effect begins to wane appreciably. Moreover, it would be interesting to see if 
combining this strategy with increased acyl chain length has a synergistic effect on PFCnD 
size reduction without compromising the ability to vaporize the agent to create US/PA 
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contrast. There are many potential avenues for further investigation into synthesis 
optimization based on shell composition alone. 
Critically, it will be necessary to develop phantoms or setups that better recapitulate 
the biological environment in order to truly assess the impact of design changes on PFCnD 
size and stability for downstream preclinical applications. Although PFCnDs are constantly 
touted for their increased stability relative to microbubbles, particle stability still appears 
to be an issue in vivo. Spontaneous vaporization of PFCnDs in vivo is an underreported 
phenomenon in the field of US contrast agent development. The majority of optimization 
studies are performed in vitro, and the in vivo environment presents a host of additional 
challenges to particle size and stability, such as protein adsorption, opsonization, biological 
breakdown, and clearance. 
From our imaging sequence studies, it will be necessary to compare the imaging 
contrast afforded by our pulse inversion sequence to sequences that take advantage of 
enhanced frame rates and/or angular compounding. It is possible that an optimal imaging 
sequence may need to include both pulse inversion and angular compounding, but the 
temporal resolution necessary to capture PFHnD dynamics places a stringent restriction on 
the minimum necessary frame rate for these sequences to be effective. Moreover, from the 
in vivo studies presented in this dissertation, it is obvious that there are a host of 
confounding phenomenon that can mimic the temporal dynamics and enhancement 
expected from PFHnDs. More work is necessary to integrate the US and PA effects of 
optically triggered PFHnDs to better isolate these agents from background, especially in 
sparse concentrations. Specific in vivo detection of PFCnDs remains an active area of 
research. 
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6.2 Lymphatic Imaging and Therapeutic Applications 
In Aim 2, we utilized the PFHnDs developed in 3.1 to investigate lymphatic drainage 
in both naïve and tumor-bearing mice. During this process, we developed a 
computationally simple post-processing algorithm in order to leverage the unique US and 
PA contrast enhancement of optically triggered PFHnDs to highlight regions with a high 
probability of containing these agents. Our in vivo studies highlighted the ability to track 
PFHnDs draining through regional lymphatics longitudinally over the course of 24 hours. 
Histology obtained at 24 hours confirmed the draining path of the PFHnDs ipsilateral to 
the initial subcutaneous injection site. To our knowledge, this study is the first report of the 
longitudinal imaging of a single injected bolus of a phase-change US/PA agent. 
Additionally, we developed a new class of adjuvant-carrying PFHnDs that could be 
implemented for US/PA image-guided immunotherapy and demonstrated the ability of 
these particles to stimulate antigen presenting cells in vitro. 
In terms of the in vivo detection of these agents, imaging sensitivity remains a great 
challenge. Confounding signal from the skin and deep structures, such as the large 
intestines, presents a huge challenge to specifically identifying optically triggered PFHnDs. 
One potential long-term solution to this is the development of more efficient 
photoabsorbers. We have observed contrast enhancement in our experimental workflow 
using PFHnDs without encapsulated near-infrared dye (see APPENDIX B, Figure 33 and 
Figure 34), suggesting that either our optical fluence is high enough to induce 
perfluorohexane vaporization alone or that the observed enhancement is not due to particle 
vaporization. The study of submicrometer PFHnD laser interaction is complicated by the 
diffraction limit of optical imaging methods, so it is impossible to know which hypothesis 
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is more likely. However, in the former case, a more efficient absorber would allow the use 
of a lower fluence in US/PA imaging, which could minimize confounding enhancement 
from endogenous absorption. Sono-photoacoustic imaging,82,220,221 which synchronizes the 
laser pulse with the rarefactive phase of a focused ultrasound pulse, may be another avenue 
to achieve contrast enhancement from optically-triggered PFHnDs with a lower fluence 
and less endogenous enhancement. 
More immediately, future work related to the presented longitudinal data will focus 
on optimizing data processing. The masked PA data shown were the result of a median 
filter applied to the enhancement results from all six laser pulses acquired at each plane. 
This step was intended to suppress nonspecific signal that may be decorrelated. However, 
given the persistence of obviously correlated endogenous absorption, it may be necessary 
to use other techniques, such as compounding, to enhance exogenous signal from PFHnDs 
relative to background. Additionally, it will be necessary to acquire saline-injected controls 
in order to better characterize confounding signal from endogenous sources and dye-
independent PFHnD absorption. 
Furthermore, these longitudinal in vivo studies have revealed bioeffects from the 
subcutaneous administration of PFCnDs that are yet unreported in the literature. Hours 
after injection, we observed a reflective bolus near the initial injection site in all mice 
imaged within 4.1 (see APPENDIX B, Figure 28). The cause of this phenomenon is 
unknown. Possible explanations are spontaneous vaporization of injected particles, 
aggregation of injected particles, diffusion of oxygen into the fluoroalkane core of 
particles, or side effects from a local inflammatory response. More investigation is 
necessary to elucidate the mechanism of this consistently observed effect. 
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For the adjuvant-containing pICnDs, the immediate future will bring further 
optimization and enhanced characterization. The shell composition of these particles likely 
requires optimization in order to bind the maximum amount of poly(I:C) without 
compromising membrane stability. The current level of adjuvant binding, as assessed by 
our in vitro Griess assay, is unlikely to be sufficient to generate an effective TH1 response 
in vivo. A fluorescent-tagged poly(I:C) can be used during incubation to provide a more 
quantitative assessment of adjuvant binding than zeta potential measurements. 
Additionally, once the formulation is finalized, it will be necessary to perform an ELISA 
for IL-12 to ensure that pICnDs are appropriately stimulating APCs to enact a TH1, and not 
TH2, response. 
The scale up of pICnDs to an in vivo setting will introduce a host of additional 
challenges. First, delivery of sufficient adjuvant to the TDLN, without inciting excessive 
nonspecific inflammation, will need to be confirmed. Then, it will be necessary to assess 
the cellular response of the TDLN. Ultimately, we will need to demonstrate that pICnD 
delivery induces the activation of a critical amount of CTLs. Characterizing this cellular 
response will require an appreciable amount of lymph node cell isolation and 
characterization via flow cytometry. Only after an appropriate cellular response at the 
draining node is documented will we be able to probe the whether this immunotherapeutic 
approach is able to incite CTLs to train on tumor antigens to attenuate solid tumor growth 
and metastatic spread. 
6.3 Extravasation Within Primary Breast Tumors 
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In Aim 3, we first engineered targeted PFHnDs via bioconjugation of thiolated 
antibodies to maleimide groups incorporated into the nanodroplet lipid shell surface. We 
demonstrated that this bioconjugation technique affords PFHnDs specificity for their 
appropriate molecular target in vitro. Next, we attempted to image targeted PFHnD 
extravasation in vivo in two immunocompetent, orthotopic small animal models of primary 
breast cancer. We also implemented an angiotensin receptor blocker microdosing regimen 
in order to reduce primary tumor solid stress, which should improve intravascular particle 
delivery. These approaches pave the way for successful and translatable results for the 
US/PA imaging of extravasated PFCnDs in the future. Lastly, we created a new class of 
PFHnDs that display on-particle FRET sensitized emission. These particles can provide a 
functional reporter of intact particle state, which can serve as a “gold standard” assay for 
PFHnD particle extravasation assessment. Altogether, these developments and approaches 
provide novel contributions to the field of phase-change contrast agent research. 
The preliminary in vivo results presented in this dissertation reveal a multitude of 
areas for future work on this application. First, it will be necessary to improve the 
consistency of IV delivery via improved jugular injection technique and to determine the 
maximum tolerated dose of PFCnDs. Extravasation studies in other agents estimate that 
only 1% of the injected dose of IV particles will reach the tumor stroma.222 Thus, the 
optimal injected dose will be a balance between safety and imaging sensitivity. As alluded 
to in 6.2, the sensitivity of US/PA imaging to optically triggered PFHnDs is still an active 
area of research. Improvements in the system, sequence, and post-processing should help 
balance the delicate calculus of considerations in determining the optimal injected dose. 
 157 
Our approach to tumor microenvironment modulation may help increase the low 
delivery efficiency to primary tumors. However, we still need to characterize the effect of 
this regimen at the molecular level via histological analysis of primary tumor vasculature. 
The researchers who first reported this microdosing strategy performed a lectin injection 
and assessed tumor vessels for CD31 and lectin co-staining as a marker of perfusion.191 
Because those perfusion assessments were performed in xenograft models, it is unclear if 
the effects will directly translate when implemented in syngeneic models or GEMMs. It is 
likely that the losartan microdosing regimen will need to be altered to account for 
variability in the natural history of these different small animal models. 
Additional work will likely be necessary to improve the probability of successful 
PFHnD extravasation. The targeted particles used for IV delivery within our preliminary 
in vivo studies ranged from 400 to 600 nm in average diameter. This is well above the 
empirically determined pore cutoff size for the 4T1 syngeneic model,206 and it may also be 
too large for analogous GEMMs. From our in vitro studies in 5.1, we observed a large size 
increase after conjugation of monoclonal antibodies. This may be because of the physical 
size of the antibodies themselves, but it may also be due to other nonspecific phenomena, 
such as increased particle aggregation. The optimal resuspension protocol for 
bioconjugated PFHnDs may be different than that for naïve PFHnDs. If the antibody size 
is indeed the primary issue at hand, then alterative targeting moieties may need to be 
improved in order to achieve further size reduction of the targeted construct. The 
Functional and Molecular Imaging Research Laboratory at Dartmouth College has 
developed a currently unpublished directional method for creating targeted PFHnDs using 
purified antigen-binding fragments instead of the full monoclonal antibody. Their 
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approach, though highly labor-intensive, may be the best option for achieving molecular 
specificity to cancer markers while retaining small PFCnD size. It is worth noting, 
however, that directional methods based on those used for gold nanoparticles utilize a 
PEGylated bifunctional linker.223 To avoid an unnecessary particle size increase by using 
a PEGylated element to connect the particle and fragment, it will likely be necessary to 
synthesize a small molecule linker with both requisite functional groups. 
In terms of the various particles displayed in Aim 3, future work will continue the 
optimization of these agents. With targeted PFHnDs, we have demonstrated specificity for 
monoclonal-HER2-antibody targeted PFHnDs to HER2-positive cells in vitro; however, 
we have not performed this analysis for polyclonal-EpCAM-antibody targeted PFHnDs to 
4T1 cells in vitro. It is possible that the polyclonal nature of the antibody clone we selected 
does not afford sufficient specificity to these cells. In this case, it will be necessary to find 
a monoclonal antibody to mouse EpCAM or to select an alternative molecular target, 
assuming we want to continue in vivo efforts in the high-throughput syngeneic 4T1 model. 
For the on-particle FRET PFHnDs, additional development will be necessary to 
advance the platform. A fluoroalkane-soluble SQ650 dye will be especially critical. This 
will allow for the creation of dual-labelled PFCnDs from a single-emulsion method with 
enhanced acceptor fluorophore signal in each particle. Additionally, it will strengthen the 
assertion that the platform is sensitive to intact particle status. Unmodified SQ650 is 
soluble in organic solvents. As such, it may migrate to the hydrophobic shell layer of the 
dual-labelled particle formulation presented in this dissertation, despite physical isolation 
of the donor and acceptor fluorophores using the dual emulsion method. Upon creation and 
characterization of a fluoroalkane-soluble SQ650 dye in this construct, it will also be 
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necessary to characterize the loss of sensitized emission upon particle destruction. This 
feature of the construct is crucial to the assertion that FRET is a marker of intact status. 
Boiling samples of PFHnDs is one potential way of destroying the particles without 
destroying the fluorophores themselves. 
Characterization of sensitized emission from ex vivo samples will be the last 
necessary step prior to the implementation of FRET PFHnDs in preclinical applications 
research. The spleen is a logical organ to assess via histology, as it is one of the primary 
reticuloendothelial organs responsible for clearing IV delivered PFCnDs. Spleen sections 
should provide samples with high concentrations of FRET PFCnDs to optimize the 
detection of FRET signal via spectral unmixing on confocal microscopy, which is not a 
trivial step for imaging intermolecular FRET pairs. 
6.4 General 
Perfluorocarbon nanodroplets are an intriguing class of contrast agents with a high 
upside for applications-based research. For these agents to gain traction, however, much 
more fundamental knowledge about their governing physics and behavior in vivo is 
necessary. Improved knowledge of the interactions between PFCnDs, ultrasound, and 
incident near-infrared photons will allow for the design of more biologically stable and 
imaging-responsive particles. Much of the current applications-based research conducted 
with PFCnDs involves intravascular studies that have already been performed, or could 
have been performed just as efficiently, with gas microbubbles. From an experimental 
design perspective, this is a logical and safe approach to research. Perfluorocarbon 
nanodroplets also have increased vascular circulation time as compared to microbubbles,224 
 160 
so there is a minor upside to the direct substitution. However, if researchers are content to 
relegate applications of PFCnDs to the vascular domain, then the platform will surely fail 
to gain any traction outside of the ultrasound community. The extravascular capabilities of 
PFCnDs are what will ultimately set these agents apart and allow them to meaningfully 
expand the footprint of ultrasound utility. The studies presented in this dissertation are a 
beginning, not an end. It will require an appreciable concerted effort from a team of diverse 
and dedicated researchers to transform the visions set forth by these preliminary studies 
into fully executed realities. If this commitment is made, then I look forward to seeing the 
progress the field makes in the years to come.  
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APPENDIX A. SUPPLEMENTAL DATA FOR NANODROPLET 
SYNTHESIS STUDIES 
Table 3: Z-Average [nm] versus time for 90:10 PFCnDs 
Time [hr] Minimum First Quartile Median Third Quartile Maximum 
0 366 472 647 956 1085 
0.5 443 538 591 736 1201 
1 549 582 661 905 1202 
2 536 595 662 825 950 
3 544 667 750 865 1174 
4 530 576 657 788 934 
5 514 574 635 748 918 
6 485 564 624 701 919 
 
Table 4: Z-Average [nm] versus time for 50:50 PFCnDs 
Time [hr] Minimum First Quartile Median Third Quartile Maximum 
0 162 169 178 194 213 
0.5 199 204 208 211 218 
1 219 221 227 242 275 
2 236 242 248 250 252 
3 250 257 260 263 265 
4 266 270 273 274 277 
5 273 278 284 285 291 




Table 5: Z-Average [nm] versus time for 10:90 PFCnDs 
Time [hr] Minimum First Quartile Median Third Quartile Maximum 
0 151 157 159 162 164 
0.5 197 199 200 201 203 
1 217 218 218 221 225 
2 236 237 240 243 244 
3 246 250 252 255 258 
4 252 259 263 271 273 
5 268 270 274 280 285 
6 272 282 284 287 292 
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APPENDIX B. SUPPLEMENTAL DATA FOR IMAGING OF 
PERFLUOROCARBON NANODROPLETS TRAFFICKING IN 
LYMPHATICS 
δ UFPI vs δ2 UFPI Imaging 
 
Figure 27: δ UFPI and δ2 UFPI Images for a PFHnD-containing region of interest. 
Images correspond to the plane from Figure 10. The δ UFPI (A) and δ2 UFPI (B) images 
are qualitatively similar. Further examining the region of interest (yellow-dashed box), the 
median linear signals as a function of time also display comparable temporal dynamics for 
both δ UFPI (C) and δ2 UFPI (D) processing. 
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Representative Post-Injection Bolus 
 
Figure 28: Representative B-mode images showing the development of injection-site 
boluses in vivo. Representative images (4T1 mouse 2; 6-hour timepoint) in left lateral 
decubitus (A) and supine (B) views show the formation of a reflective bolus (orange 
arrows) near the initial injection site. This is a consistently observed result hours after 
subcutaneous PFHnD administration. It remains unclear if this observation corresponds to 
spontaneous vaporization of PFHnDs, pooling of bulk perfluorohexane from broken-down 
PFHnDs, an inflammatory reaction, or another unknown phenomenon. Scale bar is 5 mm. 
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Volumetric US/PA Imaging Figures 
 
Figure 29: Processed US/PA volumes from 4T1 syngeneic mouse 2. This mouse 
received a 100 µL subcutaneous injection of PFHnDs at 0 hours and had a primary tumor 
in the right fourth mammary fat pad. A) Cartoon showing the left lateral decubitus position 
of the mouse for imaging. The yellow dashed lines approximate the volumes shown. 
Lymph nodes are false colored in light blue; B) Masked PA signal (red-orange) overlaid 
with the corresponding US volume 48 hours before PFHnD injection; C) Masked PA signal 
overlaid with US obtained 6 hours after PFHnD injection; D) Masked PA signal overlaid 
with US obtained 24 hours after PFHnD injection. Scale bars are approximately 5 mm. 
 166 
 
Figure 30: Processed US/PA volumes from 4T1 syngeneic mouse 3. This mouse 
received a 100 µL subcutaneous injection of PFHnDs at 0 hours and had a primary tumor 
in the right fourth mammary fat pad. A) Cartoon showing the left lateral decubitus position 
of the mouse for imaging. The yellow dashed lines approximate the volumes shown. 
Lymph nodes are false colored in light blue; B) Masked PA signal (red-orange) overlaid 
with the corresponding US volume 48 hours before PFHnD injection; C) Masked PA signal 
overlaid with US obtained 6 hours after PFHnD injection; D) Masked PA signal overlaid 
with US obtained 24 hours after PFHnD injection. Scale bars are approximately 5 mm. 
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Figure 31: Processed US/PA volumes from BALB/c mouse 2. This mouse received a 
100 µL subcutaneous injection of PFHnDs at 0 hours. A) Cartoon showing the left lateral 
decubitus position of the mouse for imaging. The yellow dashed lines approximate the 
volumes shown. Lymph nodes are false colored in light blue; B) Masked PA signal (red-
orange) overlaid with the corresponding US volume 48 hours before PFHnD injection; C) 
Masked PA signal overlaid with US obtained 6 hours after PFHnD injection; D) Masked 
PA signal overlaid with US obtained 24 hours after PFHnD injection. Scale bars are 
approximately 5 mm. 
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Figure 32: Processed US/PA volumes from BALB/c mouse 3. This mouse received a 
100 µL subcutaneous injection of PFHnDs at 0 hours. A) Cartoon showing the left lateral 
decubitus position of the mouse for imaging. The yellow dashed lines approximate the 
volumes shown. Lymph nodes are false colored in light blue; B) Masked PA signal (red-
orange) overlaid with the corresponding US volume 48 hours before PFHnD injection; C) 
Masked PA signal overlaid with US obtained 6 hours after PFHnD injection; D) Masked 
PA signal overlaid with US obtained 24 hours after PFHnD injection. Scale bars are 
approximately 5 mm. 
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Control Particle Image Volumes 
 
Figure 33: Processed US/PA volumes from a 4T1 syngeneic control. This mouse 
received a 100 µL subcutaneous injection of PFHnDs without IR1048 dye at 0 hours and 
had a primary tumor in the right fourth mammary fat pad. A) Cartoon showing the left 
lateral decubitus position of the mouse for imaging. The yellow dashed lines approximate 
the volumes shown. Lymph nodes are false colored in light blue; B) Masked PA signal 
(red-orange) overlaid with the corresponding US volume 48 hours before PFHnD injection; 
C) Masked PA signal overlaid with US obtained 6 hours after PFHnD injection; D) Masked 
PA signal overlaid with US obtained 24 hours after PFHnD injection. Scale bars are 
approximately 5 mm. 
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Figure 34: Processed US/PA volumes from a BALB/c control. This mouse received a 
100 µL subcutaneous injection of PFHnDs without IR1048 dye at 0 hours. A) Cartoon 
showing the left lateral decubitus position of the mouse for imaging. The yellow dashed 
lines approximate the volumes shown. Lymph nodes are false colored in light blue; B) 
Masked PA signal (red-orange) overlaid with the corresponding US volume 48 hours 
before PFHnD injection; C) Masked PA signal overlaid with US obtained 6 hours after 
PFHnD injection; D) Masked PA signal overlaid with US obtained 24 hours after PFHnD 
injection. Scale bars are approximately 5 mm. 
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HER2-targeted PFHnDs in the MMTVneu model 
 
Figure 35: Processed SLN US/PA volumes from an MMTVneu mouse. This mouse 
received a 150 µL subcutaneous injection of anti-HER2 targeted PFHnDs at 0 hours and 
had a primary tumor in the left fourth mammary fat pad. A) Cartoon showing the right 
lateral decubitus position of the mouse for imaging. The yellow dashed lines approximate 
the volumes shown. Lymph nodes are false colored in light blue; B) Masked PA signal 
(red-orange) overlaid with the corresponding US volume 48 hours before PFHnD injection; 
C) Masked PA signal overlaid with US obtained 6 hours after PFHnD injection; D) Masked 
PA signal (absent) overlaid with US obtained 24 hours after PFHnD injection. Scale bars 
are approximately 5 mm. 
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APPENDIX C. SUPPLEMENTAL DATA FOR POLY(I:C) 
NANODROPLET STUDIES 
 
Figure 36: Sodium nitrite ladder used for the in vitro Griess assay. The working range 
of the modified Griess reagent is 0.43 to 65 µM. A linear regression (inset) of the ladder 
data was used to convert absorbance (Y) to nitrite concentration (X) for cell-containing 
wells. The linear regression (blue line) with 95% confidence interval (gray ribbon) is 




APPENDIX D. SUPPLEMENTAL DATA FOR NANODROPLET 
EXTRAVASATION STUDIES 
 
Figure 37: Schema for in vivo primary tumor studies of PFHnD extravasation. 
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Figure 38: US/PA imaging volumes from a saline injected MMTVneu mouse. This 
mouse was not microdosed with losartan. A) Cartoon showing the right lateral decubitus 
position of the mouse for imaging. The yellow dashed lines approximate the volumes 
shown; B) Masked PA signal (red-orange) overlaid with the corresponding US volume 48 
hours before saline injection; C) Masked PA signal overlaid with US obtained immediately 
after saline injection; D) Masked PA signal overlaid with US obtained 24 hours after 
PFHnD injection. All volumes show minimal PA enhancement. Scale bars are 
approximately 5 mm. 
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Figure 39: Representative histology from an MMTVneu mouse 24 hours post-saline 
injection. Mouse received a volume equivalent IV injection of saline instead of PFHnDs. 
Sections were stained with DAPI (blue). A) Cartoon showing the location of the primary 
tumor; B) Section of the spleen showing no appreciable enhancement from Cy5 tagged 
PFHnDs (red; absent); C) Section of the primary tumor showing no appreciable 
enhancement from Cy5. These sections were used to establish the dynamic range for Cy5 
for all other spleen and primary tumor fluorescent images. Scale bar is 200 µm. 
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Figure 40: US/PA imaging volumes from a targeted PFHnD injected MMTVneu 
mouse. This mouse was microdosed with 40 mg/kg losartan for 7 days prior to IV injection 
with anti-HER2 PFHnDs. A) Cartoon showing the right lateral decubitus position of the 
mouse for imaging. The yellow dashed lines approximate the volumes shown; B) Masked 
PA signal (red-orange) overlaid with the corresponding US volume 48 hours before 
targeted PFHnD injection; C) Masked PA signal overlaid with US obtained 30 minutes 
after targeted PFHnD injection; D) Masked PA signal overlaid with US obtained 24 hours 
after targeted PFHnD injection. All volumes show minimal PA enhancement. Scale bars 
are approximately 5 mm. 
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Figure 41: Representative histology from an MMTVneu mouse 24 hours post-PFCnD 
injection. Mouse was microdosed with 40 mg/kg losartan prior to IV injection of anti-
HER2 targeted PFHnDs. Sections were stained with DAPI (blue). A) Cartoon showing the 
location of the primary tumor; B) Section of the spleen showing no appreciable 
enhancement from Cy5 tagged PFHnDs (red; absent); C) Section of the primary tumor 
showing no appreciable enhancement from Cy5 tagged PFHnDs. Scale bar is 200 µm. 
 178 
 
Figure 42: US/PA imaging volumes from a targeted PFHnD injected 4T1 syngeneic 
mouse.  This mouse was microdosed with 40 mg/kg losartan for 7 days prior to IV injection 
with anti-EpCAM PFHnDs. A) Cartoon showing the supine position of the mouse for 
imaging. The yellow dashed lines approximate the volumes shown; B) Masked PA signal 
(red-orange) overlaid with the corresponding US volume 48 hours before targeted PFHnD 
injection; C) Masked PA signal overlaid with US obtained 60 minutes after targeted 
PFHnD injection; D) Masked PA signal overlaid with US obtained 24 hours after targeted 
PFHnD injection. All volumes show static PA enhancement at the skin surface, which is 
likely artifact. Scale bars are approximately 5 mm. 
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Figure 43: Representative histology from a 4T1 syngeneic mouse 24 hours post-
PFCnD injection. Mouse was microdosed with 40 mg/kg losartan prior to IV injection of 
anti-EpCAM targeted PFHnDs. There was flash confirmation of the IV injection, but it is 
possible that this was a hematoma. Sections were stained with DAPI (blue). A) Cartoon 
showing the location of the primary tumor; B) Section of the spleen showing no appreciable 
enhancement from Cy5 tagged PFHnDs (red; absent); C) Section of the primary tumor 
showing no appreciable enhancement from Cy5 tagged PFHnDs. Scale bar is 200 µm. 
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Figure 44: US/PA imaging volumes from another targeted PFHnD injected 4T1 
syngeneic mouse.  This mouse was microdosed with 40 mg/kg losartan for 7 days prior to 
IV injection with anti-EpCAM PFHnDs. A) Cartoon showing the supine position of the 
mouse for imaging. The yellow dashed lines approximate the volumes shown; B) Masked 
PA signal (red-orange) overlaid with the corresponding US volume 48 hours before 
targeted PFHnD injection; C) Masked PA signal overlaid with US obtained 40 minutes 
after targeted PFHnD injection; D) Masked PA signal overlaid with US obtained 24 hours 
after targeted PFHnD injection. Post-injection volumes show strong PA enhancement at 
the skin surface medial (40 min) and lateral (24 hour) to the primary tumor. This is likely 
artifact. Scale bars are approximately 5 mm. 
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Figure 45: Representative histology from another 4T1 syngeneic mouse 24 hours post-
PFCnD injection. Mouse was microdosed with 40 mg/kg losartan prior to IV injection of 
anti-EpCAM targeted PFHnDs. There was no flash confirmation of the IV injection, calling 
the delivery into question. Sections were stained with DAPI (blue). A) Cartoon showing 
the location of the primary tumor; B) Section of the spleen showing no appreciable 
enhancement from Cy5 tagged PFHnDs (red; absent); C) Section of the primary tumor 
showing no appreciable enhancement from Cy5 tagged PFHnDs. Scale bar is 200 µm. 
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APPENDIX E. SUPPLEMENTAL DATA FOR DUAL 
FLUOROPHORE NANODROPLETS 
 
Figure 46: Schema of SQ650 synthesis. Squaric acid (2) and 2,3,3-trimethylindolenine 
(1) were heated under reflux in a mixture of 4:1 (v:v) n-butanol:toluene containing 
quinoline, as described in 5.3.3. Figure provided by Vadakkancheril S. Jisha, Ph.D. 
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Figure 47: Absorbance spectrum of free SQ650 in chloroform. A qualitative amount of 
SQ650 dye was used. The spectrum and its peak at 656 nm compare favorably with Cy5 
(649 nm peak). 
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Figure 48: Fluorimetry of FRET nanodroplets made with 2:1 PFH:TFT. The original 
fluoroalkane emulsion stock contained 25 mg/mL SQ650. Although the PFCnD precursor 
stock contained SQ650 in the fluoroalkane phase, the resulting nanodroplets do not exhibit 
an SQ650 emission peak with either 640-nm (light purple) or 540-nm (purple) excitation. 
Spectra were acquired with 3-nm excitation and emission slit widths and were normalized 
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